

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY SUB: 10 ROUTINE GRP: 10 ROUTINE

ANALYTE				NO. PART		TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
001 ALAN AMINO	ALT/SGPT	CLIA TEST ID #: 255	EVALUATION CRITERIA: TARGET VALUE	15	% OR 6.00	{GREATER}				
2025-781	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	17	290.625	10.717	3.69	247.000	334.000	
2025-781	8 OX.OF NADH	220 Medica E.	130 MEDICA	13	273.154	8.347	3.06	232.000	314.000	
2025-781	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	71	330.535	9.234	2.79	281.000	380.000	
2025-781	11 MOD. IFCC	184 INTEGRA	93 ROCHE	16	299.000	9.480	3.17	254.000	344.000	
2025-781	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	28	274.643	9.933	3.62	233.000	316.000	
2025-781	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	23	342.348	27.138	7.93	291.000	394.000	
2025-781	11 MOD. IFCC	203 ROCHE	93 ROCHE	48	303.333	9.722	3.20	258.000	349.000	
2025-781	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	28	349.185	13.513	3.87	297.000	402.000	
2025-781	12 IFCC witho	203 ROCHE	93 ROCHE	20	306.750	12.214	3.98	261.000	353.000	
2025-781	13 ALA &aKETO	165 VITROS	155 ALTV	126	285.976	8.480	2.97	243.000	329.000	
2025-782	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	17	201.941	13.045	6.46	172.000	232.000	
2025-782	8 OX.OF NADH	220 Medica E.	130 MEDICA	13	191.231	5.451	2.85	163.000	220.000	
2025-782	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	71	233.471	7.032	3.01	198.000	268.000	
2025-782	11 MOD. IFCC	184 INTEGRA	93 ROCHE	16	207.000	5.690	2.75	176.000	238.000	
2025-782	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	28	190.929	5.077	2.66	162.000	220.000	
2025-782	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	23	242.409	15.388	6.35	206.000	279.000	
2025-782	11 MOD. IFCC	203 ROCHE	93 ROCHE	48	212.596	5.298	2.49	181.000	244.000	
2025-782	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	28	243.185	5.285	2.17	207.000	280.000	
2025-782	12 IFCC witho	203 ROCHE	93 ROCHE	20	214.100	8.983	4.20	182.000	246.000	
2025-782	13 ALA &aKETO	165 VITROS	155 ALTV	126	202.512	6.456	3.19	172.000	233.000	
2025-783	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	17	66.313	2.113	3.19	56.000	76.000	
2025-783	8 OX.OF NADH	220 Medica E.	130 MEDICA	13	67.385	2.371	3.52	57.000	77.000	
2025-783	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	71	82.099	2.888	3.52	70.000	94.000	
2025-783	11 MOD. IFCC	184 INTEGRA	93 ROCHE	16	69.933	1.611	2.30	59.000	80.000	
2025-783	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	28	65.214	2.093	3.21	55.000	75.000	
2025-783	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	23	81.522	4.933	6.05	69.000	94.000	
2025-783	11 MOD. IFCC	203 ROCHE	93 ROCHE	48	72.021	2.077	2.88	61.000	83.000	

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY SUB: 10 ROUTINE GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2025-783	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	28	82.370	3.117	3.78	70.000	95.000		
2025-783	12 IFCC witho	203 ROCHE	93 ROCHE	20	71.900	3.254	4.53	61.000	83.000		
2025-783	13 ALA &aKETO	165 VITROS	155 ALTV	126	70.871	2.129	3.00	60.000	82.000		
001 ALAN AMINO ALT/SGPT		CLIA TEST ID #: 255	EVALUATION CRITERIA: TARGET VALUE 15 % OR 6.00 {GREATER}								
2025-784	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	17	9.588	1.239	12.93	4.000	16.000		
2025-784	8 OX.OF NADH	220 Medica E.	130 MEDICA	13	13.308	1.488	11.18	7.000	19.000		
2025-784	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	71	16.310	2.004	12.29	10.000	22.000		
2025-784	11 MOD. IFCC	184 INTEGRA	93 ROCHE	16	9.813	0.527	5.37	4.000	16.000		
2025-784	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	28	10.571	0.678	6.41	5.000	17.000		
2025-784	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	23	12.913	2.320	17.97	7.000	19.000		
2025-784	11 MOD. IFCC	203 ROCHE	93 ROCHE	48	11.298	0.650	5.75	5.000	17.000		
2025-784	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	28	13.357	1.260	9.43	7.000	19.000		
2025-784	12 IFCC witho	203 ROCHE	93 ROCHE	20	11.300	1.100	9.73	5.000	17.000		
2025-784	13 ALA &aKETO	165 VITROS	155 ALTV	126	9.320	0.722	7.75	3.000	15.000		
2025-785	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	17	122.250	4.100	3.35	104.000	141.000		
2025-785	8 OX.OF NADH	220 Medica E.	130 MEDICA	13	121.308	2.700	2.23	103.000	140.000		
2025-785	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	71	147.887	4.271	2.89	126.000	170.000		
2025-785	11 MOD. IFCC	184 INTEGRA	93 ROCHE	16	128.938	4.160	3.23	110.000	148.000		
2025-785	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	28	119.037	3.717	3.12	101.000	137.000		
2025-785	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	23	150.043	8.745	5.83	128.000	173.000		
2025-785	11 MOD. IFCC	203 ROCHE	93 ROCHE	48	131.833	3.859	2.93	112.000	152.000		
2025-785	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	28	152.519	4.425	2.90	130.000	175.000		
2025-785	12 IFCC witho	203 ROCHE	93 ROCHE	20	132.400	5.517	4.17	113.000	152.000		
2025-785	13 ALA &aKETO	165 VITROS	155 ALTV	126	128.472	3.931	3.06	109.000	148.000		
002 ALBUMIN		CLIA TEST ID #: 265	EVALUATION CRITERIA: TARGET VALUE 8 %								
2025-781	3 DYE BI-B.G	165 VITROS	63 KODAK	134	4.952	0.167	3.36	4.600	5.300		
2025-781	3 DYE BI-B.G	184 INTEGRA	93 ROCHE	25	4.720	0.113	2.40	4.300	5.100		
2025-781	3 DYE BI-B.G	186 BECK. COUL	76 AU-BECKMAN	29	4.662	0.103	2.21	4.300	5.000		
2025-781	3 DYE BI-B.G	191 RX-SERIES	126 RANDOX	24	4.600	0.168	3.66	4.200	5.000		

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-781	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	16	4.550	0.094	2.06	4.200	4.900
2025-781	3	DYE BI-B.G	203	ROCHE	93	ROCHE	67	4.705	0.108	2.29	4.300	5.100
2025-781	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	28	4.715	0.135	2.87	4.300	5.100
2025-781	3	DYE BI-B.G	220	Medica E.	130	MEDICA	14	4.793	0.128	2.67	4.400	5.200
2025-781	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	74	4.327	0.130	3.00	4.000	4.700
002	ALBUMIN	CLIA TEST ID #: 265				EVALUATION CRITERIA: TARGET VALUE 8 %						
2025-782	3	DYE BI-B.G	165	VITROS	63	KODAK	134	4.024	0.127	3.15	3.700	4.300
2025-782	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	25	3.960	0.123	3.11	3.600	4.300
2025-782	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	29	3.872	0.078	2.02	3.600	4.200
2025-782	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	24	3.846	0.138	3.60	3.500	4.200
2025-782	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	16	3.781	0.063	1.68	3.500	4.100
2025-782	3	DYE BI-B.G	203	ROCHE	93	ROCHE	67	3.971	0.079	2.00	3.700	4.300
2025-782	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	28	3.875	0.124	3.21	3.600	4.200
2025-782	3	DYE BI-B.G	220	Medica E.	130	MEDICA	14	3.971	0.080	2.00	3.700	4.300
2025-782	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	74	3.536	0.082	2.31	3.300	3.800
2025-783	3	DYE BI-B.G	165	VITROS	63	KODAK	134	2.543	0.086	3.38	2.300	2.700
2025-783	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	25	2.744	0.094	3.43	2.500	3.000
2025-783	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	29	2.590	0.061	2.34	2.400	2.800
2025-783	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	24	2.654	0.096	3.60	2.400	2.900
2025-783	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	16	2.500	0.061	2.45	2.300	2.700
2025-783	3	DYE BI-B.G	203	ROCHE	93	ROCHE	67	2.730	0.090	3.29	2.500	2.900
2025-783	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	28	2.564	0.093	3.64	2.400	2.800
2025-783	3	DYE BI-B.G	220	Medica E.	130	MEDICA	14	2.629	0.096	3.65	2.400	2.800
2025-783	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	74	2.285	0.072	3.13	2.100	2.500
2025-784	3	DYE BI-B.G	165	VITROS	63	KODAK	134	1.954	0.064	3.29	1.800	2.100
2025-784	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	25	2.184	0.078	3.59	2.000	2.400
2025-784	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	29	2.055	0.072	3.52	1.900	2.200
2025-784	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	24	2.142	0.076	3.54	2.000	2.300

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-784	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	16	1.975	0.066	3.35	1.800	2.100
2025-784	3	DYE BI-B.G	203	ROCHE	93	ROCHE	67	2.194	0.062	2.85	2.000	2.400
2025-784	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	28	2.039	0.056	2.73	1.900	2.200
2025-784	3	DYE BI-B.G	220	Medica E.	130	MEDICA	14	2.021	0.086	4.25	1.900	2.200
2025-784	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	74	1.782	0.063	3.52	1.600	1.900
002	ALBUMIN	CLIA TEST ID #: 265				EVALUATION CRITERIA: TARGET VALUE 8 %						
2025-785	3	DYE BI-B.G	165	VITROS	63	KODAK	134	3.162	0.114	3.60	2.900	3.400
2025-785	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	25	3.260	0.089	2.74	3.000	3.500
2025-785	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	29	3.131	0.070	2.24	2.900	3.400
2025-785	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	24	3.142	0.122	3.89	2.900	3.400
2025-785	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	16	2.994	0.066	2.20	2.800	3.200
2025-785	3	DYE BI-B.G	203	ROCHE	93	ROCHE	67	3.242	0.087	2.67	3.000	3.500
2025-785	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	28	3.114	0.112	3.61	2.900	3.400
2025-785	3	DYE BI-B.G	220	Medica E.	130	MEDICA	14	3.193	0.103	3.23	2.900	3.400
2025-785	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	74	2.801	0.077	2.76	2.600	3.000
003	ALKALINE PHOSPHATE	CLIA TEST ID #: 275				EVALUATION CRITERIA: TARGET VALUE 20 %						
2025-781	3	COLORIMET.	184	INTEGRA	93	ROCHE	20	246.250	11.623	4.72	197.000	296.000
2025-781	3	COLORIMET.	203	ROCHE	93	ROCHE	44	243.227	10.831	4.45	195.000	292.000
2025-781	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	11	210.182	22.631	10.77	168.000	252.000
2025-781	6	KINETIC 37	165	VITROS	63	KODAK	134	169.857	9.003	5.30	136.000	204.000
2025-781	8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	29	189.552	26.191	13.82	152.000	227.000
2025-781	10	IFCC	203	ROCHE	93	ROCHE	15	239.267	9.161	3.83	191.000	287.000
2025-781	10	IFCC	219	ATELLICA	143	SIEMENS	28	236.036	11.024	4.67	189.000	283.000
2025-781	11	Modified I	38	SIEMENS DI	143	SIEMENS	68	258.441	9.817	3.80	207.000	310.000
2025-781	11	Modified I	38	SIEMENS DI	143	SIEMENS	68	268.400	18.768	6.99	215.000	322.000
2025-781	11	Modified I	191	RX-SERIES	126	RANDOX	19	238.000	9.710	4.08	190.000	286.000
2025-781	11	Modified I	191	RX-SERIES	126	RANDOX	19	204.000	12.454	6.11	163.000	245.000
2025-781	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	10	213.900	20.656	9.66	171.000	257.000
2025-781	12	P NITRO PH	220	Medica E.	130	MEDICA	13	204.462	8.445	4.13	164.000	245.000

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH		
003	ALKALINE PHOSPHATE	CLIA TEST ID #: 275				EVALUATION CRITERIA: TARGET VALUE 20 %						
2025-782	3	COLORIMET.	184	INTEGRA	93	ROCHE	20	175.450	7.972	4.54	140.000	211.000
2025-782	3	COLORIMET.	203	ROCHE	93	ROCHE	44	174.477	7.838	4.49	140.000	209.000
2025-782	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	11	154.000	16.304	10.59	123.000	185.000
2025-782	6	KINETIC 37	165	VITROS	63	KODAK	134	149.774	8.066	5.39	120.000	180.000
2025-782	8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	29	135.138	18.671	13.82	108.000	162.000
2025-782	10	IFCC	203	ROCHE	93	ROCHE	15	172.267	7.550	4.38	138.000	207.000
2025-782	10	IFCC	219	ATELLICA	143	SIEMENS	28	166.214	7.934	4.77	133.000	199.000
2025-782	11	Modified I	38	SIEMENS DI	143	SIEMENS	68	190.600	8.800	4.62	152.000	229.000
2025-782	11	Modified I	38	SIEMENS DI	143	SIEMENS	68	186.164	7.776	4.18	149.000	223.000
2025-782	11	Modified I	191	RX-SERIES	126	RANDOX	19	153.579	15.655	10.19	123.000	184.000
2025-782	11	Modified I	191	RX-SERIES	126	RANDOX	19	171.429	5.473	3.19	137.000	206.000
2025-782	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	10	153.300	15.126	9.87	123.000	184.000
2025-782	12	P NITRO PH	220	Medica E.	130	MEDICA	13	146.385	3.972	2.71	117.000	176.000
2025-783	3	COLORIMET.	184	INTEGRA	93	ROCHE	20	74.550	3.943	5.29	60.000	89.000
2025-783	3	COLORIMET.	203	ROCHE	93	ROCHE	44	73.500	3.596	4.89	59.000	88.000
2025-783	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	11	65.909	7.868	11.94	53.000	79.000
2025-783	6	KINETIC 37	165	VITROS	63	KODAK	134	86.662	4.294	4.95	69.000	104.000
2025-783	8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	29	56.310	8.141	14.46	45.000	68.000
2025-783	10	IFCC	203	ROCHE	93	ROCHE	15	72.400	3.007	4.15	58.000	87.000
2025-783	10	IFCC	219	ATELLICA	143	SIEMENS	28	70.000	3.338	4.77	56.000	84.000
2025-783	11	Modified I	38	SIEMENS DI	143	SIEMENS	68	77.478	4.053	5.23	62.000	93.000
2025-783	11	Modified I	38	SIEMENS DI	143	SIEMENS	68	81.200	6.369	7.84	65.000	97.000
2025-783	11	Modified I	191	RX-SERIES	126	RANDOX	19	71.571	2.382	3.33	57.000	86.000
2025-783	11	Modified I	191	RX-SERIES	126	RANDOX	19	67.474	7.214	10.69	54.000	81.000
2025-783	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	10	64.900	5.856	9.02	52.000	78.000
2025-783	12	P NITRO PH	220	Medica E.	130	MEDICA	13	63.615	1.943	3.05	51.000	76.000
2025-784	3	COLORIMET.	184	INTEGRA	93	ROCHE	20	31.200	1.860	5.96	25.000	37.000

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-784	3	COLORIMET.	203	ROCHE	93	ROCHE	44	30.605	1.527	4.99	24.000	37.000
2025-784	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	11	27.182	3.511	12.92	22.000	33.000
2025-784	6	KINETIC 37	165	VITROS	63	KODAK	134	46.121	2.677	5.80	37.000	55.000
2025-784	8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	29	23.241	3.461	14.89	19.000	28.000
2025-784	10	IFCC	203	ROCHE	93	ROCHE	15	30.533	1.310	4.29	24.000	37.000
2025-784	10	IFCC	219	ATELLICA	143	SIEMENS	28	29.393	1.780	6.05	24.000	35.000
2025-784	11	Modified I	38	SIEMENS DI	143	SIEMENS	68	32.800	1.939	5.91	26.000	39.000
2025-784	11	Modified I	38	SIEMENS DI	143	SIEMENS	68	31.925	3.252	10.19	26.000	38.000
2025-784	11	Modified I	191	RX-SERIES	126	RANDOX	19	27.722	2.181	7.87	22.000	33.000
2025-784	11	Modified I	191	RX-SERIES	126	RANDOX	19	29.857	0.990	3.31	24.000	36.000
2025-784	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	10	27.300	3.164	11.59	22.000	33.000
2025-784	12	P NITRO PH	220	Medica E.	130	MEDICA	13	28.154	1.026	3.65	23.000	34.000
003	ALKALINE PHOSPHATE		CLIA TEST ID #: 275			EVALUATION CRITERIA: TARGET VALUE 20 %						
2025-785	3	COLORIMET.	184	INTEGRA	93	ROCHE	20	116.900	5.300	4.53	94.000	140.000
2025-785	3	COLORIMET.	203	ROCHE	93	ROCHE	44	115.512	5.492	4.75	92.000	139.000
2025-785	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	11	101.364	11.641	11.48	81.000	122.000
2025-785	6	KINETIC 37	165	VITROS	63	KODAK	134	119.353	6.767	5.67	95.000	143.000
2025-785	8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	29	89.241	12.626	14.15	71.000	107.000
2025-785	10	IFCC	203	ROCHE	93	ROCHE	15	114.400	5.083	4.44	92.000	137.000
2025-785	10	IFCC	219	ATELLICA	143	SIEMENS	28	111.143	5.914	5.32	89.000	133.000
2025-785	11	Modified I	38	SIEMENS DI	143	SIEMENS	68	123.500	5.776	4.68	99.000	148.000
2025-785	11	Modified I	38	SIEMENS DI	143	SIEMENS	68	128.400	6.119	4.77	103.000	154.000
2025-785	11	Modified I	191	RX-SERIES	126	RANDOX	19	112.714	4.431	3.93	90.000	135.000
2025-785	11	Modified I	191	RX-SERIES	126	RANDOX	19	101.556	7.769	7.65	81.000	122.000
2025-785	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	10	102.100	10.425	10.21	82.000	123.000
2025-785	12	P NITRO PH	220	Medica E.	130	MEDICA	13	98.462	2.274	2.31	79.000	118.000
004	AMYLASE		CLIA TEST ID #: 285									
2025-781	3	ENZYM. 37C	165	VITROS	63	KODAK	86	170.395	7.752	4.55	136.000	204.000
2025-781	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	16	227.000	4.153	1.83	182.000	272.000
2025-781	9	ENZ/COL.37	203	ROCHE	93	ROCHE	33	237.394	5.862	2.47	190.000	285.000

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-781	10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	13	180.538	10.293	5.70	144.000	217.000
2025-781	11	KINETIC	219	ATELLICA	143	SIEMENS	19	265.778	8.702	3.27	213.000	319.000
004	AMYLASE		CLIA TEST ID #: 285		EVALUATION CRITERIA: TARGET VALUE 20 %							
2025-782	3	ENZYM. 37C	165	VITROS	63	KODAK	86	125.353	6.506	5.19	100.000	150.000
2025-782	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	16	162.625	3.314	2.04	130.000	195.000
2025-782	9	ENZ/COL.37	203	ROCHE	93	ROCHE	33	169.182	4.159	2.46	135.000	203.000
2025-782	10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	13	129.846	7.553	5.82	104.000	156.000
2025-782	11	KINETIC	219	ATELLICA	143	SIEMENS	19	189.389	3.803	2.01	152.000	227.000
2025-783	3	ENZYM. 37C	165	VITROS	63	KODAK	86	52.709	5.736	10.88	42.000	63.000
2025-783	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	16	64.625	1.364	2.11	52.000	78.000
2025-783	9	ENZ/COL.37	203	ROCHE	93	ROCHE	33	69.121	1.788	2.59	55.000	83.000
2025-783	10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	13	51.077	1.979	3.87	41.000	61.000
2025-783	11	KINETIC	219	ATELLICA	143	SIEMENS	19	76.474	2.909	3.80	61.000	92.000
2025-784	3	ENZYM. 37C	165	VITROS	63	KODAK	86	30.341	1.118	3.68	24.000	36.000
2025-784	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	16	24.000	0.791	3.29	19.000	29.000
2025-784	9	ENZ/COL.37	203	ROCHE	93	ROCHE	33	27.515	1.048	3.81	22.000	33.000
2025-784	10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	13	18.462	1.500	8.12	15.000	22.000
2025-784	11	KINETIC	219	ATELLICA	143	SIEMENS	19	30.737	1.250	4.07	25.000	37.000
2025-785	3	ENZYM. 37C	165	VITROS	63	KODAK	86	82.523	7.021	8.51	66.000	99.000
2025-785	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	16	106.625	2.058	1.93	85.000	128.000
2025-785	9	ENZ/COL.37	203	ROCHE	93	ROCHE	33	111.121	2.556	2.30	89.000	133.000
2025-785	10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	13	83.692	3.930	4.70	67.000	100.000
2025-785	11	KINETIC	219	ATELLICA	143	SIEMENS	19	124.167	2.967	2.39	99.000	149.000
005	ASP. AMINO AST/SGOT		CLIA TEST ID #: 295		EVALUATION CRITERIA: TARGET VALUE 15 % OR 6.00 {GREATER}							
2025-781	1	ASPAR&KETO	165	VITROS	63	KODAK	134	456.336	20.976	4.60	388.000	525.000
2025-781	1	ASPAR&KETO	220	Medica E.	130	MEDICA	14	297.429	10.034	3.37	253.000	342.000
2025-781	5	ENZYM.37C	38	SIEMENS DI	143	SIEMENS	75	332.149	10.025	3.02	282.000	382.000

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY SUB: 10 ROUTINE GRP: 10 ROUTINE

ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2025-781	11 MOD. IFCC	184 INTEGRA	93 ROCHE	18	337.944	16.708	4.94	287.000	389.000		
2025-781	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	29	292.345	13.486	4.61	248.000	336.000		
2025-781	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	23	374.043	22.768	6.09	318.000	430.000		
2025-781	11 MOD. IFCC	203 ROCHE	93 ROCHE	45	341.711	11.646	3.41	290.000	393.000		
2025-781	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	28	373.259	10.637	2.85	317.000	429.000		
2025-781	12 IFCC witho	203 ROCHE	93 ROCHE	20	343.350	10.776	3.14	292.000	395.000		
2025-781	13 NADH wo P5	197 ARCHITECT	1 ABBOTT	14	394.786	18.743	4.75	336.000	454.000		
005 ASP. AMINO AST/SGOT		CLIA TEST ID #: 295	EVALUATION CRITERIA: TARGET VALUE 15 % OR 6.00 {GREATER}								
2025-782	1 ASPAR&KETO	165 VITROS	63 KODAK	134	297.075	12.250	4.12	253.000	342.000		
2025-782	1 ASPAR&KETO	220 Medica E.	130 MEDICA	14	212.071	4.949	2.33	180.000	244.000		
2025-782	5 ENZYMA.37C	38 SIEMENS DI	143 SIEMENS	75	231.581	7.062	3.05	197.000	266.000		
2025-782	11 MOD. IFCC	184 INTEGRA	93 ROCHE	18	236.833	12.725	5.37	201.000	272.000		
2025-782	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	29	204.536	7.331	3.58	174.000	235.000		
2025-782	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	23	267.043	18.763	7.03	227.000	307.000		
2025-782	11 MOD. IFCC	203 ROCHE	93 ROCHE	45	240.778	8.041	3.34	205.000	277.000		
2025-782	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	28	260.179	7.892	3.03	221.000	299.000		
2025-782	12 IFCC witho	203 ROCHE	93 ROCHE	20	241.800	7.373	3.05	206.000	278.000		
2025-782	13 NADH wo P5	197 ARCHITECT	1 ABBOTT	14	277.643	16.216	5.84	236.000	319.000		
2025-783	1 ASPAR&KETO	165 VITROS	63 KODAK	134	89.194	3.802	4.26	76.000	103.000		
2025-783	1 ASPAR&KETO	220 Medica E.	130 MEDICA	14	75.714	1.750	2.31	64.000	87.000		
2025-783	5 ENZYMA.37C	38 SIEMENS DI	143 SIEMENS	75	80.520	3.147	3.91	68.000	93.000		
2025-783	11 MOD. IFCC	184 INTEGRA	93 ROCHE	18	82.333	4.910	5.96	70.000	95.000		
2025-783	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	29	71.714	3.104	4.33	61.000	82.000		
2025-783	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	23	93.826	6.246	6.66	80.000	108.000		
2025-783	11 MOD. IFCC	203 ROCHE	93 ROCHE	45	83.750	2.877	3.44	71.000	96.000		
2025-783	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	28	91.286	2.589	2.84	78.000	105.000		
2025-783	12 IFCC witho	203 ROCHE	93 ROCHE	20	83.684	2.104	2.51	71.000	96.000		
2025-783	13 NADH wo P5	197 ARCHITECT	1 ABBOTT	14	95.000	4.192	4.41	81.000	109.000		

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY SUB: 10 ROUTINE GRP: 10 ROUTINE

ANALYTE							NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
005	ASP. AMINO AST/SGOT	CLIA TEST ID #: 295	EVALUATION CRITERIA: TARGET VALUE	15	% OR 6.00	{GREATER}						
2025-784	1 ASPAR&KETO	165 VITROS	63 KODAK	134	16.895	0.797	4.72	11.000	23.000			
2025-784	1 ASPAR&KETO	220 Medica E.	130 MEDICA	14	16.000	1.069	6.68	10.000	22.000			
2025-784	5 ENZYMA.37C	38 SIEMENS DI	143 SIEMENS	75	16.500	1.638	9.93	11.000	23.000			
2025-784	11 MOD. IFCC	184 INTEGRA	93 ROCHE	18	15.167	1.213	8.00	9.000	21.000			
2025-784	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	29	14.107	0.772	5.47	8.000	20.000			
2025-784	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	23	18.304	1.627	8.89	12.000	24.000			
2025-784	11 MOD. IFCC	203 ROCHE	93 ROCHE	45	15.841	0.824	5.20	10.000	22.000			
2025-784	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	28	18.393	1.113	6.05	12.000	24.000			
2025-784	12 IFCC witho	203 ROCHE	93 ROCHE	20	15.750	1.220	7.74	10.000	22.000			
2025-784	13 NADH wo P5	197 ARCHITECT	1 ABBOTT	14	17.214	1.206	7.00	11.000	23.000			
2025-785	1 ASPAR&KETO	165 VITROS	63 KODAK	134	170.224	6.463	3.80	145.000	196.000			
2025-785	1 ASPAR&KETO	220 Medica E.	130 MEDICA	14	134.929	2.815	2.09	115.000	155.000			
2025-785	5 ENZYMA.37C	38 SIEMENS DI	143 SIEMENS	75	145.760	4.755	3.26	124.000	168.000			
2025-785	11 MOD. IFCC	184 INTEGRA	93 ROCHE	18	148.500	8.023	5.40	126.000	171.000			
2025-785	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	29	128.966	5.714	4.43	110.000	148.000			
2025-785	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	23	168.435	12.265	7.28	143.000	194.000			
2025-785	11 MOD. IFCC	203 ROCHE	93 ROCHE	45	150.400	4.706	3.13	128.000	173.000			
2025-785	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	28	164.607	3.658	2.22	140.000	189.000			
2025-785	12 IFCC witho	203 ROCHE	93 ROCHE	20	151.105	3.478	2.30	128.000	174.000			
2025-785	13 NADH wo P5	197 ARCHITECT	1 ABBOTT	14	171.786	7.173	4.18	146.000	198.000			
006	BILIRUBIN, TOTAL	CLIA TEST ID #: 305	EVALUATION CRITERIA: TARGET VALUE	20	% OR 0.40	{GREATER}						
2025-781	4 J-G WITH B	38 SIEMENS DI	143 SIEMENS	72	4.886	0.257	5.25	3.910	5.860			
2025-781	4 J-G WITH B	38 SIEMENS DI	143 SIEMENS	72	4.913	0.285	5.81	3.930	5.900			
2025-781	4 J-G WITH B	186 BECK. COUL	76 AU-BECKMAN	28	4.745	0.117	2.48	3.800	5.690			
2025-781	4 J-G WITH B	191 RX-SERIES	126 RANDOX	17	4.677	0.388	8.30	3.740	5.610			
2025-781	7 DIAZO-DYPH	165 VITROS	63 KODAK	131	4.685	0.227	4.85	3.750	5.620			
2025-781	7 DIAZO-DYPH	165 VITROS	63 KODAK	131	4.212	0.140	3.33	3.370	5.050			
2025-781	13 AZOBIL.	184 INTEGRA	93 ROCHE	11	4.324	0.087	2.00	3.460	5.190			

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-781	13	AZOBIL.	203	ROCHE	93	ROCHE	44	4.225	0.195	4.62	3.380	5.070
2025-781	14	VANADATE	219	ATELLICA	143	SIEMENS	28	4.891	0.226	4.62	3.910	5.870
2025-781	15	DCA 2,4	220	Medica E.	130	MEDICA	12	5.563	0.197	3.54	4.450	6.680
2025-781	18	COLORIMETR	184	INTEGRA	93	ROCHE	10	4.246	0.240	5.65	3.400	5.100
2025-781	18	COLORIMETR	203	ROCHE	93	ROCHE	19	4.224	0.228	5.40	3.380	5.070
006	BILIRUBIN, TOTAL		CLIA TEST ID #: 305		EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.40 {GREATER}							
2025-782	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	72	3.317	0.221	6.66	2.650	3.980
2025-782	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	72	3.344	0.184	5.51	2.680	4.010
2025-782	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	28	3.312	0.086	2.60	2.650	3.970
2025-782	4	J-G WITH B	191	RX-SERIES	126	RANDOX	17	3.211	0.244	7.59	2.570	3.850
2025-782	7	DIAZO-DYPH	165	VITROS	63	KODAK	131	2.856	0.135	4.73	2.280	3.430
2025-782	7	DIAZO-DYPH	165	VITROS	63	KODAK	131	3.236	0.169	5.21	2.590	3.880
2025-782	13	AZOBIL.	184	INTEGRA	93	ROCHE	11	2.940	0.068	2.32	2.350	3.530
2025-782	13	AZOBIL.	203	ROCHE	93	ROCHE	44	2.893	0.125	4.34	2.310	3.470
2025-782	14	VANADATE	219	ATELLICA	143	SIEMENS	28	3.328	0.190	5.71	2.660	3.990
2025-782	15	DCA 2,4	220	Medica E.	130	MEDICA	12	3.841	0.085	2.21	3.070	4.610
2025-782	18	COLORIMETR	184	INTEGRA	93	ROCHE	10	2.930	0.138	4.72	2.340	3.520
2025-782	18	COLORIMETR	203	ROCHE	93	ROCHE	19	2.906	0.176	6.06	2.320	3.490
2025-783	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	72	1.009	0.083	8.20	0.610	1.410
2025-783	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	72	1.073	0.057	5.34	0.670	1.470
2025-783	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	28	1.081	0.036	3.29	0.680	1.480
2025-783	4	J-G WITH B	191	RX-SERIES	126	RANDOX	17	0.999	0.098	9.84	0.600	1.400
2025-783	7	DIAZO-DYPH	165	VITROS	63	KODAK	131	1.028	0.089	8.62	0.630	1.430
2025-783	7	DIAZO-DYPH	165	VITROS	63	KODAK	131	0.900	0.040	4.50	0.500	1.300
2025-783	13	AZOBIL.	184	INTEGRA	93	ROCHE	11	0.885	0.038	4.35	0.480	1.280
2025-783	13	AZOBIL.	203	ROCHE	93	ROCHE	44	0.872	0.036	4.12	0.470	1.270
2025-783	14	VANADATE	219	ATELLICA	143	SIEMENS	28	1.030	0.075	7.28	0.630	1.430
2025-783	15	DCA 2,4	220	Medica E.	130	MEDICA	12	1.192	0.028	2.34	0.790	1.590
2025-783	18	COLORIMETR	184	INTEGRA	93	ROCHE	10	0.887	0.056	6.36	0.490	1.290

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-783	18	COLORIMETR	203	ROCHE	93	ROCHE	19	0.872	0.055	6.32	0.470	1.270
006	BILIRUBIN, TOTAL		CLIA TEST ID #: 305			EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.40 {GREATER}						
2025-784	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	72	0.107	0.017	15.93	0	0.510
2025-784	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	72	0.096	0.036	37.04	0	0.500
2025-784	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	28	0.114	0.013	11.57	0	0.510
2025-784	4	J-G WITH B	191	RX-SERIES	126	RANDOX	17	0.152	0.100	65.81	0	0.550
2025-784	7	DIAZO-DYPH	165	VITROS	63	KODAK	131	0.122	0.056	45.90	0	0.520
2025-784	7	DIAZO-DYPH	165	VITROS	63	KODAK	131	0.116	0.034	29.07	0	0.520
2025-784	13	AZOBIL.	184	INTEGRA	93	ROCHE	11	0.112	0.057	50.56	0	0.510
2025-784	13	AZOBIL.	203	ROCHE	93	ROCHE	44	0.130	0.051	39.26	0	0.530
2025-784	14	VANADATE	219	ATELLICA	143	SIEMENS	28	0.159	0.024	14.86	0	0.560
2025-784	15	DCA 2,4	220	Medica E.	130	MEDICA	12	0.096	0.013	13.10	0	0.500
2025-784	18	COLORIMETR	184	INTEGRA	93	ROCHE	10	0.150	0.000	0.00	0	0.550
2025-784	18	COLORIMETR	203	ROCHE	93	ROCHE	19	0.141	0.040	28.25	0	0.540
2025-785	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	72	1.996	0.122	6.11	1.600	2.400
2025-785	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	72	2.063	0.121	5.87	1.650	2.480
2025-785	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	28	2.049	0.046	2.27	1.640	2.460
2025-785	4	J-G WITH B	191	RX-SERIES	126	RANDOX	17	1.943	0.115	5.91	1.540	2.340
2025-785	7	DIAZO-DYPH	165	VITROS	63	KODAK	131	1.987	0.097	4.90	1.590	2.390
2025-785	7	DIAZO-DYPH	165	VITROS	63	KODAK	131	1.746	0.067	3.84	1.350	2.150
2025-785	13	AZOBIL.	184	INTEGRA	93	ROCHE	11	1.776	0.048	2.72	1.380	2.180
2025-785	13	AZOBIL.	203	ROCHE	93	ROCHE	44	1.725	0.070	4.04	1.330	2.130
2025-785	14	VANADATE	219	ATELLICA	143	SIEMENS	28	2.013	0.113	5.61	1.610	2.420
2025-785	15	DCA 2,4	220	Medica E.	130	MEDICA	12	2.319	0.058	2.49	1.860	2.780
2025-785	18	COLORIMETR	184	INTEGRA	93	ROCHE	10	1.766	0.100	5.66	1.370	2.170
2025-785	18	COLORIMETR	203	ROCHE	93	ROCHE	19	1.723	0.090	5.19	1.320	2.120
010	CALCIUM, TOTAL		CLIA TEST ID #: 345			EVALUATION CRITERIA: TARGET VALUE 1.00						
2025-781	3	ARSEN.-III	165	VITROS	63	KODAK	149	10.746	0.259	2.41	9.700	11.700
2025-781	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	31	11.006	0.258	2.34	10.000	12.000

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2025-781	3 ARSEN.-III	191 RX-SERIES	126 RANDOX	26	11.015	0.396	3.59	10.000	12.000		
2025-781	3 ARSEN.-III	197 ARCHITECT	1 ABBOTT	11	10.609	0.264	2.49	9.600	11.600		
2025-781	3 ARSEN.-III	219 ATELLICA	143 SIEMENS	10	11.060	0.642	5.81	10.100	12.100		
2025-781	3 ARSEN.-III	220 Medica E.	130 MEDICA	15	10.987	0.456	4.15	10.000	12.000		
2025-781	8 CRESOLPHT.	38 SIEMENS DI	143 SIEMENS	75	10.519	0.307	2.92	9.500	11.500		
2025-781	8 CRESOLPHT.	184 INTEGRA	93 ROCHE	13	10.854	0.285	2.62	9.900	11.900		
2025-781	8 CRESOLPHT.	203 ROCHE	93 ROCHE	10	10.890	0.164	1.51	9.900	11.900		
2025-781	8 CRESOLPHT.	219 ATELLICA	143 SIEMENS	18	10.933	0.236	2.16	9.900	11.900		
2025-781	15 CA-NM-BAPT	184 INTEGRA	93 ROCHE	14	10.779	0.373	3.46	9.800	11.800		
2025-781	15 CA-NM-BAPT	203 ROCHE	93 ROCHE	56	10.891	0.268	2.46	9.900	11.900		
010 CALCIUM, TOTAL		CLIA TEST ID #: 345	EVALUATION CRITERIA: TARGET VALUE		1.00						
2025-782	3 ARSEN.-III	165 VITROS	63 KODAK	149	9.290	0.218	2.35	8.300	10.300		
2025-782	3 ARSEN.-III	186 BECK. COUL	76 AU-BECKMAN	31	9.387	0.184	1.97	8.400	10.400		
2025-782	3 ARSEN.-III	191 RX-SERIES	126 RANDOX	26	9.562	0.308	3.22	8.600	10.600		
2025-782	3 ARSEN.-III	197 ARCHITECT	1 ABBOTT	11	9.045	0.353	3.90	8.000	10.000		
2025-782	3 ARSEN.-III	219 ATELLICA	143 SIEMENS	10	9.230	0.224	2.43	8.200	10.200		
2025-782	3 ARSEN.-III	220 Medica E.	130 MEDICA	15	9.213	0.236	2.56	8.200	10.200		
2025-782	8 CRESOLPHT.	38 SIEMENS DI	143 SIEMENS	75	9.061	0.238	2.63	8.100	10.100		
2025-782	8 CRESOLPHT.	184 INTEGRA	93 ROCHE	13	9.215	0.187	2.03	8.200	10.200		
2025-782	8 CRESOLPHT.	203 ROCHE	93 ROCHE	10	9.290	0.181	1.95	8.300	10.300		
2025-782	8 CRESOLPHT.	219 ATELLICA	143 SIEMENS	18	9.172	0.274	2.99	8.200	10.200		
2025-782	15 CA-NM-BAPT	184 INTEGRA	93 ROCHE	14	9.229	0.266	2.88	8.200	10.200		
2025-782	15 CA-NM-BAPT	203 ROCHE	93 ROCHE	56	9.307	0.217	2.33	8.300	10.300		
2025-783	3 ARSEN.-III	165 VITROS	63 KODAK	149	6.849	0.167	2.44	5.800	7.800		
2025-783	3 ARSEN.-III	186 BECK. COUL	76 AU-BECKMAN	31	6.810	0.111	1.62	5.800	7.800		
2025-783	3 ARSEN.-III	191 RX-SERIES	126 RANDOX	26	7.115	0.350	4.93	6.100	8.100		
2025-783	3 ARSEN.-III	197 ARCHITECT	1 ABBOTT	11	6.618	0.185	2.79	5.600	7.600		
2025-783	3 ARSEN.-III	219 ATELLICA	143 SIEMENS	10	6.800	0.155	2.28	5.800	7.800		
2025-783	3 ARSEN.-III	220 Medica E.	130 MEDICA	15	6.460	0.212	3.29	5.500	7.500		

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-783	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	75	6.796	0.199	2.93	5.800	7.800
2025-783	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	13	6.862	0.194	2.83	5.900	7.900
2025-783	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	7.370	1.688	22.91	6.400	8.400
2025-783	8	CRESOLPHT.	219	ATELLICA	143	SIEMENS	18	6.656	0.224	3.37	5.700	7.700
2025-783	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	14	6.771	0.194	2.87	5.800	7.800
2025-783	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	56	6.855	0.158	2.31	5.900	7.900
010	CALCIUM, TOTAL	CLIA TEST ID #: 345				EVALUATION CRITERIA: TARGET VALUE 1.00						
2025-784	3	ARSEN.-III	165	VITROS	63	KODAK	149	5.854	0.153	2.61	4.900	6.900
2025-784	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	31	5.783	0.167	2.90	4.800	6.800
2025-784	3	ARSEN.-III	191	RX-SERIES	126	RANDOX	26	6.246	0.365	5.84	5.200	7.200
2025-784	3	ARSEN.-III	197	ARCHITECT	1	ABBOTT	11	5.709	0.150	2.64	4.700	6.700
2025-784	3	ARSEN.-III	219	ATELLICA	143	SIEMENS	10	5.890	0.145	2.45	4.900	6.900
2025-784	3	ARSEN.-III	220	Medica E.	130	MEDICA	15	5.287	0.178	3.37	4.300	6.300
2025-784	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	75	5.945	0.185	3.11	4.900	6.900
2025-784	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	13	5.777	0.172	2.97	4.800	6.800
2025-784	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	5.900	0.118	2.01	4.900	6.900
2025-784	8	CRESOLPHT.	219	ATELLICA	143	SIEMENS	18	5.683	0.211	3.72	4.700	6.700
2025-784	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	14	5.843	0.229	3.92	4.800	6.800
2025-784	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	56	5.923	0.139	2.34	4.900	6.900
2025-785	3	ARSEN.-III	165	VITROS	63	KODAK	149	7.860	0.192	2.44	6.900	8.900
2025-785	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	31	7.853	0.171	2.17	6.900	8.900
2025-785	3	ARSEN.-III	191	RX-SERIES	126	RANDOX	26	8.131	0.370	4.55	7.100	9.100
2025-785	3	ARSEN.-III	197	ARCHITECT	1	ABBOTT	11	7.518	0.225	2.99	6.500	8.500
2025-785	3	ARSEN.-III	219	ATELLICA	143	SIEMENS	10	7.840	0.246	3.13	6.800	8.800
2025-785	3	ARSEN.-III	220	Medica E.	130	MEDICA	15	7.600	0.190	2.50	6.600	8.600
2025-785	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	75	7.681	0.215	2.80	6.700	8.700
2025-785	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	13	7.800	0.175	2.25	6.800	8.800
2025-785	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	7.870	0.090	1.14	6.900	8.900
2025-785	8	CRESOLPHT.	219	ATELLICA	143	SIEMENS	18	7.733	0.203	2.62	6.700	8.700

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-785	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	14	7.800	0.239	3.06	6.800	8.800
2025-785	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	56	7.863	0.191	2.43	6.900	8.900
011	CHLORIDE	CLIA TEST ID #: 355				EVALUATION CRITERIA: TARGET VALUE 5 %						
2025-781	3	ISE DILUTE	184	INTEGRA	93	ROCHE	28	111.107	3.016	2.71	106.000	117.000
2025-781	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	29	105.414	1.957	1.86	100.000	111.000
2025-781	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	109.250	1.479	1.35	104.000	115.000
2025-781	3	ISE DILUTE	203	ROCHE	93	ROCHE	68	105.603	1.880	1.78	100.000	111.000
2025-781	4	ISE UND-DI	165	VITROS	63	KODAK	50	107.280	2.030	1.89	102.000	113.000
2025-781	4	ISE UND-DI	165	VITROS	156	Kit 32	98	108.361	1.922	1.77	103.000	114.000
2025-781	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	26	107.846	4.035	3.74	102.000	113.000
2025-781	4	ISE UND-DI	220	Medica E.	130	MEDICA	16	108.250	4.206	3.89	103.000	114.000
2025-781	8	IMT	219	ATELLICA	143	SIEMENS	28	109.556	2.025	1.85	104.000	115.000
2025-781	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	74	108.694	1.977	1.82	103.000	114.000
2025-781	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	74	107.667	1.247	1.16	102.000	113.000
2025-782	3	ISE DILUTE	184	INTEGRA	93	ROCHE	28	102.889	1.728	1.68	98.000	108.000
2025-782	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	29	99.586	1.810	1.82	95.000	105.000
2025-782	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	103.500	1.708	1.65	98.000	109.000
2025-782	3	ISE DILUTE	203	ROCHE	93	ROCHE	68	99.147	1.980	2.00	94.000	104.000
2025-782	4	ISE UND-DI	165	VITROS	63	KODAK	50	101.180	1.705	1.69	96.000	106.000
2025-782	4	ISE UND-DI	165	VITROS	156	Kit 32	98	101.526	1.486	1.46	96.000	107.000
2025-782	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	26	100.962	2.667	2.64	96.000	106.000
2025-782	4	ISE UND-DI	220	Medica E.	130	MEDICA	16	100.313	1.310	1.31	95.000	105.000
2025-782	8	IMT	219	ATELLICA	143	SIEMENS	28	102.250	1.785	1.75	97.000	107.000
2025-782	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	74	100.667	1.886	1.87	96.000	106.000
2025-782	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	74	101.356	1.868	1.84	96.000	106.000
2025-783	3	ISE DILUTE	184	INTEGRA	93	ROCHE	28	90.593	1.683	1.86	86.000	95.000
2025-783	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	29	89.207	1.270	1.42	85.000	94.000
2025-783	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	92.500	0.866	0.94	88.000	97.000

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-783	3	ISE DILUTE	203	ROCHE	93	ROCHE	68	86.478	1.568	1.81	82.000	91.000
2025-783	4	ISE UND-DI	165	VITROS	63	KODAK	50	90.740	1.820	2.01	86.000	95.000
2025-783	4	ISE UND-DI	165	VITROS	156	Kit 32	98	91.133	1.337	1.47	87.000	96.000
2025-783	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	26	88.269	2.683	3.04	84.000	93.000
2025-783	4	ISE UND-DI	220	Medica E.	130	MEDICA	16	87.500	0.707	0.81	83.000	92.000
2025-783	8	IMT	219	ATELLICA	143	SIEMENS	28	91.407	1.313	1.44	87.000	96.000
2025-783	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	74	87.824	1.288	1.47	83.000	92.000
2025-783	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	74	88.333	0.471	0.53	84.000	93.000
011	CHLORIDE	CLIA TEST ID #: 355		EVALUATION CRITERIA: TARGET VALUE 5 %								
2025-784	3	ISE DILUTE	184	INTEGRA	93	ROCHE	28	86.571	1.972	2.28	82.000	91.000
2025-784	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	29	86.069	1.258	1.46	82.000	90.000
2025-784	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	89.167	1.067	1.20	85.000	94.000
2025-784	3	ISE DILUTE	203	ROCHE	93	ROCHE	68	82.537	1.847	2.24	78.000	87.000
2025-784	4	ISE UND-DI	165	VITROS	63	KODAK	50	88.041	1.384	1.57	84.000	92.000
2025-784	4	ISE UND-DI	165	VITROS	156	Kit 32	98	88.103	1.256	1.43	84.000	93.000
2025-784	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	26	85.154	2.699	3.17	81.000	89.000
2025-784	4	ISE UND-DI	220	Medica E.	130	MEDICA	16	82.688	1.488	1.80	79.000	87.000
2025-784	8	IMT	219	ATELLICA	143	SIEMENS	28	88.321	1.489	1.69	84.000	93.000
2025-784	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	74	84.333	0.943	1.12	80.000	89.000
2025-784	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	74	83.521	1.273	1.52	79.000	88.000
2025-785	3	ISE DILUTE	184	INTEGRA	93	ROCHE	28	95.143	2.048	2.15	90.000	100.000
2025-785	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	29	93.034	1.771	1.90	88.000	98.000
2025-785	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	95.667	1.027	1.07	91.000	100.000
2025-785	3	ISE DILUTE	203	ROCHE	93	ROCHE	68	90.779	1.626	1.79	86.000	95.000
2025-785	4	ISE UND-DI	165	VITROS	63	KODAK	50	94.500	1.746	1.85	90.000	99.000
2025-785	4	ISE UND-DI	165	VITROS	156	Kit 32	98	94.684	1.562	1.65	90.000	99.000
2025-785	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	26	93.077	2.586	2.78	88.000	98.000
2025-785	4	ISE UND-DI	220	Medica E.	130	MEDICA	16	91.875	0.927	1.01	87.000	96.000
2025-785	8	IMT	219	ATELLICA	143	SIEMENS	28	95.393	1.780	1.87	91.000	100.000

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-785	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	74	93.000	1.663	1.79	88.000	98.000
2025-785	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	74	93.333	1.247	1.34	89.000	98.000
012 CHOLESTEROL, TOTAL		CLIA TEST ID #: 365				EVALUATION CRITERIA: TARGET VALUE 10 %						
2025-781	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	72	187.000	7.144	3.82	168.000	206.000
2025-781	1	ENZYMATIC	165	VITROS	63	KODAK	135	217.719	7.059	3.24	196.000	239.000
2025-781	1	ENZYMATIC	184	INTEGRA	93	ROCHE	11	203.273	4.202	2.07	183.000	224.000
2025-781	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	29	222.414	10.234	4.60	200.000	245.000
2025-781	1	ENZYMATIC	203	ROCHE	93	ROCHE	23	203.955	3.855	1.89	184.000	224.000
2025-781	1	ENZYMATIC	220	Medica E.	130	MEDICA	14	208.786	9.807	4.70	188.000	230.000
2025-781	5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	11	198.727	4.329	2.18	179.000	219.000
2025-781	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	28	199.607	4.152	2.08	180.000	220.000
2025-781	8	ENZYMATIC	203	ROCHE	93	ROCHE	20	204.800	4.874	2.38	184.000	225.000
2025-781	9	ENZYMATIC	203	ROCHE	93	ROCHE	19	206.474	4.476	2.17	186.000	227.000
2025-781	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	29	207.179	6.585	3.18	186.000	228.000
2025-782	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	72	162.225	5.236	3.23	146.000	178.000
2025-782	1	ENZYMATIC	165	VITROS	63	KODAK	135	185.201	5.499	2.97	167.000	204.000
2025-782	1	ENZYMATIC	184	INTEGRA	93	ROCHE	11	176.727	3.360	1.90	159.000	194.000
2025-782	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	29	194.207	9.371	4.83	175.000	214.000
2025-782	1	ENZYMATIC	203	ROCHE	93	ROCHE	23	177.478	2.842	1.60	160.000	195.000
2025-782	1	ENZYMATIC	220	Medica E.	130	MEDICA	14	182.643	4.320	2.37	164.000	201.000
2025-782	5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	11	174.000	6.537	3.76	157.000	191.000
2025-782	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	28	173.250	4.137	2.39	156.000	191.000
2025-782	8	ENZYMATIC	203	ROCHE	93	ROCHE	20	177.150	4.819	2.72	159.000	195.000
2025-782	9	ENZYMATIC	203	ROCHE	93	ROCHE	19	179.263	3.058	1.71	161.000	197.000
2025-782	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	29	177.414	5.869	3.31	160.000	195.000
2025-783	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	72	125.153	4.313	3.45	113.000	138.000
2025-783	1	ENZYMATIC	165	VITROS	63	KODAK	135	134.604	3.744	2.78	121.000	148.000
2025-783	1	ENZYMATIC	184	INTEGRA	93	ROCHE	11	136.727	3.519	2.57	123.000	150.000

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
2025-783	1	ENZYMATIC	191 RX-SERIES	126 RANDOX	29	145.897	6.429	4.41	131.000	160.000		
2025-783	1	ENZYMATIC	203 ROCHE	93 ROCHE	23	134.217	3.550	2.65	121.000	148.000		
2025-783	1	ENZYMATIC	220 Medica E.	130 MEDICA	14	139.714	2.938	2.10	126.000	154.000		
2025-783	5	FE-SALTS-N	197 ARCHITECT	1 ABBOTT	11	134.455	1.971	1.47	121.000	148.000		
2025-783	8	ENZYMATIC	186 BECK. COUL	76 AU-BECKMAN	28	131.821	3.140	2.38	119.000	145.000		
2025-783	8	ENZYMATIC	203 ROCHE	93 ROCHE	20	135.200	2.804	2.07	122.000	149.000		
2025-783	9	ENZYMATIC	203 ROCHE	93 ROCHE	19	135.526	2.927	2.16	122.000	149.000		
2025-783	9	ENZYMATIC	219 ATELLICA	143 SIEMENS	29	133.000	4.639	3.49	120.000	146.000		
012 CHOLESTEROL, TOTAL			CLIA TEST ID #: 365		EVALUATION CRITERIA: TARGET VALUE 10 %							
2025-784	1	ENZYMATIC	38 SIEMENS DI	143 SIEMENS	72	111.264	3.563	3.20	100.000	122.000		
2025-784	1	ENZYMATIC	165 VITROS	63 KODAK	135	114.696	3.465	3.02	103.000	126.000		
2025-784	1	ENZYMATIC	184 INTEGRA	93 ROCHE	11	117.636	2.568	2.18	106.000	129.000		
2025-784	1	ENZYMATIC	191 RX-SERIES	126 RANDOX	29	126.750	5.228	4.12	114.000	139.000		
2025-784	1	ENZYMATIC	203 ROCHE	93 ROCHE	23	117.000	2.571	2.20	105.000	129.000		
2025-784	1	ENZYMATIC	220 Medica E.	130 MEDICA	14	122.714	2.548	2.08	110.000	135.000		
2025-784	5	FE-SALTS-N	197 ARCHITECT	1 ABBOTT	11	118.545	2.271	1.92	107.000	130.000		
2025-784	8	ENZYMATIC	186 BECK. COUL	76 AU-BECKMAN	28	114.750	2.530	2.20	103.000	126.000		
2025-784	8	ENZYMATIC	203 ROCHE	93 ROCHE	20	118.000	2.236	1.89	106.000	130.000		
2025-784	9	ENZYMATIC	203 ROCHE	93 ROCHE	19	117.632	1.754	1.49	106.000	129.000		
2025-784	9	ENZYMATIC	219 ATELLICA	143 SIEMENS	29	115.517	3.645	3.16	104.000	127.000		
2025-785	1	ENZYMATIC	38 SIEMENS DI	143 SIEMENS	72	139.676	4.512	3.23	126.000	154.000		
2025-785	1	ENZYMATIC	165 VITROS	63 KODAK	135	154.493	4.284	2.77	139.000	170.000		
2025-785	1	ENZYMATIC	184 INTEGRA	93 ROCHE	11	151.545	2.231	1.47	136.000	167.000		
2025-785	1	ENZYMATIC	191 RX-SERIES	126 RANDOX	29	163.828	8.522	5.20	147.000	180.000		
2025-785	1	ENZYMATIC	203 ROCHE	93 ROCHE	23	151.348	3.225	2.13	136.000	166.000		
2025-785	1	ENZYMATIC	220 Medica E.	130 MEDICA	14	156.929	3.369	2.15	141.000	173.000		
2025-785	5	FE-SALTS-N	197 ARCHITECT	1 ABBOTT	11	150.091	2.968	1.98	135.000	165.000		
2025-785	8	ENZYMATIC	186 BECK. COUL	76 AU-BECKMAN	28	148.464	4.101	2.76	134.000	163.000		
2025-785	8	ENZYMATIC	203 ROCHE	93 ROCHE	20	152.500	3.557	2.33	137.000	168.000		

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-785	9	ENZYMATIC	203	ROCHE	93	ROCHE	19	152.474	2.603	1.71	137.000	168.000
2025-785	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	29	151.172	4.442	2.94	136.000	166.000
013 CHOLESTEROL, (HDL)		CLIA TEST ID #: 375				EVALUATION CRITERIA: TARGET VALUE 20 % OR 6.00 {GREATER}						
2025-781	5	DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	10	62.970	2.016	3.20	50.400	75.600
2025-781	11	ENC.-COLO.	165	VITROS	63	KODAK	133	62.141	3.658	5.89	49.700	74.600
2025-781	11	ENC.-COLO.	184	INTEGRA	93	ROCHE	26	63.152	4.795	7.59	50.500	75.800
2025-781	11	ENC.-COLO.	184	INTEGRA	93	ROCHE	26	50.667	3.528	6.96	40.500	60.800
2025-781	11	ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	29	66.652	3.119	4.68	53.300	80.000
2025-781	11	ENC.-COLO.	191	RX-SERIES	126	RANDOX	30	62.237	7.297	11.72	49.800	74.700
2025-781	11	ENC.-COLO.	203	ROCHE	93	ROCHE	57	61.160	2.797	4.57	48.900	73.400
2025-781	11	ENC.-COLO.	219	ATELLICA	143	SIEMENS	28	66.537	3.299	4.96	53.200	79.800
2025-781	11	ENC.-COLO.	220	Medica E.	130	MEDICA	14	59.143	3.681	6.22	47.300	71.000
2025-781	12	HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	11	65.545	2.463	3.76	52.400	78.700
2025-781	13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	71	42.123	2.649	6.29	33.700	50.500
2025-782	5	DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	10	55.760	2.180	3.91	44.600	66.900
2025-782	11	ENC.-COLO.	165	VITROS	63	KODAK	133	53.205	2.986	5.61	42.600	63.800
2025-782	11	ENC.-COLO.	184	INTEGRA	93	ROCHE	26	44.778	1.931	4.31	35.800	53.700
2025-782	11	ENC.-COLO.	184	INTEGRA	93	ROCHE	26	57.420	4.479	7.80	45.900	68.900
2025-782	11	ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	29	58.528	3.110	5.31	46.800	70.200
2025-782	11	ENC.-COLO.	191	RX-SERIES	126	RANDOX	30	55.645	5.430	9.76	44.500	66.800
2025-782	11	ENC.-COLO.	203	ROCHE	93	ROCHE	57	56.205	2.253	4.01	45.000	67.400
2025-782	11	ENC.-COLO.	219	ATELLICA	143	SIEMENS	28	57.650	2.460	4.27	46.100	69.200
2025-782	11	ENC.-COLO.	220	Medica E.	130	MEDICA	14	51.429	2.441	4.75	41.100	61.700
2025-782	12	HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	11	58.091	2.065	3.55	46.500	69.700
2025-782	13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	71	41.607	2.106	5.06	33.300	49.900
2025-783	5	DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	10	44.440	1.817	4.09	35.600	53.300
2025-783	11	ENC.-COLO.	165	VITROS	63	KODAK	133	41.752	2.315	5.54	33.400	50.100
2025-783	11	ENC.-COLO.	184	INTEGRA	93	ROCHE	26	47.858	4.539	9.48	38.300	57.400

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-783	11 ENC.-COLO.	184	INTEGRA	93	ROCHE	26	35.222	1.618	4.59	28.200	42.300	
2025-783	11 ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	29	45.110	1.973	4.37	36.100	54.100	
2025-783	11 ENC.-COLO.	191	RX-SERIES	126	RANDOX	30	44.037	5.525	12.55	35.200	52.800	
2025-783	11 ENC.-COLO.	203	ROCHE	93	ROCHE	57	46.963	2.058	4.38	37.600	56.400	
2025-783	11 ENC.-COLO.	219	ATELLICA	143	SIEMENS	28	44.736	2.485	5.55	35.800	53.700	
2025-783	11 ENC.-COLO.	220	Medica E.	130	MEDICA	14	39.571	1.990	5.03	31.700	47.500	
2025-783	12 HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	11	46.091	1.881	4.08	36.900	55.300	
2025-783	13 AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	71	38.966	1.931	4.96	31.200	46.800	
013 CHOLESTEROL, (HDL)		CLIA TEST ID #: 375				EVALUATION CRITERIA: TARGET VALUE 20 % OR 6.00 {GREATER}						
2025-784	5 DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	10	40.040	1.284	3.21	32.000	48.000	
2025-784	11 ENC.-COLO.	165	VITROS	63	KODAK	133	38.197	2.137	5.59	30.600	45.800	
2025-784	11 ENC.-COLO.	184	INTEGRA	93	ROCHE	26	31.222	1.315	4.21	25.000	37.500	
2025-784	11 ENC.-COLO.	184	INTEGRA	93	ROCHE	26	44.092	3.644	8.27	35.300	52.900	
2025-784	11 ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	29	40.362	1.866	4.62	32.300	48.400	
2025-784	11 ENC.-COLO.	191	RX-SERIES	126	RANDOX	30	37.652	4.200	11.16	30.100	45.200	
2025-784	11 ENC.-COLO.	203	ROCHE	93	ROCHE	57	43.254	1.920	4.44	34.600	51.900	
2025-784	11 ENC.-COLO.	219	ATELLICA	143	SIEMENS	28	40.025	2.029	5.07	32.000	48.000	
2025-784	11 ENC.-COLO.	220	Medica E.	130	MEDICA	14	35.357	1.797	5.08	28.300	42.400	
2025-784	12 HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	11	41.182	1.800	4.37	32.900	49.400	
2025-784	13 AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	71	38.034	1.923	5.06	30.400	45.600	
2025-785	5 DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	10	48.860	2.578	5.28	39.100	58.600	
2025-785	11 ENC.-COLO.	165	VITROS	63	KODAK	133	45.649	2.796	6.13	36.500	54.800	
2025-785	11 ENC.-COLO.	184	INTEGRA	93	ROCHE	26	38.889	1.792	4.61	31.100	46.700	
2025-785	11 ENC.-COLO.	184	INTEGRA	93	ROCHE	26	51.500	4.655	9.04	41.200	61.800	
2025-785	11 ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	29	50.800	2.389	4.70	40.600	61.000	
2025-785	11 ENC.-COLO.	191	RX-SERIES	126	RANDOX	30	48.400	5.891	12.17	38.700	58.100	
2025-785	11 ENC.-COLO.	203	ROCHE	93	ROCHE	57	50.639	1.924	3.80	40.500	60.800	
2025-785	11 ENC.-COLO.	219	ATELLICA	143	SIEMENS	28	49.850	2.476	4.97	39.900	59.800	
2025-785	11 ENC.-COLO.	220	Medica E.	130	MEDICA	14	44.500	2.196	4.93	35.600	53.400	

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE							NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2025-785	12	HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	11	50.545	1.924	3.81	40.400	60.700
2025-785	13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	71	39.992	2.141	5.35	32.000	48.000
014 CREATINE KINASE (CK)		CLIA TEST ID #: 385		EVALUATION CRITERIA: TARGET VALUE 20 %								
2025-781	3	KINETIC 37	165	VITROS	63	KODAK	69	318.261	24.034	7.55	255.000	382.000
2025-781	3	KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	13	390.385	20.292	5.20	312.000	468.000
2025-781	5	SZASZ-MOD.	219	ATELLICA	143	SIEMENS	20	431.947	15.122	3.50	346.000	518.000
2025-781	8	Hexokinase	203	ROCHE	93	ROCHE	11	430.545	11.492	2.67	344.000	517.000
2025-781	9	SIEMENS	38	SIEMENS DI	143	SIEMENS	20	437.000	11.832	2.71	350.000	524.000
2025-781	10	ENZYMATIC-	203	ROCHE	93	ROCHE	16	437.188	15.371	3.52	350.000	525.000
2025-782	3	KINETIC 37	165	VITROS	63	KODAK	69	250.956	16.641	6.63	201.000	301.000
2025-782	3	KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	13	278.000	16.115	5.80	222.000	334.000
2025-782	5	SZASZ-MOD.	219	ATELLICA	143	SIEMENS	20	304.550	8.003	2.63	244.000	365.000
2025-782	8	Hexokinase	203	ROCHE	93	ROCHE	11	305.727	6.062	1.98	245.000	367.000
2025-782	9	SIEMENS	38	SIEMENS DI	143	SIEMENS	20	310.600	7.599	2.45	248.000	373.000
2025-782	10	ENZYMATIC-	203	ROCHE	93	ROCHE	16	312.313	11.095	3.55	250.000	375.000
2025-783	3	KINETIC 37	165	VITROS	63	KODAK	69	110.913	7.529	6.79	89.000	133.000
2025-783	3	KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	13	107.000	5.805	5.42	86.000	128.000
2025-783	5	SZASZ-MOD.	219	ATELLICA	143	SIEMENS	20	120.789	3.518	2.91	97.000	145.000
2025-783	8	Hexokinase	203	ROCHE	93	ROCHE	11	121.091	2.778	2.29	97.000	145.000
2025-783	9	SIEMENS	38	SIEMENS DI	143	SIEMENS	20	119.684	1.893	1.58	96.000	144.000
2025-783	10	ENZYMATIC-	203	ROCHE	93	ROCHE	16	121.188	4.157	3.43	97.000	145.000
2025-784	3	KINETIC 37	165	VITROS	63	KODAK	69	35.529	3.061	8.61	28.000	43.000
2025-784	3	KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	13	33.769	2.454	7.27	27.000	41.000
2025-784	5	SZASZ-MOD.	219	ATELLICA	143	SIEMENS	20	39.950	3.369	8.43	32.000	48.000
2025-784	8	Hexokinase	203	ROCHE	93	ROCHE	11	39.545	1.076	2.72	32.000	47.000
2025-784	9	SIEMENS	38	SIEMENS DI	143	SIEMENS	20	37.421	1.533	4.10	30.000	45.000
2025-784	10	ENZYMATIC-	203	ROCHE	93	ROCHE	16	40.438	1.731	4.28	32.000	49.000

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
014	CREATINE KINASE (CK)	CLIA TEST ID #: 385	EVALUATION CRITERIA: TARGET VALUE 20 %									
2025-785	3 KINETIC 37	165 VITROS	63 KODAK	69	177.471	12.556	7.08	142.000	213.000			
2025-785	3 KINETIC 37	186 BECK. COUL	76 AU-BECKMAN	13	178.923	10.307	5.76	143.000	215.000			
2025-785	5 SZASZ-MOD.	219 ATELLICA	143 SIEMENS	20	199.350	3.825	1.92	159.000	239.000			
2025-785	8 Hexokinase	203 ROCHE	93 ROCHE	11	199.455	4.500	2.26	160.000	239.000			
2025-785	9 SIEMENS	38 SIEMENS DI	143 SIEMENS	20	201.900	5.813	2.88	162.000	242.000			
2025-785	10 ENZYMATIC-	203 ROCHE	93 ROCHE	16	201.750	5.321	2.64	161.000	242.000			
016	CREATININE	CLIA TEST ID #: 405	EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.20 {GREATER}									
2025-781	2 AK. PIC. N	191 RX-SERIES	126 RANDOX	19	4.842	0.358	7.39	4.360	5.330			
2025-781	4 ENZYMATIC	203 ROCHE	93 ROCHE	14	5.339	0.269	5.04	4.800	5.870			
2025-781	4 ENZYMATIC	220 Medica E.	130 MEDICA	17	5.604	0.217	3.87	5.040	6.160			
2025-781	6 KIN. ALK P	184 INTEGRA	93 ROCHE	14	5.278	0.212	4.02	4.750	5.810			
2025-781	6 KIN. ALK P	186 BECK. COUL	76 AU-BECKMAN	31	5.489	0.167	3.05	4.940	6.040			
2025-781	6 KIN. ALK P	197 ARCHITECT	1 ABBOTT	16	5.780	0.234	4.05	5.200	6.360			
2025-781	6 KIN. ALK P	203 ROCHE	93 ROCHE	29	5.319	0.255	4.80	4.790	5.850			
2025-781	8 IDMS-CREA	165 VITROS	63 KODAK	148	5.180	0.148	2.86	4.660	5.700			
2025-781	9 MODIFIED	219 ATELLICA	143 SIEMENS	27	5.529	0.233	4.21	4.980	6.080			
2025-781	10 JAFFE COMP	203 ROCHE	93 ROCHE	19	5.330	0.177	3.32	4.800	5.860			
2025-781	11 IDMS Jaffe	38 SIEMENS DI	143 SIEMENS	70	5.567	0.111	1.99	5.010	6.120			
2025-781	11 IDMS Jaffe	38 SIEMENS DI	143 SIEMENS	70	5.730	0.186	3.24	5.160	6.300			
2025-782	2 AK. PIC. N	191 RX-SERIES	126 RANDOX	19	3.533	0.126	3.55	3.180	3.890			
2025-782	4 ENZYMATIC	203 ROCHE	93 ROCHE	14	3.946	0.189	4.79	3.550	4.340			
2025-782	4 ENZYMATIC	220 Medica E.	130 MEDICA	17	4.016	0.084	2.09	3.610	4.420			
2025-782	6 KIN. ALK P	184 INTEGRA	93 ROCHE	14	3.870	0.114	2.95	3.480	4.260			
2025-782	6 KIN. ALK P	186 BECK. COUL	76 AU-BECKMAN	31	3.944	0.113	2.87	3.550	4.340			
2025-782	6 KIN. ALK P	197 ARCHITECT	1 ABBOTT	16	4.109	0.133	3.25	3.700	4.520			
2025-782	6 KIN. ALK P	203 ROCHE	93 ROCHE	29	3.911	0.172	4.39	3.520	4.300			
2025-782	8 IDMS-CREA	165 VITROS	63 KODAK	148	3.855	0.094	2.45	3.470	4.240			
2025-782	9 MODIFIED	219 ATELLICA	143 SIEMENS	27	3.942	0.167	4.25	3.550	4.340			

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY SUB: 10 ROUTINE GRP: 10 ROUTINE

ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-782	10	JAFFE COMP	203	ROCHE	93	ROCHE	19	3.916	0.119	3.05	3.520	4.310
2025-782	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	70	4.140	0.102	2.47	3.730	4.550
2025-782	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	70	4.097	0.125	3.04	3.690	4.510
016 CREATININE			CLIA TEST ID #: 405			EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.20 {GREATER}						
2025-783	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	19	1.531	0.135	8.80	1.330	1.730
2025-783	4	ENZYMATIC	203	ROCHE	93	ROCHE	14	1.662	0.082	4.91	1.460	1.860
2025-783	4	ENZYMATIC	220	Medica E.	130	MEDICA	17	1.678	0.079	4.71	1.480	1.880
2025-783	6	KIN. ALK P	184	INTEGRA	93	ROCHE	14	1.677	0.055	3.28	1.480	1.880
2025-783	6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	31	1.593	0.051	3.19	1.390	1.790
2025-783	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	16	1.551	0.050	3.22	1.350	1.750
2025-783	6	KIN. ALK P	203	ROCHE	93	ROCHE	29	1.638	0.069	4.24	1.440	1.840
2025-783	8	IDMS-CREA	165	VITROS	63	KODAK	148	1.610	0.041	2.54	1.410	1.810
2025-783	9	MODIFIED	219	ATELLICA	143	SIEMENS	27	1.585	0.094	5.91	1.380	1.780
2025-783	10	JAFFE COMP	203	ROCHE	93	ROCHE	19	1.635	0.055	3.36	1.430	1.830
2025-783	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	70	1.682	0.093	5.53	1.480	1.880
2025-783	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	70	1.747	0.037	2.11	1.550	1.950
2025-784	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	19	0.697	0.069	9.90	0.500	0.900
2025-784	4	ENZYMATIC	203	ROCHE	93	ROCHE	14	0.623	0.061	9.87	0.420	0.820
2025-784	4	ENZYMATIC	220	Medica E.	130	MEDICA	17	0.679	0.044	6.51	0.480	0.880
2025-784	6	KIN. ALK P	184	INTEGRA	93	ROCHE	14	0.649	0.040	6.16	0.450	0.850
2025-784	6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	31	0.575	0.045	7.81	0.370	0.770
2025-784	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	16	0.609	0.016	2.69	0.410	0.810
2025-784	6	KIN. ALK P	203	ROCHE	93	ROCHE	29	0.598	0.040	6.75	0.400	0.800
2025-784	8	IDMS-CREA	165	VITROS	63	KODAK	148	0.636	0.030	4.78	0.440	0.840
2025-784	9	MODIFIED	219	ATELLICA	143	SIEMENS	27	0.586	0.052	8.87	0.390	0.790
2025-784	10	JAFFE COMP	203	ROCHE	93	ROCHE	19	0.602	0.036	6.04	0.400	0.800
2025-784	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	70	0.703	0.029	4.08	0.500	0.900
2025-784	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	70	0.555	0.080	14.43	0.350	0.750

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
016	CREATININE	CLIA TEST ID #: 405				EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.20 {GREATER}					
2025-785	2 AK. PIC. N	191 RX-SERIES	126 RANDOX		19	2.394	0.159	6.63	2.150	2.630	
2025-785	4 ENZYMATIC	203 ROCHE	93 ROCHE		14	2.661	0.139	5.24	2.400	2.930	
2025-785	4 ENZYMATIC	220 Medica E.	130 MEDICA		17	2.655	0.068	2.55	2.390	2.920	
2025-785	6 KIN. ALK P	184 INTEGRA	93 ROCHE		14	2.621	0.092	3.49	2.360	2.880	
2025-785	6 KIN. ALK P	186 BECK. COUL	76 AU-BECKMAN		31	2.588	0.082	3.18	2.330	2.850	
2025-785	6 KIN. ALK P	197 ARCHITECT	1 ABBOTT		16	2.629	0.065	2.47	2.370	2.890	
2025-785	6 KIN. ALK P	203 ROCHE	93 ROCHE		29	2.615	0.113	4.33	2.350	2.880	
2025-785	8 IDMS-CREA	165 VITROS	63 KODAK		148	2.591	0.073	2.81	2.330	2.850	
2025-785	9 MODIFIED	219 ATELLICA	143 SIEMENS		27	2.608	0.115	4.40	2.350	2.870	
2025-785	10 JAFFE COMP	203 ROCHE	93 ROCHE		19	2.618	0.078	2.99	2.360	2.880	
2025-785	11 IDMS Jaffe	38 SIEMENS DI	143 SIEMENS		70	2.715	0.099	3.65	2.440	2.990	
2025-785	11 IDMS Jaffe	38 SIEMENS DI	143 SIEMENS		70	2.800	0.078	2.78	2.520	3.080	
017	GLUCOSE	CLIA TEST ID #: 415				EVALUATION CRITERIA: TARGET VALUE 8 % OR 6.00 {GREATER}					
2025-781	3 GL. OXI. C	165 VITROS	63 KODAK		150	123.240	3.356	2.72	113.000	133.000	
2025-781	5 HEXOKINASE	38 SIEMENS DI	143 SIEMENS		75	128.000	3.997	3.12	118.000	138.000	
2025-781	5 HEXOKINASE	186 BECK. COUL	76 AU-BECKMAN		31	120.033	2.429	2.02	110.000	130.000	
2025-781	5 HEXOKINASE	191 RX-SERIES	126 RANDOX		22	126.000	6.502	5.16	116.000	136.000	
2025-781	5 HEXOKINASE	191 RX-SERIES	126 RANDOX		22	127.333	5.793	4.55	117.000	138.000	
2025-781	5 HEXOKINASE	203 ROCHE	93 ROCHE		44	118.125	2.891	2.45	109.000	128.000	
2025-781	5 HEXOKINASE	203 ROCHE	93 ROCHE		44	119.605	2.895	2.42	110.000	129.000	
2025-781	5 HEXOKINASE	221 CS-400 DIR	157 Carolina		10	122.500	4.080	3.33	113.000	132.000	
2025-781	6 HEXOKI. CO	220 Medica E.	130 MEDICA		17	125.176	3.365	2.69	115.000	135.000	
2025-781	12 HEXOKINASE	184 INTEGRA	93 ROCHE		19	121.368	3.280	2.70	112.000	131.000	
2025-781	12 HEXOKINASE	197 ARCHITECT	1 ABBOTT		12	116.667	1.491	1.28	107.000	126.000	
2025-781	12 HEXOKINASE	203 ROCHE	93 ROCHE		23	119.217	2.519	2.11	110.000	129.000	
2025-781	12 HEXOKINASE	219 ATELLICA	143 SIEMENS		28	116.963	3.554	3.04	108.000	126.000	
2025-782	3 GL. OXI. C	165 VITROS	63 KODAK		150	93.919	2.656	2.83	86.000	101.000	
2025-782	5 HEXOKINASE	38 SIEMENS DI	143 SIEMENS		75	100.203	2.471	2.47	92.000	108.000	

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-782	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	31	93.097	2.069	2.22	86.000	101.000
2025-782	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	22	101.667	4.643	4.57	94.000	110.000
2025-782	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	22	99.682	4.665	4.68	92.000	108.000
2025-782	5	HEXOKINASE	203	ROCHE	93	ROCHE	44	92.791	2.006	2.16	85.000	100.000
2025-782	5	HEXOKINASE	203	ROCHE	93	ROCHE	44	91.750	3.666	4.00	84.000	99.000
2025-782	5	HEXOKINASE	221	CS-400 DIR	157	Carolina	10	96.500	3.828	3.97	89.000	104.000
2025-782	6	HEXOKI. CO	220	Medica E.	130	MEDICA	17	97.176	2.595	2.67	89.000	105.000
2025-782	12	HEXOKINASE	184	INTEGRA	93	ROCHE	19	94.526	2.370	2.51	87.000	102.000
2025-782	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	12	90.917	2.842	3.13	84.000	98.000
2025-782	12	HEXOKINASE	203	ROCHE	93	ROCHE	23	92.130	1.985	2.15	85.000	100.000
2025-782	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	28	90.821	2.854	3.14	84.000	98.000
017	GLUCOSE	CLIA TEST ID #: 415				EVALUATION CRITERIA: TARGET VALUE 8 % OR 6.00 {GREATER}						
2025-783	3	GL. OXI. C	165	VITROS	63	KODAK	150	48.723	1.643	3.37	43.000	55.000
2025-783	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	75	57.027	1.602	2.81	51.000	63.000
2025-783	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	31	52.258	1.217	2.33	46.000	58.000
2025-783	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	22	58.500	2.388	4.08	53.000	65.000
2025-783	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	22	58.333	4.028	6.90	52.000	64.000
2025-783	5	HEXOKINASE	203	ROCHE	93	ROCHE	44	50.500	1.414	2.80	45.000	57.000
2025-783	5	HEXOKINASE	203	ROCHE	93	ROCHE	44	51.929	1.203	2.32	46.000	58.000
2025-783	5	HEXOKINASE	221	CS-400 DIR	157	Carolina	10	56.500	1.432	2.53	51.000	63.000
2025-783	6	HEXOKI. CO	220	Medica E.	130	MEDICA	17	55.235	1.767	3.20	49.000	61.000
2025-783	12	HEXOKINASE	184	INTEGRA	93	ROCHE	19	53.000	1.686	3.18	47.000	59.000
2025-783	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	12	50.500	1.118	2.21	45.000	57.000
2025-783	12	HEXOKINASE	203	ROCHE	93	ROCHE	23	52.174	1.049	2.01	46.000	58.000
2025-783	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	28	51.519	1.686	3.27	46.000	58.000
2025-784	3	GL. OXI. C	165	VITROS	63	KODAK	150	32.791	1.048	3.20	27.000	39.000
2025-784	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	75	39.240	1.384	3.53	33.000	45.000
2025-784	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	31	35.355	1.309	3.70	29.000	41.000
2025-784	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	22	40.333	2.867	7.11	34.000	46.000

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-784	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	22	41.909	1.856	4.43	36.000	48.000
2025-784	5	HEXOKINASE	203	ROCHE	93	ROCHE	44	34.000	1.000	2.94	28.000	40.000
2025-784	5	HEXOKINASE	203	ROCHE	93	ROCHE	44	35.070	1.043	2.97	29.000	41.000
2025-784	5	HEXOKINASE	221	CS-400 DIR	157	Carolina	10	40.300	1.676	4.16	34.000	46.000
2025-784	6	HEXOKI. CO	220	Medica E.	130	MEDICA	17	38.235	1.832	4.79	32.000	44.000
2025-784	12	HEXOKINASE	184	INTEGRA	93	ROCHE	19	35.895	1.372	3.82	30.000	42.000
2025-784	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	12	33.583	0.862	2.57	28.000	40.000
2025-784	12	HEXOKINASE	203	ROCHE	93	ROCHE	23	35.000	0.978	2.79	29.000	41.000
2025-784	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	28	35.321	1.136	3.21	29.000	41.000
017	GLUCOSE		CLIA TEST ID #: 415			EVALUATION CRITERIA: TARGET VALUE 8 % OR 6.00 {GREATER}						
2025-785	3	GL. OXI. C	165	VITROS	63	KODAK	150	68.426	2.014	2.94	62.000	74.000
2025-785	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	75	74.919	1.858	2.48	69.000	81.000
2025-785	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	31	69.581	1.810	2.60	64.000	76.000
2025-785	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	22	76.091	2.922	3.84	70.000	82.000
2025-785	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	22	75.667	3.859	5.10	70.000	82.000
2025-785	5	HEXOKINASE	203	ROCHE	93	ROCHE	44	69.186	1.589	2.30	63.000	75.000
2025-785	5	HEXOKINASE	203	ROCHE	93	ROCHE	44	67.375	1.996	2.96	61.000	73.000
2025-785	5	HEXOKINASE	221	CS-400 DIR	157	Carolina	10	74.500	1.857	2.49	69.000	81.000
2025-785	6	HEXOKI. CO	220	Medica E.	130	MEDICA	17	73.059	1.474	2.02	67.000	79.000
2025-785	12	HEXOKINASE	184	INTEGRA	93	ROCHE	19	70.000	2.103	3.00	64.000	76.000
2025-785	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	12	67.083	1.498	2.23	61.000	73.000
2025-785	12	HEXOKINASE	203	ROCHE	93	ROCHE	23	68.652	1.735	2.53	63.000	75.000
2025-785	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	28	68.250	2.165	3.17	62.000	74.000
018	IRON, TOTAL		CLIA TEST ID #: 425			EVALUATION CRITERIA: TARGET VALUE 15 %						
2025-781	4	COULOMETR.	165	VITROS	63	KODAK	20	302.750	8.797	2.91	257.000	348.000
2025-781	6	FERRAC/FER	219	ATELLICA	143	SIEMENS	10	263.000	7.589	2.89	224.000	302.000
2025-782	4	COULOMETR.	165	VITROS	63	KODAK	20	212.800	8.122	3.82	181.000	245.000
2025-782	6	FERRAC/FER	219	ATELLICA	143	SIEMENS	10	195.300	5.763	2.95	166.000	225.000

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
018	IRON, TOTAL	CLIA TEST ID #: 425				EVALUATION CRITERIA: TARGET VALUE 15 %						
2025-783	4 COULOMETR.	165	VITROS	63	KODAK	20	99.950	3.309	3.31	85.000	115.000	
2025-783	6 FERRAC/FER	219	ATELLICA	143	SIEMENS	10	95.900	3.360	3.50	82.000	110.000	
2025-784	4 COULOMETR.	165	VITROS	63	KODAK	20	59.350	3.772	6.36	50.000	68.000	
2025-784	6 FERRAC/FER	219	ATELLICA	143	SIEMENS	10	54.000	1.844	3.41	46.000	62.000	
2025-785	4 COULOMETR.	165	VITROS	63	KODAK	20	144.600	5.200	3.60	123.000	166.000	
2025-785	6 FERRAC/FER	219	ATELLICA	143	SIEMENS	10	137.300	3.662	2.67	117.000	158.000	
019	LACTASE DEHY. (LDH)	CLIA TEST ID #: 435										
2025-781	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	17	459.353	29.904	6.51	390.000	528.000	
2025-781	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	17	549.750	19.266	3.50	467.000	632.000	
2025-781	6 NADH	203	ROCHE	93	ROCHE	28	569.296	19.440	3.41	484.000	655.000	
2025-781	6 NADH	219	ATELLICA	143	SIEMENS	20	557.211	13.613	2.44	474.000	641.000	
2025-781	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	27	556.889	22.185	3.98	473.000	640.000	
2025-781	9 LDH1	165	VITROS	63	KODAK	65	677.844	28.640	4.23	576.000	780.000	
2025-782	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	17	401.750	29.861	7.43	341.000	462.000	
2025-782	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	17	327.941	24.077	7.34	279.000	377.000	
2025-782	6 NADH	203	ROCHE	93	ROCHE	28	407.926	12.806	3.14	347.000	469.000	
2025-782	6 NADH	219	ATELLICA	143	SIEMENS	20	400.000	9.000	2.25	340.000	460.000	
2025-782	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	27	397.519	12.796	3.22	338.000	457.000	
2025-782	9 LDH1	165	VITROS	63	KODAK	65	493.723	11.719	2.37	420.000	568.000	
2025-783	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	17	129.000	9.864	7.65	110.000	148.000	
2025-783	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	17	155.750	5.629	3.61	132.000	179.000	
2025-783	6 NADH	203	ROCHE	93	ROCHE	28	160.074	4.690	2.93	136.000	184.000	
2025-783	6 NADH	219	ATELLICA	143	SIEMENS	20	160.300	5.684	3.55	136.000	184.000	
2025-783	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	27	153.704	5.339	3.47	131.000	177.000	
2025-783	9 LDH1	165	VITROS	63	KODAK	65	201.500	6.080	3.02	171.000	232.000	

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
019	LACTASE DEHY. (LDH)	CLIA TEST ID #: 435				EVALUATION CRITERIA: TARGET VALUE 15 %					
2025-784	3 KINETIC-37	186 BECK. COUL	76 AU-BECKMAN		17	49.000	3.082	6.29	42.000	56.000	
2025-784	3 KINETIC-37	186 BECK. COUL	76 AU-BECKMAN		17	42.294	3.321	7.85	36.000	49.000	
2025-784	6 NADH	203 ROCHE	93 ROCHE		28	53.037	2.151	4.06	45.000	61.000	
2025-784	6 NADH	219 ATELLICA	143 SIEMENS		20	52.850	1.740	3.29	45.000	61.000	
2025-784	7 SIEMENS 37	38 SIEMENS DI	143 SIEMENS		27	50.778	4.833	9.52	43.000	58.000	
2025-784	9 LDH1	165 VITROS	63 KODAK		65	70.156	6.411	9.14	60.000	81.000	
2025-785	3 KINETIC-37	186 BECK. COUL	76 AU-BECKMAN		17	212.824	15.982	7.51	181.000	245.000	
2025-785	3 KINETIC-37	186 BECK. COUL	76 AU-BECKMAN		17	257.000	10.124	3.94	218.000	296.000	
2025-785	6 NADH	203 ROCHE	93 ROCHE		28	266.037	8.284	3.11	226.000	306.000	
2025-785	6 NADH	219 ATELLICA	143 SIEMENS		20	264.900	7.266	2.74	225.000	305.000	
2025-785	7 SIEMENS 37	38 SIEMENS DI	143 SIEMENS		27	258.074	10.670	4.13	219.000	297.000	
2025-785	9 LDH1	165 VITROS	63 KODAK		65	333.438	7.812	2.34	283.000	383.000	
021	MAGNESIUM	CLIA TEST ID #: 455									
2025-781	5 COLOR./K E	165 VITROS	63 KODAK		30	5.237	0.187	3.57	4.500	6.000	
2025-781	8 XYLIDYL B.	203 ROCHE	93 ROCHE		11	4.791	0.150	3.14	4.100	5.500	
2025-781	8 XYLIDYL B.	219 ATELLICA	143 SIEMENS		11	4.727	0.293	6.19	4.000	5.400	
2025-782	5 COLOR./K E	165 VITROS	63 KODAK		30	4.013	0.112	2.78	3.400	4.600	
2025-782	8 XYLIDYL B.	203 ROCHE	93 ROCHE		11	3.736	0.077	2.06	3.200	4.300	
2025-782	8 XYLIDYL B.	219 ATELLICA	143 SIEMENS		11	3.618	0.204	5.63	3.100	4.200	
2025-783	5 COLOR./K E	165 VITROS	63 KODAK		30	2.210	0.091	4.11	1.900	2.500	
2025-783	8 XYLIDYL B.	203 ROCHE	93 ROCHE		11	2.091	0.051	2.46	1.800	2.400	
2025-783	8 XYLIDYL B.	219 ATELLICA	143 SIEMENS		11	1.991	0.116	5.85	1.700	2.300	
2025-784	5 COLOR./K E	165 VITROS	63 KODAK		30	1.433	0.070	4.88	1.200	1.600	
2025-784	8 XYLIDYL B.	203 ROCHE	93 ROCHE		11	1.400	0.000	0.00	1.200	1.600	
2025-784	8 XYLIDYL B.	219 ATELLICA	143 SIEMENS		11	1.336	0.064	4.81	1.100	1.500	

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
021	MAGNESIUM	CLIA TEST ID #: 455				EVALUATION CRITERIA: TARGET VALUE 15 %						
2025-785	5	COLOR./K E	165	VITROS	63	KODAK	30	2.963	0.114	3.85	2.500 3.400	
2025-785	8	XYLIDYL B.	203	ROCHE	93	ROCHE	11	2.791	0.079	2.84	2.400 3.200	
2025-785	8	XYLIDYL B.	219	ATELLICA	143	SIEMENS	11	2.664	0.137	5.13	2.300 3.100	
022	POTASSIUM	CLIA TEST ID #: 465				EVALUATION CRITERIA: TARGET VALUE 0.30						
2025-781	3	ISE DILUT.	184	INTEGRA	93	ROCHE	26	5.185	0.099	1.91	4.900 5.500	
2025-781	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	30	5.086	0.073	1.43	4.800 5.400	
2025-781	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	14	5.221	0.086	1.65	4.900 5.500	
2025-781	3	ISE DILUT.	203	ROCHE	93	ROCHE	69	5.187	0.088	1.70	4.900 5.500	
2025-781	4	ISE UNLIL.	165	VITROS	63	KODAK	51	5.142	0.104	2.02	4.800 5.400	
2025-781	4	ISE UNLIL.	165	VITROS	156	Kit 32	97	5.158	0.096	1.87	4.900 5.500	
2025-781	4	ISE UNLIL.	191	RX-SERIES	126	RANLIL	26	4.950	0.161	3.25	4.700 5.300	
2025-781	4	ISE UNLIL.	191	RX-SERIES	126	RANLIL	26	5.077	0.193	3.80	4.800 5.400	
2025-781	4	ISE UNLIL.	220	Medica E.	130	MEDICA	16	5.044	0.146	2.89	4.700 5.300	
2025-781	5	IMT	219	ATELLICA	143	SIEMENS	28	5.044	0.110	2.18	4.700 5.300	
2025-781	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	73	5.107	0.093	1.83	4.800 5.400	
2025-782	3	ISE DILUT.	184	INTEGRA	93	ROCHE	26	4.165	0.073	1.75	3.900 4.500	
2025-782	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	30	4.117	0.073	1.78	3.800 4.400	
2025-782	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	14	4.143	0.155	3.73	3.800 4.400	
2025-782	3	ISE DILUT.	203	ROCHE	93	ROCHE	69	4.193	0.086	2.04	3.900 4.500	
2025-782	4	ISE UNLIL.	165	VITROS	63	KODAK	51	4.138	0.072	1.74	3.800 4.400	
2025-782	4	ISE UNLIL.	165	VITROS	156	Kit 32	97	4.140	0.071	1.73	3.800 4.400	
2025-782	4	ISE UNLIL.	191	RX-SERIES	126	RANLIL	26	4.150	0.142	3.42	3.900 4.500	
2025-782	4	ISE UNLIL.	191	RX-SERIES	126	RANLIL	26	3.983	0.146	3.67	3.700 4.300	
2025-782	4	ISE UNLIL.	220	Medica E.	130	MEDICA	16	4.000	0.071	1.77	3.700 4.300	
2025-782	5	IMT	219	ATELLICA	143	SIEMENS	28	4.021	0.072	1.80	3.700 4.300	
2025-782	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	73	4.103	0.073	1.78	3.800 4.400	
2025-783	3	ISE DILUT.	184	INTEGRA	93	ROCHE	26	2.654	0.050	1.88	2.400 3.000	

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-783	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	30	2.663	0.060	2.27	2.400	3.000
2025-783	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	14	2.636	0.048	1.82	2.300	2.900
2025-783	3	ISE DILUT.	203	ROCHE	93	ROCHE	69	2.672	0.068	2.54	2.400	3.000
2025-783	4	ISE UNDIL.	165	VITROS	63	KODAK	51	2.612	0.055	2.10	2.300	2.900
2025-783	4	ISE UNDIL.	165	VITROS	156	Kit 32	97	2.612	0.044	1.67	2.300	2.900
2025-783	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	26	2.752	0.114	4.13	2.500	3.100
2025-783	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	26	2.717	0.107	3.93	2.400	3.000
2025-783	4	ISE UNDIL.	220	Medica E.	130	MEDICA	16	2.550	0.061	2.40	2.300	2.900
2025-783	5	IMT	219	ATELLICA	143	SIEMENS	28	2.550	0.063	2.46	2.300	2.900
2025-783	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	73	2.572	0.063	2.46	2.300	2.900
022	POTASSIUM	CLIA TEST ID #: 465				EVALUATION CRITERIA: TARGET VALUE 0.30						
2025-784	3	ISE DILUT.	184	INTEGRA	93	ROCHE	26	2.031	0.054	2.65	1.700	2.300
2025-784	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	30	2.103	0.055	2.60	1.800	2.400
2025-784	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	14	2.014	0.052	2.56	1.700	2.300
2025-784	3	ISE DILUT.	203	ROCHE	93	ROCHE	69	2.068	0.071	3.44	1.800	2.400
2025-784	4	ISE UNDIL.	165	VITROS	63	KODAK	51	2.012	0.043	2.12	1.700	2.300
2025-784	4	ISE UNDIL.	165	VITROS	156	Kit 32	97	2.005	0.036	1.81	1.700	2.300
2025-784	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	26	2.188	0.127	5.83	1.900	2.500
2025-784	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	26	2.200	0.082	3.71	1.900	2.500
2025-784	4	ISE UNDIL.	220	Medica E.	130	MEDICA	16	1.956	0.061	3.11	1.700	2.300
2025-784	5	IMT	219	ATELLICA	143	SIEMENS	28	1.961	0.056	2.84	1.700	2.300
2025-784	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	73	1.939	0.057	2.92	1.600	2.200
2025-785	3	ISE DILUT.	184	INTEGRA	93	ROCHE	26	3.273	0.059	1.81	3.000	3.600
2025-785	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	30	3.253	0.067	2.06	3.000	3.600
2025-785	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	14	3.243	0.082	2.53	2.900	3.500
2025-785	3	ISE DILUT.	203	ROCHE	93	ROCHE	69	3.294	0.062	1.87	3.000	3.600
2025-785	4	ISE UNDIL.	165	VITROS	63	KODAK	51	3.249	0.072	2.23	2.900	3.500
2025-785	4	ISE UNDIL.	165	VITROS	156	Kit 32	97	3.234	0.066	2.03	2.900	3.500
2025-785	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	26	3.319	0.136	4.10	3.000	3.600

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-785	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	26	3.300	0.129	3.91	3.000 3.600	
2025-785	4	ISE UNDIL.	220	Medica E.	130	MEDICA	16	3.153	0.062	1.96	2.900 3.500	
2025-785	5	IMT	219	ATELLICA	143	SIEMENS	28	3.182	0.066	2.07	2.900 3.500	
2025-785	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	73	3.204	0.063	1.98	2.900 3.500	
023	SODIUM		CLIA TEST ID #: 475				EVALUATION CRITERIA: TARGET VALUE 4.00					
2025-781	3	ISE DILUTE	184	INTEGRA	93	ROCHE	26	155.308	2.784	1.79	151.000 159.000	
2025-781	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	30	154.967	2.273	1.47	151.000 159.000	
2025-781	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	11	157.364	2.186	1.39	153.000 161.000	
2025-781	3	ISE DILUTE	203	ROCHE	93	ROCHE	63	155.302	2.909	1.87	151.000 159.000	
2025-781	4	ISE UNDIL.	165	VITROS	63	KODAK	48	158.021	3.072	1.94	154.000 162.000	
2025-781	4	ISE UNDIL.	165	VITROS	156	Kit 32	100	158.800	2.871	1.81	155.000 163.000	
2025-781	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	26	155.760	2.804	1.80	152.000 160.000	
2025-781	4	ISE UNDIL.	220	Medica E.	130	MEDICA	16	155.313	4.369	2.81	151.000 159.000	
2025-781	5	IMT	197	ARCHITECT	1	ABBOTT	10	155.600	3.747	2.41	152.000 160.000	
2025-781	5	IMT	219	ATELLICA	143	SIEMENS	28	154.407	3.022	1.96	150.000 158.000	
2025-781	5	IMT	219	ATELLICA	143	SIEMENS	28	149.714	2.433	1.62	146.000 154.000	
2025-781	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	74	155.714	2.433	1.56	152.000 160.000	
2025-781	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	74	155.264	2.315	1.49	151.000 159.000	
2025-782	3	ISE DILUTE	184	INTEGRA	93	ROCHE	26	145.654	1.980	1.36	142.000 150.000	
2025-782	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	30	146.533	2.579	1.76	143.000 151.000	
2025-782	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	11	148.182	5.340	3.60	144.000 152.000	
2025-782	3	ISE DILUTE	203	ROCHE	93	ROCHE	63	146.683	2.805	1.91	143.000 151.000	
2025-782	4	ISE UNDIL.	165	VITROS	63	KODAK	48	147.104	2.210	1.50	143.000 151.000	
2025-782	4	ISE UNDIL.	165	VITROS	156	Kit 32	100	147.182	2.129	1.45	143.000 151.000	
2025-782	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	26	146.462	3.565	2.43	142.000 150.000	
2025-782	4	ISE UNDIL.	220	Medica E.	130	MEDICA	16	145.875	2.342	1.61	142.000 150.000	
2025-782	5	IMT	197	ARCHITECT	1	ABBOTT	10	146.200	2.227	1.52	142.000 150.000	
2025-782	5	IMT	219	ATELLICA	143	SIEMENS	28	141.429	1.400	0.99	137.000 145.000	
2025-782	5	IMT	219	ATELLICA	143	SIEMENS	28	144.929	2.329	1.61	141.000 149.000	

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2025-782	6 QUICK LYTE	38 SIEMENS DI	143	SIEMENS	74	147.384	2.470	1.68	143.000	151.000	
2025-782	6 QUICK LYTE	38 SIEMENS DI	143	SIEMENS	74	147.429	2.060	1.40	143.000	151.000	
023 SODIUM		CLIA TEST ID #: 475	EVALUATION CRITERIA: TARGET VALUE 4.00								
2025-783	3 ISE DILUTE	184 INTEGRA	93	ROCHE	26	131.000	1.922	1.47	127.000	135.000	
2025-783	3 ISE DILUTE	186 BECK. COUL	76	AU-BECKMAN	30	130.483	1.405	1.08	126.000	134.000	
2025-783	3 ISE DILUTE	197 ARCHITECT	1	ABBOTT	11	131.273	2.093	1.59	127.000	135.000	
2025-783	3 ISE DILUTE	203 ROCHE	93	ROCHE	63	130.571	2.301	1.76	127.000	135.000	
2025-783	4 ISE UNLIL.	165 VITROS	63	KODAK	48	129.149	1.978	1.53	125.000	133.000	
2025-783	4 ISE UNLIL.	165 VITROS	156	Kit 32	100	129.210	1.681	1.30	125.000	133.000	
2025-783	4 ISE UNLIL.	191 RX-SERIES	126	RANDOX	26	131.462	3.895	2.96	127.000	135.000	
2025-783	4 ISE UNLIL.	220 Medica E.	130	MEDICA	16	130.625	1.576	1.21	127.000	135.000	
2025-783	5 IMT	197 ARCHITECT	1	ABBOTT	10	129.600	2.764	2.13	126.000	134.000	
2025-783	5 IMT	219 ATELLICA	143	SIEMENS	28	130.593	2.182	1.67	127.000	135.000	
2025-783	5 IMT	219 ATELLICA	143	SIEMENS	28	129.429	1.917	1.48	125.000	133.000	
2025-783	6 QUICK LYTE	38 SIEMENS DI	143	SIEMENS	74	130.429	1.400	1.07	126.000	134.000	
2025-783	6 QUICK LYTE	38 SIEMENS DI	143	SIEMENS	74	132.630	1.913	1.44	129.000	137.000	
2025-784	3 ISE DILUTE	184 INTEGRA	93	ROCHE	26	126.077	1.999	1.59	122.000	130.000	
2025-784	3 ISE DILUTE	186 BECK. COUL	76	AU-BECKMAN	30	125.800	1.720	1.37	122.000	130.000	
2025-784	3 ISE DILUTE	197 ARCHITECT	1	ABBOTT	11	126.091	2.429	1.93	122.000	130.000	
2025-784	3 ISE DILUTE	203 ROCHE	93	ROCHE	63	125.556	2.166	1.73	122.000	130.000	
2025-784	4 ISE UNLIL.	165 VITROS	63	KODAK	48	124.104	1.794	1.45	120.000	128.000	
2025-784	4 ISE UNLIL.	165 VITROS	156	Kit 32	100	123.735	1.482	1.20	120.000	128.000	
2025-784	4 ISE UNLIL.	191 RX-SERIES	126	RANDOX	26	126.000	2.298	1.82	122.000	130.000	
2025-784	4 ISE UNLIL.	220 Medica E.	130	MEDICA	16	124.813	2.007	1.61	121.000	129.000	
2025-784	5 IMT	197 ARCHITECT	1	ABBOTT	10	125.100	2.587	2.07	121.000	129.000	
2025-784	5 IMT	219 ATELLICA	143	SIEMENS	28	125.714	1.829	1.46	122.000	130.000	
2025-784	5 IMT	219 ATELLICA	143	SIEMENS	28	126.036	2.129	1.69	122.000	130.000	
2025-784	6 QUICK LYTE	38 SIEMENS DI	143	SIEMENS	74	125.000	1.690	1.35	121.000	129.000	
2025-784	6 QUICK LYTE	38 SIEMENS DI	143	SIEMENS	74	128.247	1.893	1.48	124.000	132.000	

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
023	SODIUM	CLIA TEST ID #: 475				EVALUATION CRITERIA: TARGET VALUE 4.00					
2025-785	3 ISE DILUTE	184 INTEGRA	93	ROCHE	26	136.038	1.765	1.30	132.000	140.000	
2025-785	3 ISE DILUTE	186 BECK. COUL	76	AU-BECKMAN	30	136.600	2.403	1.76	133.000	141.000	
2025-785	3 ISE DILUTE	197 ARCHITECT	1	ABBOTT	11	136.545	1.777	1.30	133.000	141.000	
2025-785	3 ISE DILUTE	203 ROCHE	93	ROCHE	63	136.190	1.999	1.47	132.000	140.000	
2025-785	4 ISE UNLIL.	165 VITROS	63	KODAK	48	135.708	2.081	1.53	132.000	140.000	
2025-785	4 ISE UNLIL.	165 VITROS	156	Kit 32	100	135.586	1.995	1.47	132.000	140.000	
2025-785	4 ISE UNLIL.	191 RX-SERIES	126	RANLIX	26	135.960	2.068	1.52	132.000	140.000	
2025-785	4 ISE UNLIL.	220 Medica E.	130	MEDICA	16	136.063	2.164	1.59	132.000	140.000	
2025-785	5 IMT	197 ARCHITECT	1	ABBOTT	10	136.800	2.482	1.81	133.000	141.000	
2025-785	5 IMT	219 ATELLICA	143	SIEMENS	28	135.893	2.257	1.66	132.000	140.000	
2025-785	5 IMT	219 ATELLICA	143	SIEMENS	28	134.000	1.512	1.13	130.000	138.000	
2025-785	6 QUICK LYTE	38 SIEMENS DI	143	SIEMENS	74	138.014	1.847	1.34	134.000	142.000	
2025-785	6 QUICK LYTE	38 SIEMENS DI	143	SIEMENS	74	136.571	2.611	1.91	133.000	141.000	
024	TOTAL PROTEIN	CLIA TEST ID #: 485				EVALUATION CRITERIA: TARGET VALUE 8 %					
2025-781	1 BIURET	38 SIEMENS DI	143	SIEMENS	73	7.394	0.186	2.52	6.800	8.000	
2025-781	1 BIURET	165 VITROS	63	KODAK	133	7.011	0.183	2.61	6.400	7.600	
2025-781	1 BIURET	184 INTEGRA	93	ROCHE	16	6.856	0.194	2.82	6.300	7.400	
2025-781	1 BIURET	186 BECK. COUL	76	AU-BECKMAN	28	7.157	0.166	2.31	6.600	7.700	
2025-781	1 BIURET	191 RX-SERIES	126	RANLIX	23	7.109	0.243	3.42	6.500	7.700	
2025-781	1 BIURET	197 ARCHITECT	1	ABBOTT	18	7.317	0.142	1.95	6.700	7.900	
2025-781	1 BIURET	203 ROCHE	93	ROCHE	53	7.119	0.178	2.50	6.500	7.700	
2025-781	1 BIURET	219 ATELLICA	143	SIEMENS	28	7.193	0.214	2.98	6.600	7.800	
2025-781	1 BIURET	220 Medica E.	130	MEDICA	14	6.886	0.261	3.80	6.300	7.400	
2025-781	3 BIURET COL	203 ROCHE	93	ROCHE	17	7.106	0.126	1.77	6.500	7.700	
2025-782	1 BIURET	38 SIEMENS DI	143	SIEMENS	73	6.088	0.158	2.59	5.600	6.600	
2025-782	1 BIURET	165 VITROS	63	KODAK	133	5.815	0.135	2.32	5.300	6.300	
2025-782	1 BIURET	184 INTEGRA	93	ROCHE	16	5.631	0.149	2.64	5.200	6.100	
2025-782	1 BIURET	186 BECK. COUL	76	AU-BECKMAN	28	5.864	0.126	2.15	5.400	6.300	

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-782	1	BIURET	191	RX-SERIES	126	RANDOX	23	5.830	0.180	3.09	5.400	6.300
2025-782	1	BIURET	197	ARCHITECT	1	ABBOTT	18	6.039	0.138	2.29	5.600	6.500
2025-782	1	BIURET	203	ROCHE	93	ROCHE	53	5.894	0.138	2.34	5.400	6.400
2025-782	1	BIURET	219	ATELLICA	143	SIEMENS	28	5.857	0.215	3.66	5.400	6.300
2025-782	1	BIURET	220	Medica E.	130	MEDICA	14	5.686	0.151	2.65	5.200	6.100
2025-782	3	BIURET COL	203	ROCHE	93	ROCHE	17	5.847	0.104	1.77	5.400	6.300
024 TOTAL PROTEIN		CLIA TEST ID #: 485				EVALUATION CRITERIA: TARGET VALUE 8 %						
2025-783	1	BIURET	38	SIEMENS DI	143	SIEMENS	73	4.058	0.096	2.38	3.700	4.400
2025-783	1	BIURET	165	VITROS	63	KODAK	133	4.015	0.096	2.38	3.700	4.300
2025-783	1	BIURET	184	INTEGRA	93	ROCHE	16	3.788	0.132	3.48	3.500	4.100
2025-783	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	28	3.889	0.082	2.10	3.600	4.200
2025-783	1	BIURET	191	RX-SERIES	126	RANDOX	23	3.900	0.138	3.55	3.600	4.200
2025-783	1	BIURET	197	ARCHITECT	1	ABBOTT	18	3.961	0.059	1.49	3.600	4.300
2025-783	1	BIURET	203	ROCHE	93	ROCHE	53	3.928	0.120	3.06	3.600	4.200
2025-783	1	BIURET	219	ATELLICA	143	SIEMENS	28	3.900	0.151	3.88	3.600	4.200
2025-783	1	BIURET	220	Medica E.	130	MEDICA	14	3.821	0.147	3.85	3.500	4.100
2025-783	3	BIURET COL	203	ROCHE	93	ROCHE	17	3.900	0.103	2.64	3.600	4.200
2025-784	1	BIURET	38	SIEMENS DI	143	SIEMENS	73	3.228	0.080	2.49	3.000	3.500
2025-784	1	BIURET	165	VITROS	63	KODAK	133	3.229	0.082	2.54	3.000	3.500
2025-784	1	BIURET	184	INTEGRA	93	ROCHE	16	2.975	0.090	3.03	2.700	3.200
2025-784	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	28	3.093	0.084	2.72	2.800	3.300
2025-784	1	BIURET	191	RX-SERIES	126	RANDOX	23	3.117	0.113	3.62	2.900	3.400
2025-784	1	BIURET	197	ARCHITECT	1	ABBOTT	18	3.106	0.070	2.27	2.900	3.400
2025-784	1	BIURET	203	ROCHE	93	ROCHE	53	3.123	0.094	3.02	2.900	3.400
2025-784	1	BIURET	219	ATELLICA	143	SIEMENS	28	3.086	0.130	4.22	2.800	3.300
2025-784	1	BIURET	220	Medica E.	130	MEDICA	14	3.029	0.148	4.90	2.800	3.300
2025-784	3	BIURET COL	203	ROCHE	93	ROCHE	17	3.082	0.086	2.78	2.800	3.300
2025-785	1	BIURET	38	SIEMENS DI	143	SIEMENS	73	4.905	0.116	2.36	4.500	5.300

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
2025-785	1	BIURET	165 VITROS	63	KODAK	133	4.776	0.100	2.10	4.400	5.200	
2025-785	1	BIURET	184 INTEGRA	93	ROCHE	16	4.594	0.148	3.22	4.200	5.000	
2025-785	1	BIURET	186 BECK. COUL	76	AU-BECKMAN	28	4.704	0.115	2.44	4.300	5.100	
2025-785	1	BIURET	191 RX-SERIES	126	RANDOX	23	4.678	0.141	3.02	4.300	5.100	
2025-785	1	BIURET	197 ARCHITECT	1	ABBOTT	18	4.771	0.057	1.20	4.400	5.200	
2025-785	1	BIURET	203 ROCHE	93	ROCHE	53	4.743	0.139	2.94	4.400	5.100	
2025-785	1	BIURET	219 ATELLICA	143	SIEMENS	28	4.725	0.182	3.86	4.300	5.100	
2025-785	1	BIURET	220 Medica E.	130	MEDICA	14	4.636	0.226	4.87	4.300	5.000	
2025-785	3	BIURET COL	203 ROCHE	93	ROCHE	17	4.724	0.116	2.47	4.300	5.100	
025 TRIGLYCERIDES			CLIA TEST ID #: 495			EVALUATION CRITERIA: TARGET VALUE 15 %						
2025-781	2	ENZ. COLO.	165 VITROS	63	KODAK	136	214.985	10.411	4.84	183.000	247.000	
2025-781	2	ENZ. COLO.	184 INTEGRA	93	ROCHE	12	184.000	5.307	2.88	156.000	212.000	
2025-781	2	ENZ. COLO.	203 ROCHE	93	ROCHE	37	184.389	3.889	2.11	157.000	212.000	
2025-781	2	ENZ. COLO.	220 Medica E.	130	MEDICA	14	169.286	7.823	4.62	144.000	195.000	
2025-781	4	ENZ. (GPD)	38 SIEMENS DI	143	SIEMENS	72	181.423	4.212	2.32	154.000	209.000	
2025-781	5	HANTZCH-C)	197 ARCHITECT	1	ABBOTT	12	179.250	4.361	2.43	152.000	206.000	
2025-781	9	GPO TRIND.	186 BECK. COUL	76	AU-BECKMAN	29	190.214	4.499	2.37	162.000	219.000	
2025-781	9	GPO TRIND.	191 RX-SERIES	126	RANDOX	24	168.667	11.025	6.54	143.000	194.000	
2025-781	9	GPO TRIND.	191 RX-SERIES	126	RANDOX	24	185.826	8.967	4.83	158.000	214.000	
2025-781	10	ENZYM. GPO	184 INTEGRA	93	ROCHE	12	183.917	5.235	2.85	156.000	212.000	
2025-781	10	ENZYM. GPO	203 ROCHE	93	ROCHE	29	182.103	5.148	2.83	155.000	209.000	
2025-781	10	ENZYM. GPO	219 ATELLICA	143	SIEMENS	28	193.593	5.852	3.02	165.000	223.000	
2025-782	2	ENZ. COLO.	165 VITROS	63	KODAK	136	174.074	7.815	4.49	148.000	200.000	
2025-782	2	ENZ. COLO.	184 INTEGRA	93	ROCHE	12	155.083	3.013	1.94	132.000	178.000	
2025-782	2	ENZ. COLO.	203 ROCHE	93	ROCHE	37	154.139	3.425	2.22	131.000	177.000	
2025-782	2	ENZ. COLO.	220 Medica E.	130	MEDICA	14	141.214	4.554	3.22	120.000	162.000	
2025-782	4	ENZ. (GPD)	38 SIEMENS DI	143	SIEMENS	72	148.873	3.749	2.52	127.000	171.000	
2025-782	5	HANTZCH-C)	197 ARCHITECT	1	ABBOTT	12	148.167	5.383	3.63	126.000	170.000	
2025-782	9	GPO TRIND.	186 BECK. COUL	76	AU-BECKMAN	29	156.179	3.873	2.48	133.000	180.000	

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-782	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	24	154.913	5.064	3.27	132.000	178.000
2025-782	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	24	132.667	19.154	14.44	113.000	153.000
2025-782	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	12	153.750	4.085	2.66	131.000	177.000
2025-782	10	ENZYM. GPO	203	ROCHE	93	ROCHE	29	153.179	3.252	2.12	130.000	176.000
2025-782	10	ENZYM. GPO	219	ATELLICA	143	SIEMENS	28	159.107	4.776	3.00	135.000	183.000
025 TRIGLYCERIDES			CLIA TEST ID #: 495			EVALUATION CRITERIA: TARGET VALUE 15 %						
2025-783	2	ENZ. COLO.	165	VITROS	63	KODAK	136	113.309	4.883	4.31	96.000	130.000
2025-783	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	12	105.833	1.993	1.88	90.000	122.000
2025-783	2	ENZ. COLO.	203	ROCHE	93	ROCHE	37	105.457	1.872	1.78	90.000	121.000
2025-783	2	ENZ. COLO.	220	Medica E.	130	MEDICA	14	99.143	3.044	3.07	84.000	114.000
2025-783	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	72	95.887	3.308	3.45	82.000	110.000
2025-783	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	97.500	2.141	2.20	83.000	112.000
2025-783	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	29	103.536	2.383	2.30	88.000	119.000
2025-783	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	24	94.333	3.091	3.28	80.000	108.000
2025-783	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	24	104.522	5.725	5.48	89.000	120.000
2025-783	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	12	106.417	2.985	2.80	90.000	122.000
2025-783	10	ENZYM. GPO	203	ROCHE	93	ROCHE	29	104.690	3.281	3.13	89.000	120.000
2025-783	10	ENZYM. GPO	219	ATELLICA	143	SIEMENS	28	106.679	4.691	4.40	91.000	123.000
2025-784	2	ENZ. COLO.	165	VITROS	63	KODAK	136	88.341	3.708	4.20	75.000	102.000
2025-784	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	12	84.667	1.795	2.12	72.000	97.000
2025-784	2	ENZ. COLO.	203	ROCHE	93	ROCHE	37	83.914	1.442	1.72	71.000	97.000
2025-784	2	ENZ. COLO.	220	Medica E.	130	MEDICA	14	80.429	2.770	3.44	68.000	92.000
2025-784	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	72	74.211	3.893	5.25	63.000	85.000
2025-784	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	76.667	2.014	2.63	65.000	88.000
2025-784	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	29	81.679	2.237	2.74	69.000	94.000
2025-784	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	24	85.739	4.013	4.68	73.000	99.000
2025-784	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	24	96.667	23.697	24.51	82.000	111.000
2025-784	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	12	84.917	2.660	3.13	72.000	98.000
2025-784	10	ENZYM. GPO	203	ROCHE	93	ROCHE	29	82.929	2.251	2.71	70.000	95.000

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-784	10 ENZYM. GPO	219	APELLICA	143	SIEMENS	28	85.071	3.443	4.05	72.000	98.000	
025	TRIGLYCERIDES	CLIA TEST ID #: 495				EVALUATION CRITERIA: TARGET VALUE 15 %						
2025-785	2 ENZ. COLO.	165	VITROS	63	KODAK	136	137.919	6.103	4.43	117.000	159.000	
2025-785	2 ENZ. COLO.	184	INTEGRA	93	ROCHE	12	126.667	2.173	1.72	108.000	146.000	
2025-785	2 ENZ. COLO.	203	ROCHE	93	ROCHE	37	126.500	2.609	2.06	108.000	145.000	
2025-785	2 ENZ. COLO.	220	Medica E.	130	MEDICA	14	115.786	4.616	3.99	98.000	133.000	
2025-785	4 ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	72	117.500	3.620	3.08	100.000	135.000	
2025-785	5 HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	117.750	2.487	2.11	100.000	135.000	
2025-785	9 GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	29	126.310	3.743	2.96	107.000	145.000	
2025-785	9 GPO TRIND.	191	RX-SERIES	126	RANDOX	24	141.333	34.567	24.46	120.000	163.000	
2025-785	9 GPO TRIND.	191	RX-SERIES	126	RANDOX	24	125.174	4.400	3.52	106.000	144.000	
2025-785	10 ENZYM. GPO	184	INTEGRA	93	ROCHE	12	126.833	3.869	3.05	108.000	146.000	
2025-785	10 ENZYM. GPO	203	ROCHE	93	ROCHE	29	124.724	3.247	2.60	106.000	143.000	
2025-785	10 ENZYM. GPO	219	APELLICA	143	SIEMENS	28	128.893	4.639	3.60	110.000	148.000	
026	UREA NITROGEN (BUN)	CLIA TEST ID #: 505				EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}						
2025-781	2 UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	76	33.667	1.268	3.77	31.000	37.000	
2025-781	2 UREAS.GLDH	184	INTEGRA	93	ROCHE	29	32.448	1.404	4.33	30.000	35.000	
2025-781	2 UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	30	33.414	0.929	2.78	30.000	36.000	
2025-781	2 UREAS.GLDH	191	RX-SERIES	126	RANDOX	24	31.500	2.082	6.61	29.000	34.000	
2025-781	2 UREAS.GLDH	203	ROCHE	93	ROCHE	69	32.750	1.062	3.24	30.000	36.000	
2025-781	2 UREAS.GLDH	219	APELLICA	143	SIEMENS	28	32.519	0.957	2.94	30.000	35.000	
2025-781	5 CHROMATOG.	197	ARCHITECT	1	ABBOTT	14	35.000	1.512	4.32	32.000	38.000	
2025-781	8 UREASE QUI	165	VITROS	63	KODAK	149	31.020	0.886	2.86	28.000	34.000	
2025-781	10 UREASE 37	220	Medica E.	130	MEDICA	17	32.294	1.318	4.08	29.000	35.000	
2025-782	2 UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	76	25.013	1.039	4.15	23.000	27.000	
2025-782	2 UREAS.GLDH	184	INTEGRA	93	ROCHE	29	24.172	1.085	4.49	22.000	26.000	
2025-782	2 UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	30	24.867	1.087	4.37	23.000	27.000	
2025-782	2 UREAS.GLDH	191	RX-SERIES	126	RANDOX	24	24.083	1.656	6.88	22.000	26.000	
2025-782	2 UREAS.GLDH	203	ROCHE	93	ROCHE	69	24.529	0.776	3.16	22.000	27.000	

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-782	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	28	24.679	1.037	4.20	22.000	27.000
2025-782	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	14	25.429	0.821	3.23	23.000	28.000
2025-782	8	UREASE QUI	165	VITROS	63	KODAK	149	22.446	0.729	3.25	20.000	24.000
2025-782	10	UREASE 37	220	Medica E.	130	MEDICA	17	24.235	0.730	3.01	22.000	26.000
026 UREA NITROGEN (BUN)		CLIA TEST ID #: 505				EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}						
2025-783	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	76	12.066	0.893	7.41	10.000	14.000
2025-783	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	29	12.000	0.643	5.36	10.000	14.000
2025-783	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	30	12.567	0.559	4.45	11.000	15.000
2025-783	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	24	12.375	0.992	8.02	10.000	14.000
2025-783	2	UREAS.GLDH	203	ROCHE	93	ROCHE	69	12.191	0.691	5.67	10.000	14.000
2025-783	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	28	12.536	0.626	4.99	11.000	15.000
2025-783	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	14	12.571	0.728	5.79	11.000	15.000
2025-783	8	UREASE QUI	165	VITROS	63	KODAK	149	10.716	0.480	4.48	9.000	13.000
2025-783	10	UREASE 37	220	Medica E.	130	MEDICA	17	12.471	0.499	4.00	10.000	14.000
2025-784	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	76	6.733	0.699	10.38	5.000	9.000
2025-784	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	29	6.966	0.490	7.04	5.000	9.000
2025-784	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	30	7.333	0.471	6.43	5.000	9.000
2025-784	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	24	7.130	0.612	8.58	5.000	9.000
2025-784	2	UREAS.GLDH	203	ROCHE	93	ROCHE	69	7.059	0.338	4.79	5.000	9.000
2025-784	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	28	7.393	0.673	9.10	5.000	9.000
2025-784	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	14	7.429	0.904	12.16	5.000	9.000
2025-784	8	UREASE QUI	165	VITROS	63	KODAK	149	5.520	0.563	10.20	4.000	8.000
2025-784	10	UREASE 37	220	Medica E.	130	MEDICA	17	7.235	0.546	7.54	5.000	9.000
2025-785	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	76	17.539	0.924	5.27	16.000	20.000
2025-785	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	29	17.000	0.743	4.37	15.000	19.000
2025-785	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	30	17.700	0.823	4.65	16.000	20.000
2025-785	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	24	17.250	0.924	5.36	15.000	19.000
2025-785	2	UREAS.GLDH	203	ROCHE	93	ROCHE	69	17.522	0.677	3.86	16.000	20.000

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-785	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	28	17.704	0.597	3.37	16.000	20.000
2025-785	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	14	18.000	0.845	4.70	16.000	20.000
2025-785	8	UREASE QUI	165	VITROS	63	KODAK	149	15.577	0.558	3.58	14.000	18.000
2025-785	10	UREASE 37	220	Medica E.	130	MEDICA	17	17.588	0.600	3.41	16.000	20.000
027	URIC ACID		CLIA TEST ID #: 515				EVALUATION CRITERIA: TARGET VALUE 10 %					
2025-781	2	URICASE	38	SIEMENS DI	143	SIEMENS	39	8.813	0.238	2.70	7.900	9.700
2025-781	2	URICASE	165	VITROS	63	KODAK	92	8.800	0.225	2.55	7.900	9.700
2025-781	2	URICASE	184	INTEGRA	93	ROCHE	10	8.710	0.388	4.46	7.800	9.600
2025-781	2	URICASE	203	ROCHE	93	ROCHE	37	8.532	0.185	2.16	7.700	9.400
2025-781	2	URICASE	219	ATELLICA	143	SIEMENS	22	9.014	0.175	1.95	8.100	9.900
2025-781	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	8.800	0.203	2.30	7.900	9.700
2025-781	6	ENZY. COL	203	ROCHE	93	ROCHE	20	8.530	0.193	2.26	7.700	9.400
2025-782	2	URICASE	38	SIEMENS DI	143	SIEMENS	39	6.564	0.179	2.73	5.900	7.200
2025-782	2	URICASE	165	VITROS	63	KODAK	92	6.453	0.139	2.16	5.800	7.100
2025-782	2	URICASE	184	INTEGRA	93	ROCHE	10	6.380	0.404	6.34	5.700	7.000
2025-782	2	URICASE	203	ROCHE	93	ROCHE	37	6.378	0.144	2.25	5.700	7.000
2025-782	2	URICASE	219	ATELLICA	143	SIEMENS	22	6.686	0.179	2.68	6.000	7.400
2025-782	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	6.600	0.134	2.03	5.900	7.300
2025-782	6	ENZY. COL	203	ROCHE	93	ROCHE	20	6.355	0.160	2.51	5.700	7.000
2025-783	2	URICASE	38	SIEMENS DI	143	SIEMENS	39	3.190	0.093	2.91	2.900	3.500
2025-783	2	URICASE	165	VITROS	63	KODAK	92	3.058	0.077	2.52	2.800	3.400
2025-783	2	URICASE	184	INTEGRA	93	ROCHE	10	3.040	0.323	10.63	2.700	3.300
2025-783	2	URICASE	203	ROCHE	93	ROCHE	37	3.065	0.085	2.76	2.800	3.400
2025-783	2	URICASE	219	ATELLICA	143	SIEMENS	22	3.267	0.089	2.73	2.900	3.600
2025-783	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	3.274	0.064	1.94	2.900	3.600
2025-783	6	ENZY. COL	203	ROCHE	93	ROCHE	20	3.030	0.084	2.78	2.700	3.300
2025-784	2	URICASE	38	SIEMENS DI	143	SIEMENS	39	1.800	0.085	4.71	1.600	2.000

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-784	2	URICASE	165	VITROS	63	KODAK	92	1.732	0.057	3.29	1.600	1.900
2025-784	2	URICASE	184	INTEGRA	93	ROCHE	10	1.600	0.272	17.00	1.400	1.800
2025-784	2	URICASE	203	ROCHE	93	ROCHE	37	1.647	0.055	3.35	1.500	1.800
2025-784	2	URICASE	219	ATELLICA	143	SIEMENS	22	1.832	0.070	3.82	1.600	2.000
2025-784	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	1.884	0.059	3.11	1.700	2.100
2025-784	6	ENZY. COL	203	ROCHE	93	ROCHE	20	1.650	0.050	3.03	1.500	1.800
027	URIC ACID		CLIA TEST ID #: 515		EVALUATION CRITERIA: TARGET VALUE 10 %							
2025-785	2	URICASE	38	SIEMENS DI	143	SIEMENS	39	4.597	0.133	2.89	4.100	5.100
2025-785	2	URICASE	165	VITROS	63	KODAK	92	4.458	0.098	2.20	4.000	4.900
2025-785	2	URICASE	184	INTEGRA	93	ROCHE	10	4.480	0.343	7.65	4.000	4.900
2025-785	2	URICASE	203	ROCHE	93	ROCHE	37	4.458	0.106	2.39	4.000	4.900
2025-785	2	URICASE	219	ATELLICA	143	SIEMENS	22	4.714	0.122	2.58	4.200	5.200
2025-785	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	4.695	0.083	1.76	4.200	5.200
2025-785	6	ENZY. COL	203	ROCHE	93	ROCHE	20	4.430	0.110	2.48	4.000	4.900
135	GGT (GAMMA GLU. TRA)		CLIA TEST ID #: 411		EVALUATION CRITERIA: TARGET VALUE 15 % OR 5.00 {GREATER}							
2025-781	5	KINETIC 37	165	VITROS	63	KODAK	26	483.640	12.759	2.64	411.000	556.000
2025-781	5	KINETIC 37	219	ATELLICA	143	SIEMENS	12	380.250	22.657	5.96	323.000	437.000
2025-782	5	KINETIC 37	165	VITROS	63	KODAK	26	359.320	8.671	2.41	305.000	413.000
2025-782	5	KINETIC 37	219	ATELLICA	143	SIEMENS	12	256.750	6.610	2.57	218.000	295.000
2025-783	5	KINETIC 37	165	VITROS	63	KODAK	26	132.800	3.124	2.35	113.000	153.000
2025-783	5	KINETIC 37	219	ATELLICA	143	SIEMENS	12	87.750	2.712	3.09	75.000	101.000
2025-784	5	KINETIC 37	165	VITROS	63	KODAK	26	18.640	0.933	5.01	14.000	24.000
2025-784	5	KINETIC 37	219	ATELLICA	143	SIEMENS	12	14.917	0.862	5.78	10.000	20.000
2025-785	5	KINETIC 37	165	VITROS	63	KODAK	26	236.960	4.450	1.88	201.000	273.000
2025-785	5	KINETIC 37	219	ATELLICA	143	SIEMENS	12	160.917	4.071	2.53	137.000	185.000

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
136	LACTIC ACID	CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 20 %						
2025-781	1 LACTATE-P.	165	VITROS	63	KODAK	27	5.296	0.179	3.39	4.200	6.400	
2025-782	1 LACTATE-P.	165	VITROS	63	KODAK	27	3.667	0.115	3.15	2.900	4.400	
2025-783	1 LACTATE-P.	165	VITROS	63	KODAK	27	1.081	0.047	4.39	0.900	1.300	
2025-784	1 LACTATE-P.	165	VITROS	63	KODAK	27	0.500	0.000	0.00	0.400	0.600	
2025-785	1 LACTATE-P.	165	VITROS	63	KODAK	27	2.144	0.079	3.66	1.700	2.600	
137	LIPASE											
2025-781	1 COLORIMET.	203	ROCHE	93	ROCHE	19	70.944	1.957	2.76	57.000	85.000	
2025-781	1 COLORIMET.	219	ATELLICA	143	SIEMENS	16	78.867	1.996	2.53	63.000	95.000	
2025-781	2 ENZIMATIC	165	VITROS	63	KODAK	83	550.843	21.765	3.95	441.000	661.000	
2025-781	4 ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	12	72.250	2.890	4.00	58.000	87.000	
2025-781	4 ENZ/COLOR	203	ROCHE	93	ROCHE	16	72.250	2.305	3.19	58.000	87.000	
2025-781	5 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	11	69.364	5.757	8.30	55.000	83.000	
2025-782	1 COLORIMET.	203	ROCHE	93	ROCHE	19	54.222	1.902	3.51	43.000	65.000	
2025-782	1 COLORIMET.	219	ATELLICA	143	SIEMENS	16	59.438	1.694	2.85	48.000	71.000	
2025-782	2 ENZIMATIC	165	VITROS	63	KODAK	83	405.707	16.617	4.10	325.000	487.000	
2025-782	4 ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	12	54.333	2.461	4.53	43.000	65.000	
2025-782	4 ENZ/COLOR	203	ROCHE	93	ROCHE	16	54.438	1.968	3.61	44.000	65.000	
2025-782	5 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	11	53.818	3.010	5.59	43.000	65.000	
2025-783	1 COLORIMET.	203	ROCHE	93	ROCHE	19	28.421	1.270	4.47	23.000	34.000	
2025-783	1 COLORIMET.	219	ATELLICA	143	SIEMENS	16	31.563	1.731	5.48	25.000	38.000	
2025-783	2 ENZIMATIC	165	VITROS	63	KODAK	83	173.373	7.133	4.11	139.000	208.000	
2025-783	4 ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	12	26.250	0.924	3.52	21.000	32.000	
2025-783	4 ENZ/COLOR	203	ROCHE	93	ROCHE	16	28.125	1.053	3.74	23.000	34.000	

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE							
ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2025-783	5	SIEMENS	37	38	SIEMENS DI	143	SIEMENS	11	28.636	1.298	4.53	23.000	34.000
137	LIPASE	CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 20 %							
2025-784	1	COLORIMET.	203	ROCHE	93	ROCHE	19	16.947	0.825	4.87	14.000	20.000	
2025-784	1	COLORIMET.	219	ATELLICA	143	SIEMENS	16	18.938	1.519	8.02	15.000	23.000	
2025-784	2	ENZIMATIC	165	VITROS	63	KODAK	83	60.892	3.774	6.20	49.000	73.000	
2025-784	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	12	14.250	1.422	9.98	11.000	17.000	
2025-784	4	ENZ/COLOR	203	ROCHE	93	ROCHE	16	17.125	0.696	4.06	14.000	21.000	
2025-784	5	SIEMENS	37	38	SIEMENS DI	143	SIEMENS	11	18.273	0.862	4.72	15.000	22.000
2025-785	1	COLORIMET.	203	ROCHE	93	ROCHE	19	39.421	1.928	4.89	32.000	47.000	
2025-785	1	COLORIMET.	219	ATELLICA	143	SIEMENS	16	43.563	1.580	3.63	35.000	52.000	
2025-785	2	ENZIMATIC	165	VITROS	63	KODAK	83	274.771	11.184	4.07	220.000	330.000	
2025-785	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	12	38.083	1.801	4.73	30.000	46.000	
2025-785	4	ENZ/COLOR	203	ROCHE	93	ROCHE	16	39.438	1.223	3.10	32.000	47.000	
2025-785	5	SIEMENS	37	38	SIEMENS DI	143	SIEMENS	11	39.727	1.483	3.73	32.000	48.000
138	PHOSPHORUS	CLIA TEST ID #: 460				EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.30 {GREATER}							
2025-781	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	40	5.274	0.125	2.37	4.700	5.800	
2025-781	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	40	5.600	0.169	3.02	5.000	6.200	
2025-781	1	PHOSPHOMO.	165	VITROS	63	KODAK	90	4.927	0.170	3.45	4.400	5.400	
2025-781	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	12	5.025	0.179	3.55	4.500	5.500	
2025-781	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	23	5.152	0.141	2.74	4.600	5.700	
2025-781	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	23	5.600	0.169	3.02	5.000	6.200	
2025-781	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	55	5.005	0.135	2.71	4.500	5.500	
2025-781	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	26	5.192	0.160	3.08	4.700	5.700	
2025-782	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	40	4.557	0.176	3.86	4.100	5.000	
2025-782	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	40	4.218	0.126	2.99	3.800	4.600	
2025-782	1	PHOSPHOMO.	165	VITROS	63	KODAK	90	4.008	0.111	2.77	3.600	4.400	
2025-782	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	12	3.958	0.138	3.49	3.600	4.400	
2025-782	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	23	4.557	0.176	3.86	4.100	5.000	

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-782	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	23	4.086	0.139	3.40	3.700	4.500
2025-782	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	55	3.975	0.105	2.64	3.600	4.400
2025-782	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	26	4.127	0.129	3.12	3.700	4.500
138	PHOSPHORUS	CLIA TEST ID #: 460				EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.30 {GREATER}						
2025-783	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	40	2.544	0.101	3.96	2.200	2.800
2025-783	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	40	2.900	0.053	1.84	2.600	3.200
2025-783	1	PHOSPHOMO.	165	VITROS	63	KODAK	90	2.621	0.094	3.57	2.300	2.900
2025-783	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	12	2.442	0.132	5.41	2.100	2.700
2025-783	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	23	2.455	0.084	3.41	2.200	2.800
2025-783	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	23	2.900	0.053	1.84	2.600	3.200
2025-783	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	55	2.382	0.090	3.76	2.100	2.700
2025-783	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	26	2.481	0.118	4.75	2.200	2.800
2025-784	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	40	2.171	0.070	3.22	1.900	2.500
2025-784	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	40	1.828	0.071	3.91	1.500	2.100
2025-784	1	PHOSPHOMO.	165	VITROS	63	KODAK	90	1.948	0.064	3.27	1.600	2.200
2025-784	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	12	1.725	0.116	6.75	1.400	2.000
2025-784	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	23	2.171	0.070	3.22	1.900	2.500
2025-784	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	23	1.774	0.103	5.81	1.500	2.100
2025-784	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	55	1.667	0.071	4.29	1.400	2.000
2025-784	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	26	1.768	0.105	5.93	1.500	2.100
2025-785	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	40	3.264	0.097	2.98	2.900	3.600
2025-785	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	40	3.629	0.175	4.82	3.300	4.000
2025-785	1	PHOSPHOMO.	165	VITROS	63	KODAK	90	3.227	0.106	3.28	2.900	3.500
2025-785	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	12	3.067	0.137	4.48	2.800	3.400
2025-785	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	23	3.136	0.107	3.41	2.800	3.500
2025-785	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	23	3.629	0.175	4.82	3.300	4.000
2025-785	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	55	3.045	0.095	3.12	2.700	3.400
2025-785	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	26	3.177	0.112	3.53	2.900	3.500

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH		
169	CO2	CLIA TEST ID #: 351				EVALUATION CRITERIA: TARGET VALUE 20 %						
2025-781	1	Generic Me	184	INTEGRA	93	ROCHE	10	20.500	2.617	12.77	16.000	25.000
2025-781	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	25	24.600	2.245	9.13	20.000	30.000
2025-781	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	25	21.889	1.969	8.99	18.000	26.000
2025-781	1	Generic Me	203	ROCHE	93	ROCHE	25	20.760	2.388	11.50	17.000	25.000
2025-781	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	58	24.328	2.285	9.39	19.000	29.000
2025-781	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	58	21.889	1.969	8.99	18.000	26.000
2025-781	2	ENZYMATIC	165	VITROS	63	KODAK	46	21.889	1.969	8.99	18.000	26.000
2025-781	2	ENZYMATIC	165	VITROS	63	KODAK	46	22.022	2.382	10.82	18.000	26.000
2025-781	2	ENZYMATIC	165	VITROS	156	Kit 32	84	22.690	1.851	8.16	18.000	27.000
2025-781	2	ENZYMATIC	203	ROCHE	93	ROCHE	11	20.545	1.616	7.87	16.000	25.000
2025-781	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	27	23.538	2.390	10.15	19.000	28.000
2025-781	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	27	27.333	0.471	1.72	22.000	33.000
2025-782	1	Generic Me	184	INTEGRA	93	ROCHE	10	17.000	3.066	18.03	14.000	20.000
2025-782	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	25	19.840	2.148	10.83	16.000	24.000
2025-782	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	25	17.444	1.066	6.11	14.000	21.000
2025-782	1	Generic Me	203	ROCHE	93	ROCHE	25	17.240	1.965	11.40	14.000	21.000
2025-782	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	58	17.444	1.066	6.11	14.000	21.000
2025-782	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	58	20.776	2.068	9.95	17.000	25.000
2025-782	2	ENZYMATIC	165	VITROS	63	KODAK	46	17.444	1.066	6.11	14.000	21.000
2025-782	2	ENZYMATIC	165	VITROS	63	KODAK	46	17.304	2.205	12.74	14.000	21.000
2025-782	2	ENZYMATIC	165	VITROS	156	Kit 32	84	17.542	1.630	9.29	14.000	21.000
2025-782	2	ENZYMATIC	203	ROCHE	93	ROCHE	11	15.909	1.676	10.54	13.000	19.000
2025-782	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	27	22.000	0.816	3.71	18.000	26.000
2025-782	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	27	19.308	2.266	11.74	15.000	23.000
2025-783	1	Generic Me	184	INTEGRA	93	ROCHE	10	11.500	2.579	22.42	9.000	14.000
2025-783	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	25	11.111	1.792	16.12	9.000	13.000
2025-783	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	25	12.720	2.108	16.57	10.000	15.000

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-783	1	Generic Me	203	ROCHE	93	ROCHE	25	11.320	1.191	10.52	9.000	14.000
2025-783	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	58	14.690	1.773	12.07	12.000	18.000
2025-783	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	58	11.111	1.792	16.12	9.000	13.000
2025-783	2	ENZYMATIC	165	VITROS	63	KODAK	46	10.326	1.733	16.78	8.000	12.000
2025-783	2	ENZYMATIC	165	VITROS	63	KODAK	46	11.111	1.792	16.12	9.000	13.000
2025-783	2	ENZYMATIC	165	VITROS	156	Kit 32	84	10.458	1.531	14.64	8.000	13.000
2025-783	2	ENZYMATIC	203	ROCHE	93	ROCHE	11	11.091	1.379	12.43	9.000	13.000
2025-783	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	27	13.423	2.097	15.62	11.000	16.000
2025-783	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	27	16.333	0.943	5.77	13.000	20.000
169	CO2	CLIA TEST ID #: 351				EVALUATION CRITERIA: TARGET VALUE 20 %						
2025-784	1	Generic Me	184	INTEGRA	93	ROCHE	10	10.000	2.864	28.64	8.000	12.000
2025-784	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	25	10.417	1.077	10.34	8.000	13.000
2025-784	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	25	7.333	1.333	18.18	6.000	9.000
2025-784	1	Generic Me	203	ROCHE	93	ROCHE	25	9.000	1.233	13.70	7.000	11.000
2025-784	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	58	7.333	1.333	18.18	6.000	9.000
2025-784	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	58	12.172	1.428	11.73	10.000	15.000
2025-784	2	ENZYMATIC	165	VITROS	63	KODAK	46	7.333	1.333	18.18	6.000	9.000
2025-784	2	ENZYMATIC	165	VITROS	63	KODAK	46	7.826	1.340	17.12	6.000	9.000
2025-784	2	ENZYMATIC	165	VITROS	156	Kit 32	84	7.939	1.310	16.50	6.000	10.000
2025-784	2	ENZYMATIC	203	ROCHE	93	ROCHE	11	8.636	1.298	15.03	7.000	10.000
2025-784	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	27	13.333	0.471	3.54	11.000	16.000
2025-784	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	27	11.269	1.630	14.47	9.000	14.000
2025-785	1	Generic Me	184	INTEGRA	93	ROCHE	10	14.000	4.074	29.10	11.000	17.000
2025-785	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	25	15.080	1.809	12.00	12.000	18.000
2025-785	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	25	13.000	1.414	10.88	10.000	16.000
2025-785	1	Generic Me	203	ROCHE	93	ROCHE	25	12.840	1.541	12.00	10.000	15.000
2025-785	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	58	16.638	1.963	11.80	13.000	20.000
2025-785	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	58	13.000	1.414	10.88	10.000	16.000
2025-785	2	ENZYMATIC	165	VITROS	63	KODAK	46	12.391	1.738	14.03	10.000	15.000

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY SUB: 10 ROUTINE GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2025-785	2 ENZYMATIC	165 VITROS	63 KODAK	46	13.000	1.414	10.88	10.000	16.000		
2025-785	2 ENZYMATIC	165 VITROS	156 Kit 32	84	12.786	1.619	12.66	10.000	15.000		
2025-785	2 ENZYMATIC	203 ROCHE	93 ROCHE	11	12.545	1.616	12.88	10.000	15.000		
2025-785	2 ENZYMATIC	219 ATELLICA	143 SIEMENS	27	15.577	1.597	10.26	12.000	19.000		
2025-785	2 ENZYMATIC	219 ATELLICA	143 SIEMENS	27	17.667	0.943	5.34	14.000	21.000		
170 DIRECT BILIRUBIN		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD OR 20 % {GREATER}								
2025-781	4 JEND.-GROG	38 SIEMENS DI	143 SIEMENS	38	0.889	0.046	5.15	0.700	1.100		
2025-781	5 JEND.-GROG	197 ARCHITECT	1 ABBOTT	11	1.409	0.108	7.69	1.100	1.700		
2025-781	11 SPECT. WIT	165 VITROS	63 KODAK	68	0.516	0.214	41.46	0	1.200		
2025-781	13 AZOBIL.W/D	203 ROCHE	93 ROCHE	21	1.319	0.189	14.35	0.800	1.900		
2025-781	14 VANADATE O	219 ATELLICA	143 SIEMENS	24	1.704	0.081	4.73	1.400	2.000		
2025-782	4 JEND.-GROG	38 SIEMENS DI	143 SIEMENS	38	0.653	0.085	13.03	0.400	0.900		
2025-782	5 JEND.-GROG	197 ARCHITECT	1 ABBOTT	11	1.073	0.075	6.99	0.800	1.300		
2025-782	11 SPECT. WIT	165 VITROS	63 KODAK	68	0.240	0.185	76.79	0	0.800		
2025-782	13 AZOBIL.W/D	203 ROCHE	93 ROCHE	21	0.943	0.129	13.72	0.600	1.300		
2025-782	14 VANADATE O	219 ATELLICA	143 SIEMENS	24	1.263	0.086	6.79	1.000	1.500		
2025-783	4 JEND.-GROG	38 SIEMENS DI	143 SIEMENS	38	0.208	0.027	13.12	0.100	0.300		
2025-783	5 JEND.-GROG	197 ARCHITECT	1 ABBOTT	11	0.382	0.039	10.10	0.300	0.500		
2025-783	11 SPECT. WIT	165 VITROS	63 KODAK	68	0.029	0.082	279.69	0	0.300		
2025-783	13 AZOBIL.W/D	203 ROCHE	93 ROCHE	21	0.310	0.053	16.99	0.200	0.500		
2025-783	14 VANADATE O	219 ATELLICA	143 SIEMENS	24	0.488	0.044	9.00	0.400	0.600		
2025-784	4 JEND.-GROG	38 SIEMENS DI	143 SIEMENS	38	0.068	0.046	67.94	0	0.200		
2025-784	5 JEND.-GROG	197 ARCHITECT	1 ABBOTT	11	0.100	0.000	0.00	0.100	0.100		
2025-784	11 SPECT. WIT	165 VITROS	63 KODAK	68	0.005	0.021	458.26	0	0.100		
2025-784	13 AZOBIL.W/D	203 ROCHE	93 ROCHE	21	0.105	0.049	46.35	0.000	0.300		
2025-784	14 VANADATE O	219 ATELLICA	143 SIEMENS	24	0.100	0.000	0.00	0.100	0.100		

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE							
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
170	DIRECT BILIRUBIN	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD OR 20 % {GREATER}								
2025-785	4 JEND.-GROG	38 SIEMENS DI	143 SIEMENS	38	0.400	0.033	8.22	0.300	0.500		
2025-785	5 JEND.-GROG	197 ARCHITECT	1 ABBOTT	11	0.682	0.057	8.43	0.500	0.900		
2025-785	11 SPECT. WIT	165 VITROS	63 KODAK	68	0.059	0.138	233.78	0	0.500		
2025-785	13 AZOBIL.W/D	203 ROCHE	93 ROCHE	21	0.605	0.095	15.71	0.300	0.900		
2025-785	14 VANADATE O	219 ATELLICA	143 SIEMENS	24	0.822	0.059	7.14	0.600	1.000		

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 15 WHOLE BLOOD GLUCOSE							
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
157	WHOLE BLOOD GLUCOSE		EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}								
2025-881	23 ABBOTT PRE			24	101.625	5.604	5.51	91.000	112.000		
2025-881	27 STAT SRIP.			96	90.000	10.000	11.11	81.000	99.000		
2025-881	27 STAT SRIP.			96	83.677	6.794	8.12	75.000	92.000		
2025-881	33 AC.CHEK II			34	91.706	3.544	3.86	83.000	101.000		
2025-881	34 FREE STYL			34	103.206	15.926	15.43	93.000	114.000		
2025-882	23 ABBOTT PRE			24	203.042	6.705	3.30	183.000	223.000		
2025-882	27 STAT SRIP.			96	153.189	14.136	9.23	138.000	169.000		
2025-882	27 STAT SRIP.			96	143.000	10.000	6.99	129.000	157.000		
2025-882	33 AC.CHEK II			34	180.939	7.015	3.88	163.000	199.000		
2025-882	34 FREE STYL			34	209.206	37.038	17.70	188.000	230.000		
2025-883	23 ABBOTT PRE			24	439.750	27.446	6.24	396.000	484.000		
2025-883	27 STAT SRIP.			96	272.000	20.000	7.35	245.000	299.000		
2025-883	27 STAT SRIP.			96	302.135	27.562	9.12	272.000	332.000		
2025-883	33 AC.CHEK II			34	439.294	22.051	5.02	395.000	483.000		
2025-883	34 FREE STYL			34	457.324	69.521	15.20	412.000	503.000		

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY SUB: 10 ROUTINE GRP: 15 WHOLE BLOOD GLUCOSE

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
157 WHOLE BLOOD GLUCOSE				CLIA TEST ID #: 0 EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}					
2025-884	23	ABBOTT PRE		24	102.125	5.517	5.40	92.000	112.000
2025-884	27	STAT SRIP.		96	84.156	7.527	8.94	76.000	93.000
2025-884	27	STAT SRIP.		96	90.000	10.000	11.11	81.000	99.000
2025-884	33	AC.CHEK II		34	92.235	3.557	3.86	83.000	101.000
2025-884	34	FREE STYL		34	102.382	20.225	19.75	92.000	113.000
2025-885	23	ABBOTT PRE		24	203.375	7.889	3.88	183.000	224.000
2025-885	27	STAT SRIP.		96	143.000	10.000	6.99	129.000	157.000
2025-885	27	STAT SRIP.		96	153.615	11.911	7.75	138.000	169.000
2025-885	33	AC.CHEK II		34	181.176	7.733	4.27	163.000	199.000
2025-885	34	FREE STYL		34	209.382	34.252	16.36	188.000	230.000

SPEC: 10 CHEMISTRY SUB: 20 BLOOD GASES GRP: 30 BLOOD GASES

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
007 BLOOD GASES-pCO2				CLIA TEST ID #: 335 EVALUATION CRITERIA: TARGET VALUE 8 % OR 5.00 {GREATER}					
2025-831	256	GEM PREMI.		11	66.636	1.432	2.15	61.300	72.000
2025-831	265	ROCHE COBA		31	65.465	1.437	2.20	60.200	70.700
2025-832	256	GEM PREMI.		11	40.000	0.853	2.13	35.000	45.000
2025-832	265	ROCHE COBA		31	42.600	0.952	2.23	37.600	47.600
2025-833	256	GEM PREMI.		11	22.273	0.962	4.32	17.300	27.300
2025-833	265	ROCHE COBA		31	23.690	0.560	2.36	18.700	28.700

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 20 BLOOD GASES			GRP: 30 BLOOD GASES				
ANALYTE										
SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
007 BLOOD GASES-pCO2			CLIA TEST ID #: 335	EVALUATION CRITERIA: TARGET VALUE 8 % OR 5.00 {GREATER}						
2025-834	256	GEM PREMI.			11	54.545	1.971	3.61	49.500	59.500
2025-834	265	ROCHE COBA			31	54.752	1.649	3.01	49.800	59.800
2025-835	256	GEM PREMI.			11	21.727	0.750	3.45	16.700	26.700
2025-835	265	ROCHE COBA			31	23.419	0.472	2.02	18.400	28.400
008 BLOOD GASES-pH			CLIA TEST ID #: 315	EVALUATION CRITERIA: TARGET VALUE 0.04						
2025-831	256	GEM PREMI.			10	7.158	0.015	0.21	7.118	7.198
2025-831	265	ROCHE COBA			32	7.176	0.006	0.08	7.136	7.216
2025-832	256	GEM PREMI.			10	7.441	0.009	0.13	7.401	7.481
2025-832	265	ROCHE COBA			32	7.419	0.007	0.10	7.379	7.459
2025-833	256	GEM PREMI.			10	7.622	0.012	0.15	7.582	7.662
2025-833	265	ROCHE COBA			32	7.567	0.008	0.10	7.527	7.607
2025-834	256	GEM PREMI.			10	7.229	0.012	0.17	7.189	7.269
2025-834	265	ROCHE COBA			32	7.227	0.007	0.10	7.187	7.267
2025-835	256	GEM PREMI.			10	7.623	0.011	0.14	7.583	7.663
2025-835	265	ROCHE COBA			32	7.570	0.009	0.12	7.530	7.610
009 BLOOD GASES-pO2			CLIA TEST ID #: 325	EVALUATION CRITERIA: TARGET VALUE 15 % OR 15.00 {GREATER}						
2025-831	256	GEM PREMI.			10	68.100	3.330	4.89	53.100	83.100
2025-831	265	ROCHE COBA			32	57.244	18.282	31.94	42.200	72.200
2025-831	265	ROCHE COBA			32	59.540	1.989	3.34	44.500	74.500
2025-832	256	GEM PREMI.			10	111.400	5.181	4.65	94.700	128.100
2025-832	265	ROCHE COBA			32	109.500	6.214	5.68	93.100	125.900
2025-832	265	ROCHE COBA			32	108.750	7.389	6.79	92.400	125.100

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 20 BLOOD GASES		GRP: 30 BLOOD GASES				
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
009	BLOOD GASES-pO2	CLIA TEST ID #: 325	EVALUATION CRITERIA: TARGET VALUE	15	% OR 15.00	{GREATER}			
2025-833	256 GEM PREMI.			10	178.200	9.261	5.20	151.500	204.900
2025-833	265 ROCHE COBA			32	181.153	5.572	3.08	154.000	208.300
2025-833	265 ROCHE COBA			32	183.340	2.362	1.29	155.800	210.800
2025-834	256 GEM PREMI.			10	257.100	34.317	13.35	218.500	295.700
2025-834	265 ROCHE COBA			32	300.260	40.271	13.41	255.200	345.300
2025-834	265 ROCHE COBA			32	276.169	29.368	10.63	234.700	317.600
2025-835	256 GEM PREMI.			10	175.500	10.181	5.80	149.200	201.800
2025-835	265 ROCHE COBA			32	180.931	5.899	3.26	153.800	208.100
2025-835	265 ROCHE COBA			32	185.840	4.968	2.67	158.000	213.700

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
029	FOLL. STIM. HOR.-FSH	CLIA TEST ID #: 542	EVALUATION CRITERIA: TARGET VALUE	18	% OR 2.00	{GREATER}			
2025-811	116 ROCHE COBA			17	11.829	0.523	4.42	9.700	14.000
2025-811	125 B.C.ACCESS			11	12.518	1.235	9.87	10.300	14.800
2025-811	125 B.C.ACCESS			11	9.822	0.376	3.83	7.800	11.800
2025-811	149 ARC i2000s			12	10.817	0.607	5.61	8.800	12.800
2025-811	169 ATELLICA			10	11.090	3.254	29.35	9.100	13.100
2025-812	116 ROCHE COBA			17	17.100	0.610	3.57	14.000	20.200
2025-812	125 B.C.ACCESS			11	14.900	0.519	3.48	12.200	17.600
2025-812	125 B.C.ACCESS			11	17.391	1.803	10.37	14.300	20.500
2025-812	149 ARC i2000s			12	15.225	0.815	5.35	12.500	18.000
2025-812	169 ATELLICA			10	17.550	1.403	7.99	14.400	20.700

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
029	FOLL. STIM. HOR.-FSH	CLIA TEST ID #: 542	EVALUATION CRITERIA: TARGET VALUE	18	% OR 2.00	{GREATER}				
2025-813	116 ROCHE COBA			17	6.518	0.285	4.38	4.500	8.500	
2025-813	125 B.C.ACCESS			11	6.636	0.662	9.98	4.600	8.600	
2025-813	125 B.C.ACCESS			11	4.722	0.225	4.76	2.700	6.700	
2025-813	149 ARC i2000s			12	5.817	0.273	4.70	3.800	7.800	
2025-813	169 ATELLICA			10	6.660	0.233	3.50	4.700	8.700	
2025-814	116 ROCHE COBA			17	32.412	1.210	3.73	26.600	38.200	
2025-814	125 B.C.ACCESS			11	30.678	1.074	3.50	25.200	36.200	
2025-814	125 B.C.ACCESS			11	33.464	3.448	10.30	27.400	39.500	
2025-814	149 ARC i2000s			12	30.342	1.143	3.77	24.900	35.800	
2025-814	169 ATELLICA			10	33.000	1.832	5.55	27.100	38.900	
2025-815	116 ROCHE COBA			17	24.182	0.965	3.99	19.800	28.500	
2025-815	125 B.C.ACCESS			11	25.255	2.451	9.71	20.700	29.800	
2025-815	125 B.C.ACCESS			11	22.267	0.889	3.99	18.300	26.300	
2025-815	149 ARC i2000s			12	22.150	1.235	5.58	18.200	26.100	
2025-815	169 ATELLICA			10	25.180	1.511	6.00	20.600	29.700	
030	FREE THYROXINE	CLIA TEST ID #: 545	EVALUATION CRITERIA: TARGET VALUE	15	% OR 0.30	{GREATER}				
2025-811	115 VITROS ECI			47	2.765	0.184	6.67	2.400	3.200	
2025-811	115 VITROS ECI			47	3.400	0.047	1.39	2.900	3.900	
2025-811	116 ROCHE COBA			51	1.354	0.061	4.48	1.100	1.700	
2025-811	125 B.C.ACCESS			39	1.151	0.098	8.54	0.900	1.500	
2025-811	149 ARC i2000s			23	1.170	0.069	5.88	0.900	1.500	
2025-811	160 SIEMENS EX			40	1.372	0.075	5.46	1.100	1.700	
2025-811	169 ATELLICA			23	1.139	0.071	6.20	0.800	1.400	
2025-812	115 VITROS ECI			47	4.800	0.094	1.96	4.100	5.500	
2025-812	115 VITROS ECI			47	4.049	0.285	7.04	3.400	4.700	
2025-812	116 ROCHE COBA			51	1.739	0.060	3.43	1.400	2.000	

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)			
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-812	125	B.C.ACCESS		39	1.476	0.078	5.25	1.200	1.800
2025-812	149	ARC i2000s		23	1.539	0.092	5.98	1.200	1.800
2025-812	160	SIEMENS EX		40	1.750	0.095	5.42	1.500	2.100
2025-812	169	APELLICA		23	1.465	0.070	4.77	1.200	1.800
030	FREE THYROXINE		CLIA TEST ID #: 545	EVALUATION CRITERIA: TARGET VALUE 15 % OR 0.30 {GREATER}					
2025-813	115	VITROS ECI		47	1.513	0.096	6.34	1.200	1.800
2025-813	115	VITROS ECI		47	0.900	0.082	9.07	0.600	1.200
2025-813	116	ROCHE COBA		51	0.888	0.032	3.66	0.600	1.200
2025-813	125	B.C.ACCESS		39	0.808	0.053	6.59	0.500	1.100
2025-813	149	ARC i2000s		23	0.817	0.048	5.88	0.500	1.100
2025-813	160	SIEMENS EX		40	0.926	0.074	8.01	0.600	1.200
2025-813	169	APELLICA		23	0.778	0.051	6.52	0.500	1.100
2025-814	115	VITROS ECI		47	2.767	0.189	6.82	2.400	3.200
2025-814	115	VITROS ECI		47	6.496	0.242	3.73	5.500	7.500
2025-814	116	ROCHE COBA		51	2.725	0.086	3.15	2.300	3.100
2025-814	125	B.C.ACCESS		39	2.203	0.106	4.83	1.900	2.500
2025-814	149	ARC i2000s		23	2.330	0.180	7.74	2.000	2.700
2025-814	160	SIEMENS EX		40	2.750	0.130	4.74	2.300	3.200
2025-814	169	APELLICA		23	2.250	0.084	3.73	1.900	2.600
2025-815	115	VITROS ECI		47	5.387	0.313	5.81	4.600	6.200
2025-815	115	VITROS ECI		47	2.233	0.170	7.61	1.900	2.600
2025-815	116	ROCHE COBA		51	2.225	0.076	3.43	1.900	2.600
2025-815	125	B.C.ACCESS		39	1.861	0.093	5.01	1.600	2.200
2025-815	149	ARC i2000s		23	1.930	0.116	6.00	1.600	2.200
2025-815	160	SIEMENS EX		40	2.210	0.114	5.14	1.900	2.500
2025-815	169	APELLICA		23	1.874	0.067	3.59	1.600	2.200
032	hCG-QUANTITATIVE		CLIA TEST ID #: 555	EVALUATION CRITERIA: TARGET VALUE 18 % OR 3.00 {GREATER}					
2025-811	115	VITROS ECI		24	111.129	8.349	7.51	91.100	131.100

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-811	116	ROCHE COBA		18	109.844	4.836	4.40	90.100	129.600	
2025-811	169	APELLICA		12	117.608	6.970	5.93	96.400	138.800	
032	hCG-QUANTITATIVE		CLIA TEST ID #: 555	EVALUATION CRITERIA: TARGET VALUE 18 % OR 3.00 {GREATER}						
2025-812	115	VITROS ECI		24	221.333	14.836	6.70	181.500	261.200	
2025-812	116	ROCHE COBA		18	221.878	7.316	3.30	181.900	261.800	
2025-812	169	APELLICA		12	229.775	20.825	9.06	188.400	271.100	
2025-813	115	VITROS ECI		24	2.400	0.000	0.00	0	5.400	
2025-813	116	ROCHE COBA		18	0.694	0.106	15.21	0	3.700	
2025-813	169	APELLICA		12	2.525	0.224	8.87	0	5.500	
2025-814	115	VITROS ECI		24	554.900	35.597	6.41	455.000	654.800	
2025-814	116	ROCHE COBA		18	554.633	19.936	3.59	454.800	654.500	
2025-814	169	APELLICA		12	564.817	39.314	6.96	463.100	666.500	
2025-815	115	VITROS ECI		24	372.804	21.966	5.89	305.700	439.900	
2025-815	116	ROCHE COBA		18	372.572	15.909	4.27	305.500	439.600	
2025-815	169	APELLICA		12	391.317	18.956	4.84	320.900	461.800	
035	PROLACTIN		CLIA TEST ID #: 563	EVALUATION CRITERIA: TARGET VALUE 20 %						
2025-811	116	ROCHE COBA		17	5.500	0.240	4.36	4.400	6.600	
2025-811	125	B.C.ACCESS		11	7.745	0.345	4.45	6.200	9.300	
2025-811	169	APELLICA		10	5.150	0.191	3.71	4.100	6.200	
2025-812	116	ROCHE COBA		17	9.488	0.362	3.82	7.600	11.400	
2025-812	125	B.C.ACCESS		11	13.291	0.619	4.65	10.600	15.900	
2025-812	169	APELLICA		10	8.560	0.329	3.85	6.800	10.300	
2025-813	116	ROCHE COBA		17	1.625	0.066	4.07	1.300	2.000	
2025-813	125	B.C.ACCESS		11	1.836	0.077	4.20	1.500	2.200	
2025-813	169	APELLICA		10	1.580	0.098	6.20	1.300	1.900	

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
035	PROLACTIN		CLIA TEST ID #: 563	EVALUATION CRITERIA: TARGET VALUE 20 %							
2025-814	116	ROCHE COBA		17	21.881	0.909	4.15	17.500	26.300		
2025-814	125	B.C.ACCESS		11	29.136	1.338	4.59	23.300	35.000		
2025-814	169	APELLICA		10	18.740	0.510	2.72	15.000	22.500		
2025-815	116	ROCHE COBA		17	15.025	0.563	3.75	12.000	18.000		
2025-815	125	B.C.ACCESS		11	20.636	1.144	5.54	16.500	24.800		
2025-815	169	APELLICA		10	13.500	0.319	2.37	10.800	16.200		
037	TESTOSTERONE		CLIA TEST ID #: 570	EVALUATION CRITERIA: TARGET VALUE 30 % OR 0.20 {GREATER}							
2025-811	116	ROCHE COBA		10	352.790	17.156	4.86	247.000	458.600		
2025-811	149	ARC i2000s		10	324.210	16.829	5.19	226.900	421.500		
2025-811	169	APELLICA		10	351.100	19.762	5.63	245.800	456.400		
2025-812	116	ROCHE COBA		10	566.940	28.772	5.07	396.900	737.000		
2025-812	149	ARC i2000s		10	540.520	32.073	5.93	378.400	702.700		
2025-812	169	APELLICA		10	513.220	38.404	7.48	359.300	667.200		
2025-813	116	ROCHE COBA		10	99.850	7.562	7.57	69.900	129.800		
2025-813	149	ARC i2000s		10	107.860	6.600	6.12	75.500	140.200		
2025-813	169	APELLICA		10	106.060	6.811	6.42	74.200	137.900		
2025-814	116	ROCHE COBA		10	1022.000	309.664	30.30	715.400	1328.600		
2025-814	149	ARC i2000s		10	1211.960	106.803	8.81	848.400	1575.500		
2025-814	169	APELLICA		10	911.690	57.783	6.34	638.200	1185.200		
2025-815	116	ROCHE COBA		10	828.200	35.865	4.33	579.700	1076.700		
2025-815	149	ARC i2000s		10	1525.860	1958.612	128.36	1068.100	1983.600		
2025-815	169	APELLICA		10	716.590	35.687	4.98	501.600	931.600		
039	THYRO. STI. HOR.-TSH		CLIA TEST ID #: 585	EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.20 {GREATER}							
2025-811	115	VITROS ECI		57	2.120	0.072	3.39	1.700	2.500		

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY SUB: 30 ENDOCRINOLOGY GRP: 40 ENDOCRINOLOGY (GEN.)

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2025-811	116	ROCHE COBA		58	1.945	0.109	5.58	1.600	2.300
2025-811	125	B.C.ACCESS		47	2.389	0.173	7.24	1.900	2.900
2025-811	125	B.C.ACCESS		47	1.661	0.092	5.54	1.300	2.000
2025-811	149	ARC i2000s		25	1.580	0.069	4.38	1.300	1.900
2025-811	160	SIEMENS EX		62	1.374	0.108	7.90	1.100	1.600
2025-811	169	APELLICA		26	1.658	0.104	6.30	1.300	2.000
039	THYRO. STI. HOR.-TSH	CLIA TEST ID #: 585	EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.20 {GREATER}						
2025-812	115	VITROS ECI		57	3.572	0.104	2.91	2.900	4.300
2025-812	116	ROCHE COBA		58	3.084	0.171	5.54	2.500	3.700
2025-812	125	B.C.ACCESS		47	2.724	0.148	5.42	2.200	3.300
2025-812	125	B.C.ACCESS		47	3.844	0.317	8.24	3.100	4.600
2025-812	149	ARC i2000s		25	2.592	0.093	3.61	2.100	3.100
2025-812	160	SIEMENS EX		62	2.185	0.139	6.36	1.700	2.600
2025-812	169	APELLICA		26	2.696	0.183	6.78	2.200	3.200
2025-813	115	VITROS ECI		57	0.525	0.047	8.95	0.300	0.700
2025-813	116	ROCHE COBA		58	0.740	0.049	6.61	0.500	0.900
2025-813	125	B.C.ACCESS		47	0.656	0.050	7.58	0.500	0.900
2025-813	125	B.C.ACCESS		47	0.591	0.035	5.93	0.400	0.800
2025-813	149	ARC i2000s		25	0.520	0.040	7.69	0.300	0.700
2025-813	160	SIEMENS EX		62	0.545	0.053	9.70	0.300	0.700
2025-813	169	APELLICA		26	0.569	0.046	8.11	0.400	0.800
2025-814	115	VITROS ECI		57	7.500	0.178	2.38	6.000	9.000
2025-814	116	ROCHE COBA		58	6.200	0.302	4.87	5.000	7.400
2025-814	125	B.C.ACCESS		47	5.867	0.344	5.86	4.700	7.000
2025-814	125	B.C.ACCESS		47	8.311	0.617	7.43	6.600	10.000
2025-814	149	ARC i2000s		25	5.516	0.244	4.43	4.400	6.600
2025-814	160	SIEMENS EX		62	4.469	0.301	6.73	3.600	5.400
2025-814	169	APELLICA		26	5.708	0.306	5.36	4.600	6.800

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY SUB: 30 ENDOCRINOLOGY GRP: 40 ENDOCRINOLOGY (GEN.)

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
039	THYRO. STI. HOR.-TSH	CLIA TEST ID #: 585	EVALUATION CRITERIA: TARGET VALUE	20	%	OR 0.20	{GREATER}		
2025-815	115 VITROS ECI			57	5.435	0.132	2.42	4.300	6.500
2025-815	116 ROCHE COBA			58	4.572	0.225	4.92	3.700	5.500
2025-815	125 B.C.ACCESS			47	5.856	0.437	7.47	4.700	7.000
2025-815	125 B.C.ACCESS			47	4.189	0.231	5.50	3.400	5.000
2025-815	149 ARC i2000s			25	3.976	0.166	4.17	3.200	4.800
2025-815	160 SIEMENS EX			62	3.258	0.262	8.06	2.600	3.900
2025-815	169 ATELLICA			26	4.131	0.203	4.92	3.300	5.000
040	THYROXINE (T4)	CLIA TEST ID #: 595	EVALUATION CRITERIA: TARGET VALUE	20	%	OR 1.00	{GREATER}		
2025-811	32 SIEM DIME.			38	5.576	0.434	7.78	4.500	6.700
2025-811	32 SIEM DIME.			38	6.467	0.287	4.43	5.200	7.800
2025-811	115 VITROS ECI			46	4.633	0.200	4.32	3.600	5.600
2025-811	116 ROCHE COBA			47	5.298	0.427	8.05	4.200	6.400
2025-811	125 B.C.ACCESS			38	5.147	0.382	7.41	4.100	6.200
2025-811	149 ARC i2000s			22	5.041	0.320	6.35	4.000	6.000
2025-811	169 ATELLICA			23	6.467	0.287	4.43	5.200	7.800
2025-811	169 ATELLICA			23	5.732	0.287	5.00	4.600	6.900
2025-812	32 SIEM DIME.			38	7.451	0.401	5.38	6.000	8.900
2025-812	32 SIEM DIME.			38	8.333	0.309	3.71	6.700	10.000
2025-812	115 VITROS ECI			46	6.361	0.247	3.89	5.100	7.600
2025-812	116 ROCHE COBA			47	7.041	0.399	5.67	5.600	8.400
2025-812	125 B.C.ACCESS			38	7.153	0.518	7.25	5.700	8.600
2025-812	149 ARC i2000s			22	6.959	0.261	3.74	5.600	8.400
2025-812	169 ATELLICA			23	7.739	0.740	9.56	6.200	9.300
2025-812	169 ATELLICA			23	8.333	0.309	3.71	6.700	10.000
2025-813	32 SIEM DIME.			38	3.395	0.357	10.52	2.400	4.400
2025-813	32 SIEM DIME.			38	4.033	0.330	8.18	3.000	5.000
2025-813	115 VITROS ECI			46	2.938	0.143	4.88	1.900	3.900

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2025-813	116	ROCHE COBA		47	3.448	0.234	6.78	2.400	4.400
2025-813	125	B.C.ACCESS		38	3.082	0.269	8.74	2.100	4.100
2025-813	149	ARC i2000s		22	2.977	0.289	9.71	2.000	4.000
2025-813	169	APELLICA		23	4.033	0.330	8.18	3.000	5.000
2025-813	169	APELLICA		23	3.736	0.201	5.39	2.700	4.700
040	THYROXINE (T4)		CLIA TEST ID #: 595	EVALUATION CRITERIA: TARGET VALUE 20 % OR 1.00 {GREATER}					
2025-814	32	SIEM DIME.		38	13.613	0.747	5.49	10.900	16.300
2025-814	32	SIEM DIME.		38	14.867	0.309	2.08	11.900	17.800
2025-814	115	VITROS ECI		46	11.037	0.448	4.06	8.800	13.200
2025-814	116	ROCHE COBA		47	12.232	0.716	5.85	9.800	14.700
2025-814	125	B.C.ACCESS		38	11.524	0.569	4.94	9.200	13.800
2025-814	149	ARC i2000s		22	12.800	0.666	5.20	10.200	15.400
2025-814	169	APELLICA		23	12.243	0.710	5.80	9.800	14.700
2025-814	169	APELLICA		23	14.867	0.309	2.08	11.900	17.800
2025-815	32	SIEM DIME.		38	10.432	0.467	4.47	8.300	12.500
2025-815	32	SIEM DIME.		38	11.067	0.525	4.74	8.900	13.300
2025-815	115	VITROS ECI		46	8.537	0.355	4.15	6.800	10.200
2025-815	116	ROCHE COBA		47	9.515	0.587	6.17	7.600	11.400
2025-815	125	B.C.ACCESS		38	9.339	0.576	6.17	7.500	11.200
2025-815	149	ARC i2000s		22	9.877	0.448	4.54	7.900	11.900
2025-815	169	APELLICA		23	11.067	0.525	4.74	8.900	13.300
2025-815	169	APELLICA		23	10.252	0.737	7.19	8.200	12.300
141	FOLATE		CLIA TEST ID #: 541	EVALUATION CRITERIA: TARGET VALUE 30 % OR 1.00 {GREATER}					
2025-811	115	VITROS ECI		18	1.683	0.211	12.56	0.700	2.700
2025-811	116	ROCHE COBA		24	2.000	0.000	0.00	1.000	3.000
2025-811	125	B.C.ACCESS		12	2.483	0.182	7.32	1.500	3.500
2025-811	149	ARC i2000s		14	2.200	0.124	5.64	1.200	3.200
2025-812	115	VITROS ECI		18	2.828	0.352	12.46	1.800	3.800

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2025-812	116	ROCHE COBA		24	2.467	0.335	13.58	1.500	3.500	
2025-812	125	B.C.ACCESS		12	4.208	0.111	2.65	2.900	5.500	
2025-812	149	ARC i2000s		14	3.614	0.358	9.91	2.500	4.700	
141	FOLATE		CLIA TEST ID #: 541	EVALUATION CRITERIA: TARGET VALUE 30 % OR 1.00 {GREATER}						
2025-813	115	VITROS ECI		18	0.806	0.135	16.79	0	1.800	
2025-813	116	ROCHE COBA		24	2.000	0.000	0.00	1.000	3.000	
2025-813	125	B.C.ACCESS		12	0.933	0.149	15.97	0	1.900	
2025-813	149	ARC i2000s		14	1.171	0.785	67.02	0.200	2.200	
2025-814	115	VITROS ECI		18	7.218	0.623	8.64	5.100	9.400	
2025-814	116	ROCHE COBA		24	6.800	0.911	13.40	4.800	8.800	
2025-814	125	B.C.ACCESS		12	9.492	0.315	3.32	6.600	12.300	
2025-814	149	ARC i2000s		14	8.808	0.506	5.75	6.200	11.500	
2025-815	115	VITROS ECI		18	4.750	0.543	11.43	3.300	6.200	
2025-815	116	ROCHE COBA		24	4.479	0.702	15.67	3.100	5.800	
2025-815	125	B.C.ACCESS		12	6.625	0.280	4.23	4.600	8.600	
2025-815	149	ARC i2000s		14	5.931	0.343	5.78	4.200	7.700	
142	hLH (HUMAN LUT. HOR)		CLIA TEST ID #: 560	EVALUATION CRITERIA: TARGET VALUE 20 %						
2025-811	116	ROCHE COBA		14	6.675	0.185	2.78	5.300	8.000	
2025-811	116	ROCHE COBA		14	9.654	0.411	4.25	7.700	11.600	
2025-811	125	B.C.ACCESS		11	8.673	0.501	5.78	6.900	10.400	
2025-811	149	ARC i2000s		10	5.770	0.279	4.84	4.600	6.900	
2025-811	169	ATELLICA		10	7.970	0.269	3.37	6.400	9.600	
2025-812	116	ROCHE COBA		14	15.057	1.047	6.95	12.000	18.100	
2025-812	116	ROCHE COBA		14	10.950	0.304	2.78	8.800	13.100	
2025-812	125	B.C.ACCESS		11	13.818	0.875	6.33	11.100	16.600	
2025-812	149	ARC i2000s		10	9.110	0.802	8.80	7.300	10.900	
2025-812	169	ATELLICA		10	12.260	0.755	6.16	9.800	14.700	

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)							
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE		
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
142 hLH (HUMAN LUT. HOR)				CLIA TEST ID #: 560						EVALUATION CRITERIA: TARGET VALUE 20 %	
2025-813	116	ROCHE COBA		14	2.175	0.066	3.04	1.700	2.600		
2025-813	116	ROCHE COBA		14	4.123	0.137	3.32	3.300	4.900		
2025-813	125	B.C.ACCESS		11	2.873	0.196	6.82	2.300	3.400		
2025-813	149	ARC i2000s		10	2.150	0.430	19.98	1.700	2.600		
2025-813	169	ATELLICA		10	3.140	0.092	2.92	2.500	3.800		
2025-814	116	ROCHE COBA		14	29.900	2.232	7.47	23.900	35.900		
2025-814	116	ROCHE COBA		14	21.338	0.507	2.38	17.100	25.600		
2025-814	125	B.C.ACCESS		11	27.473	2.221	8.08	22.000	33.000		
2025-814	149	ARC i2000s		10	18.820	1.280	6.80	15.100	22.600		
2025-814	169	ATELLICA		10	25.280	0.985	3.90	20.200	30.300		
2025-815	116	ROCHE COBA		14	15.975	0.504	3.16	12.800	19.200		
2025-815	116	ROCHE COBA		14	21.592	0.905	4.19	17.300	25.900		
2025-815	125	B.C.ACCESS		11	20.145	1.596	7.92	16.100	24.200		
2025-815	149	ARC i2000s		10	13.950	0.674	4.83	11.200	16.700		
2025-815	169	ATELLICA		10	18.300	0.377	2.06	14.600	22.000		

SPE: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)								
TEST	LEVEL 1	LEVEL 2	LEVEL 3	PART	REFEREE	COMMER	REPORTED	PART	# LABS	# "SF"	Score	
SAMPLE	RESULT	RESULT	RESULT	LOW/HIGH	LOW/HIGH	LOW/HIGH	VALUE	LABS	ANSW	LABS		
031 hCG-QUALITATIVE												
2025-811	113	BIO-SIGN		002	002	002	002	002 - POSITIVE	18	18	18	100
2025-811	142	INSTANT VI		002	002	002	002	002 - POSITIVE	25	25	25	100
2025-811	150	AIM STEP		002	002	002	002	002 - POSITIVE	115	115	115	100
2025-811	164	HCG Alere		002	002	002	002	002 - POSITIVE	80	80	80	100
2025-811	166	FaStep		002	002	002	002	002 - POSITIVE	13	13	13	100
2025-811	167	Tanner Sci		002	002	002	002	002 - POSITIVE	10	10	10	100

Participant Summary
MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 40 ENDOCRINOLOGY (GEN.)						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2025-811	168	STANBIO 20		002 002	002 002		002 - POSITIVE	15	15	15	100		
		031 hCG-QUALITATIVE											
2025-812	113	BIO-SIGN		002 002	002 002		002 - POSITIVE	18	18	18	100		
2025-812	142	INSTANT VI		002 002	002 002		002 - POSITIVE	25	25	25	100		
2025-812	150	AIM STEP		002 002	002 002		002 - POSITIVE	115	115	115	100		
2025-812	164	HCG Alere		002 002	002 002		002 - POSITIVE	80	80	80	100		
2025-812	166	FaStep		002 002	002 002		002 - POSITIVE	13	13	13	100		
2025-812	167	Tanner Sci		002 002	002 002		002 - POSITIVE	10	10	10	100		
2025-812	168	STANBIO 20		002 002	002 002		002 - POSITIVE	15	15	15	100		
2025-813	113	BIO-SIGN		001 001	001 001		001 - NEGATIVE	18	18	18	100		
2025-813	142	INSTANT VI		001 001	001 001		002 - POSITIVE	25	1	24	0		
2025-813	142	INSTANT VI		001 001	001 001		001 - NEGATIVE	25	24	24	100		
2025-813	150	AIM STEP		001 001	001 001		001 - NEGATIVE	115	114	114	100		
2025-813	150	AIM STEP		001 001	001 001		002 - POSITIVE	115	1	114	0		
2025-813	164	HCG Alere		001 001	001 001		001 - NEGATIVE	80	80	80	100		
2025-813	166	FaStep		001 001	001 001		001 - NEGATIVE	13	13	13	100		
2025-813	167	Tanner Sci		001 001	001 001		001 - NEGATIVE	10	10	10	100		
2025-813	168	STANBIO 20		001 001	001 001		001 - NEGATIVE	15	15	15	100		
2025-814	113	BIO-SIGN		002 002	002 002		002 - POSITIVE	18	18	18	100		
2025-814	142	INSTANT VI		002 002	002 002		002 - POSITIVE	25	25	25	100		
2025-814	150	AIM STEP		002 002	002 002		002 - POSITIVE	115	114	114	100		
2025-814	150	AIM STEP		002 002	002 002		001 - NEGATIVE	115	1	114	0		
2025-814	164	HCG Alere		002 002	002 002		002 - POSITIVE	80	80	80	100		
2025-814	166	FaStep		002 002	002 002		002 - POSITIVE	13	13	13	100		
2025-814	167	Tanner Sci		002 002	002 002		002 - POSITIVE	10	10	10	100		
2025-814	168	STANBIO 20		002 002	002 002		002 - POSITIVE	15	15	15	100		

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 40 ENDOCRINOLOGY (GEN.)						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
031 hCG-QUALITATIVE												
2025-815	113	BIO-SIGN		002 002	002 002		002 - POSITIVE	18	18	18	100	
2025-815	142	INSTANT VI		002 002	002 002		002 - POSITIVE	25	25	25	100	
2025-815	150	AIM STEP		002 002	002 002		002 - POSITIVE	115	114	114	100	
2025-815	150	AIM STEP		002 002	002 002		001 - NEGATIVE	115	1	114	0	
2025-815	164	HCG Alere		002 002	002 002		002 - POSITIVE	80	80	80	100	
2025-815	166	FaStep		002 002	002 002		002 - POSITIVE	13	13	13	100	
2025-815	167	Tanner Sci		002 002	002 002		002 - POSITIVE	10	10	10	100	
2025-815	168	STANBIO 20		002 002	002 002		002 - POSITIVE	15	15	15	100	

SPE: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
151 hCG ONLY QUALITATIVE											
2025-801	018	BIO SIGN		002 002	002 002		002 - POSITIVE	25	25	25	100
2025-801	114	INSTANT VI		002 002	002 002		002 - POSITIVE	59	59	59	100
2025-801	118	AIM STEP		002 002	002 002		002 - POSITIVE	241	241	241	100
2025-801	130	ALERE HCG		002 002	002 002		002 - POSITIVE	101	101	101	100
2025-801	133	FaStep		002 002	002 002		002 - POSITIVE	35	35	35	100
2025-801	134	Tanner Sc.		002 002	002 002		002 - POSITIVE	55	55	55	100
2025-801	135	STANBIO 20		002 002	002 002		002 - POSITIVE	10	10	10	100
2025-801	136	CLARITY		002 002	002 002		002 - POSITIVE	22	22	22	100
2025-801	137	CARDINAL		002 002	002 002		002 - POSITIVE	12	12	12	100
2025-802	018	BIO SIGN		002 002	002 002		002 - POSITIVE	25	25	25	100
2025-802	114	INSTANT VI		002 002	002 002		002 - POSITIVE	59	59	59	100

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-802	118	AIM STEP		002 002	002 002		002 - POSITIVE	241	241	241	100	
2025-802	130	ALERE HCG		002 002	002 002		002 - POSITIVE	101	101	101	100	
2025-802	133	FaStep		002 002	002 002		002 - POSITIVE	35	35	35	100	
2025-802	134	Tanner Sc.		002 002	002 002		002 - POSITIVE	55	55	55	100	
2025-802	135	STANBIO 20		002 002	002 002		002 - POSITIVE	10	10	10	100	
2025-802	136	CLARITY		002 002	002 002		002 - POSITIVE	22	22	22	100	
2025-802	137	CARDINAL		002 002	002 002		002 - POSITIVE	12	12	12	100	
151 hCG ONLY QUALITATIVE												
2025-803	018	BIO SIGN		001 001	001 001		001 - NEGATIVE	25	25	25	100	
2025-803	114	INSTANT VI		001 001	001 001		001 - NEGATIVE	59	59	59	100	
2025-803	118	AIM STEP		001 001	001 001		002 - POSITIVE	241	1	240	0	
2025-803	118	AIM STEP		001 001	001 001		001 - NEGATIVE	241	240	240	100	
2025-803	130	ALERE HCG		001 001	001 001		001 - NEGATIVE	101	101	101	100	
2025-803	133	FaStep		001 001	001 001		001 - NEGATIVE	35	35	35	100	
2025-803	134	Tanner Sc.		001 001	001 001		001 - NEGATIVE	55	55	55	100	
2025-803	135	STANBIO 20		001 001	001 001		001 - NEGATIVE	10	10	10	100	
2025-803	136	CLARITY		001 001	001 001		001 - NEGATIVE	22	22	22	100	
2025-803	137	CARDINAL		001 001	001 001		001 - NEGATIVE	12	12	12	100	
2025-804	018	BIO SIGN		001 001	001 001		001 - NEGATIVE	25	25	25	100	
2025-804	114	INSTANT VI		001 001	001 001		001 - NEGATIVE	59	59	59	100	
2025-804	118	AIM STEP		001 001	001 001		001 - NEGATIVE	241	241	241	100	
2025-804	130	ALERE HCG		001 001	001 001		001 - NEGATIVE	101	101	101	100	
2025-804	133	FaStep		001 001	001 001		001 - NEGATIVE	35	35	35	100	
2025-804	134	Tanner Sc.		001 001	001 001		001 - NEGATIVE	55	55	55	100	
2025-804	135	STANBIO 20		001 001	001 001		001 - NEGATIVE	10	10	10	100	
2025-804	136	CLARITY		001 001	001 001		001 - NEGATIVE	22	22	22	100	
2025-804	137	CARDINAL		001 001	001 001		001 - NEGATIVE	12	12	12	100	

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
151 hCG ONLY QUALITATIVE												
2025-805	018	BIO SIGN		002 002	002 002		002 - POSITIVE	25	25	25	100	
2025-805	114	INSTANT VI		002 002	002 002		002 - POSITIVE	59	59	59	100	
2025-805	118	AIM STEP		002 002	002 002		002 - POSITIVE	241	240	240	100	
2025-805	118	AIM STEP		002 002	002 002		001 - NEGATIVE	241	1	240	0	
2025-805	130	ALERE HCG		002 002	002 002		002 - POSITIVE	101	101	101	100	
2025-805	133	FaStep		002 002	002 002		002 - POSITIVE	35	35	35	100	
2025-805	134	Tanner Sc.		002 002	002 002		002 - POSITIVE	55	55	55	100	
2025-805	135	STANBIO 20		002 002	002 002		002 - POSITIVE	10	10	10	100	
2025-805	136	CLARITY		002 002	002 002		002 - POSITIVE	22	21	21	100	
2025-805	136	CLARITY		002 002	002 002		001 - NEGATIVE	22	1	21	0	
2025-805	137	CARDINAL		002 002	002 002		002 - POSITIVE	12	12	12	100	

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 55 ENDO.(T3 UPTAKE)					
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
173	T3 UPTAKE	CLIA TEST ID #: 565	EVALUATION CRITERIA: TARGET VALUE 18 %									
2025-811	1 %U	84 VITROS ECI	1 25-35	45	55.377	1.553	2.80	45.410	65.340			
2025-811	1 %U	91 B.C.ACCESS	2 35-45	17	47.588	2.501	5.26	39.020	56.150			
2025-811	2 TUV	95 Arc i2000s	3 0.7 - 1.2	17	0.778	0.047	6.01	0.640	0.920			
2025-811	4 %	32 DIMENSION	2 35-45	39	38.455	1.401	3.64	31.530	45.380			
2025-811	4 %	91 B.C.ACCESS	2 35-45	13	46.846	2.647	5.65	38.410	55.280			
2025-811	4 %	106 ATELLICA	1 25-35	18	45.229	3.132	6.93	37.090	53.370			
2025-811	5 TBI	98 ROCHE COBA	4 0.8-1.3	43	0.763	0.046	6.08	0.630	0.900			
2025-812	1 %U	84 VITROS ECI	1 25-35	45	51.985	1.849	3.56	42.630	61.340			
2025-812	1 %U	91 B.C.ACCESS	2 35-45	17	47.565	2.642	5.55	39.000	56.130			
2025-812	2 TUV	95 Arc i2000s	3 0.7 - 1.2	17	0.875	0.047	5.35	0.720	1.030			

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 55 ENDO.(T3 UPTAKE)						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
2025-812	4 %	32 DIMENSION	2 35-45	39	38.319	1.805	4.71	31.420	45.220			
2025-812	4 %	91 B.C.ACCESS	2 35-45	13	47.138	2.735	5.80	38.650	55.620			
2025-812	4 %	106 ATELLICA	1 25-35	18	43.077	2.330	5.41	35.320	50.830			
2025-812	5 TBI	98 ROCHE COBA	4 0.8-1.3	43	0.731	0.052	7.09	0.600	0.860			
173 T3 UPTAKE		CLIA TEST ID #: 565	EVALUATION CRITERIA: TARGET VALUE 18 %									
2025-813	1 %U	84 VITROS ECI	1 25-35	45	57.711	1.983	3.44	47.320	68.100			
2025-813	1 %U	91 B.C.ACCESS	2 35-45	17	48.712	2.259	4.64	39.940	57.480			
2025-813	2 TUV	95 Arc i2000s	3 0.7 - 1.2	17	0.675	0.042	6.26	0.550	0.800			
2025-813	4 %	32 DIMENSION	2 35-45	39	37.895	1.663	4.39	31.070	44.720			
2025-813	4 %	91 B.C.ACCESS	2 35-45	13	48.662	3.358	6.90	39.900	57.420			
2025-813	4 %	106 ATELLICA	1 25-35	18	50.673	2.920	5.76	41.550	59.790			
2025-813	5 TBI	98 ROCHE COBA	4 0.8-1.3	43	0.829	0.044	5.29	0.680	0.980			
2025-814	1 %U	84 VITROS ECI	1 25-35	45	45.407	1.598	3.52	37.230	53.580			
2025-814	1 %U	91 B.C.ACCESS	2 35-45	17	45.412	3.157	6.95	37.240	53.590			
2025-814	2 TUV	95 Arc i2000s	3 0.7 - 1.2	17	1.092	0.056	5.16	0.900	1.290			
2025-814	4 %	32 DIMENSION	2 35-45	39	39.329	1.666	4.24	32.250	46.410			
2025-814	4 %	91 B.C.ACCESS	2 35-45	13	45.485	2.264	4.98	37.300	53.670			
2025-814	4 %	106 ATELLICA	1 25-35	18	35.486	1.638	4.62	29.100	41.870			
2025-814	5 TBI	98 ROCHE COBA	4 0.8-1.3	43	0.616	0.062	10.00	0.510	0.730			
2025-815	1 %U	84 VITROS ECI	1 25-35	45	48.158	1.684	3.50	39.490	56.830			
2025-815	1 %U	91 B.C.ACCESS	2 35-45	17	46.188	3.269	7.08	37.870	54.500			
2025-815	2 TUV	95 Arc i2000s	3 0.7 - 1.2	17	0.981	0.059	5.99	0.800	1.160			
2025-815	4 %	32 DIMENSION	2 35-45	39	38.935	1.626	4.18	31.930	45.940			
2025-815	4 %	91 B.C.ACCESS	2 35-45	13	45.800	2.838	6.20	37.560	54.040			
2025-815	4 %	106 ATELLICA	1 25-35	18	38.400	2.083	5.43	31.490	45.310			
2025-815	5 TBI	98 ROCHE COBA	4 0.8-1.3	43	0.675	0.057	8.43	0.550	0.800			

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 40 TOXICOLOGY			GRP: 60 TOXICOLOGY				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
043 DIGOXIN		CLIA TEST ID #: 645	EVALUATION CRITERIA: TARGET VALUE	15	%	OR 0.20	{GREATER}			
2025-811	50 VITROS			17	0.694	0.073	10.45	0.500	0.900	
2025-812	50 VITROS			17	0.900	0.077	8.52	0.700	1.100	
2025-813	50 VITROS			17	0.482	0.062	12.79	0.300	0.700	
2025-814	50 VITROS			17	1.659	0.103	6.22	1.400	1.900	
2025-815	50 VITROS			17	1.224	0.088	7.16	1.000	1.400	
045 FERRITIN		CLIA TEST ID #: 410	EVALUATION CRITERIA: TARGET VALUE	20	%					
2025-811	17 BECK.C.ACC			10	41.550	3.586	8.63	33.200	49.900	
2025-811	50 VITROS			22	40.291	2.073	5.14	32.200	48.300	
2025-811	90 ROCHE COBA			18	69.922	6.846	9.79	55.900	83.900	
2025-811	98 ARC i200sr			10	66.630	2.481	3.72	53.300	80.000	
2025-811	105 ATELLICA			15	43.467	2.118	4.87	34.800	52.200	
2025-812	17 BECK.C.ACC			10	65.640	4.777	7.28	52.500	78.800	
2025-812	50 VITROS			22	63.318	2.678	4.23	50.700	76.000	
2025-812	90 ROCHE COBA			18	107.656	7.619	7.08	86.100	129.200	
2025-812	98 ARC i200sr			10	109.380	5.111	4.67	87.500	131.300	
2025-812	105 ATELLICA			15	69.627	5.725	8.22	55.700	83.600	
2025-813	17 BECK.C.ACC			10	17.750	1.520	8.56	14.200	21.300	
2025-813	50 VITROS			22	18.623	0.937	5.03	14.900	22.300	
2025-813	90 ROCHE COBA			18	31.811	3.205	10.08	25.400	38.200	
2025-813	98 ARC i200sr			10	26.120	2.595	9.94	20.900	31.300	
2025-813	105 ATELLICA			15	19.033	0.848	4.46	15.200	22.800	

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 40 TOXICOLOGY			GRP: 60 TOXICOLOGY					
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
045	FERRITIN			CLIA TEST ID #: 410	EVALUATION CRITERIA: TARGET VALUE 20 %						
2025-814	17	BECK.C.ACC		10	141.800	10.371	7.31	113.400	170.200		
2025-814	50	VITROS		22	137.168	6.773	4.94	109.700	164.600		
2025-814	90	ROCHE COBA		18	228.878	13.839	6.05	183.100	274.700		
2025-814	98	ARC i200sr		10	233.610	9.106	3.90	186.900	280.300		
2025-814	105	ATELLICA		15	153.000	7.849	5.13	122.400	183.600		
2025-815	17	BECK.C.ACC		10	99.600	8.406	8.44	79.700	119.500		
2025-815	50	VITROS		22	97.073	5.005	5.16	77.700	116.500		
2025-815	90	ROCHE COBA		18	163.444	12.131	7.42	130.800	196.100		
2025-815	98	ARC i200sr		10	163.950	6.021	3.67	131.200	196.700		
2025-815	105	ATELLICA		15	107.653	5.974	5.55	86.100	129.200		
046	GENTAMICIN			CLIA TEST ID #: 665	EVALUATION CRITERIA: TARGET VALUE 25 %						
2025-811	50	VITROS		17	2.200	0.108	4.93	1.700	2.800		
2025-812	50	VITROS		17	4.253	0.124	2.92	3.200	5.300		
2025-813	50	VITROS		17	0.600	0.000	0.00	0.500	0.800		
2025-814	50	VITROS		17	10.635	0.606	5.70	8.000	13.300		
2025-815	50	VITROS		17	7.053	0.453	6.42	5.300	8.800		
050	PHENYTOIN			CLIA TEST ID #: 695	EVALUATION CRITERIA: TARGET VALUE 15 % OR 2.00 {GREATER}						
2025-811	50	VITROS		18	4.556	0.214	4.70	2.600	6.600		
2025-812	50	VITROS		18	8.844	0.344	3.88	6.800	10.800		
2025-813	50	VITROS		18	3.118	0.471	15.09	1.100	5.100		

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 40 TOXICOLOGY		GRP: 60 TOXICOLOGY						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
050	PHENYTOIN									
		CLIA TEST ID #:	695	EVALUATION CRITERIA: TARGET VALUE 15 % OR 2.00 {GREATER}						
2025-814	50 VITROS			18	21.167	0.913	4.32	18.000	24.300	
2025-815	50 VITROS			18	14.594	0.735	5.04	12.400	16.800	
054	THEOPHYLLINE									
		CLIA TEST ID #:	735	EVALUATION CRITERIA: TARGET VALUE 20 %						
2025-811	50 VITROS			14	11.929	0.585	4.90	9.500	14.300	
2025-812	50 VITROS			14	20.529	0.956	4.66	16.400	24.600	
2025-813	50 VITROS			14	2.964	0.462	15.60	2.400	3.600	
2025-814	50 VITROS			14	41.929	1.632	3.89	33.500	50.300	
2025-815	50 VITROS			14	31.836	1.179	3.70	25.500	38.200	
127	VANCOMYCIN									
		CLIA TEST ID #:	756	EVALUATION CRITERIA: TARGET VALUE 15 % OR 2.00 {GREATER}						
2025-811	50 VITROS			22	7.314	0.370	5.05	5.300	9.300	
2025-811	92 ROCHE COBA			12	7.642	0.328	4.29	5.600	9.600	
2025-812	50 VITROS			22	14.100	0.575	4.08	12.000	16.200	
2025-812	92 ROCHE COBA			12	15.375	0.836	5.44	13.100	17.700	
2025-813	50 VITROS			22	5.000	0.000	0.00	3.000	7.000	
2025-813	92 ROCHE COBA			12	4.000	0.000	0.00	2.000	6.000	
2025-814	50 VITROS			22	38.009	2.136	5.62	32.300	43.700	
2025-814	92 ROCHE COBA			12	38.292	1.459	3.81	32.500	44.000	
2025-815	50 VITROS			22	24.082	1.199	4.98	20.500	27.700	
2025-815	92 ROCHE COBA			12	26.083	0.826	3.17	22.200	30.000	

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 50 URINALYSIS		GRP: 70 URINALYSIS					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
065 URINA-PROTEIN QUANT.				CLIA TEST ID #: 0 EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}					
2025-841	58	VITROS		47	5.000	0.000	0.00	0.000	10.000
2025-841	62	SIEM DIM.		39	21.150	2.103	9.95	15.900	26.400
2025-841	79	BECK. COUL		19	4.639	0.751	16.20	0	9.600
2025-841	93	ARCHITECT		16	6.588	0.602	9.14	1.600	11.600
2025-841	113	ROCHE COBA		44	4.245	1.024	24.12	0	9.200
2025-841	146	APELLICA		21	22.414	2.007	8.95	16.800	28.000
2025-842	58	VITROS		47	169.651	8.817	5.20	127.200	212.100
2025-842	62	SIEM DIM.		39	116.542	2.247	1.93	87.400	145.700
2025-842	79	BECK. COUL		19	99.611	3.002	3.01	74.700	124.500
2025-842	93	ARCHITECT		16	100.320	2.978	2.97	75.200	125.400
2025-842	113	ROCHE COBA		44	94.632	2.349	2.48	71.000	118.300
2025-842	146	APELLICA		21	115.110	1.701	1.48	86.300	143.900
2025-843	58	VITROS		47	5.000	0.000	0.00	0.000	10.000
2025-843	62	SIEM DIM.		39	15.524	1.508	9.71	10.500	20.500
2025-843	79	BECK. COUL		19	4.878	0.600	12.29	0	9.900
2025-843	93	ARCHITECT		16	6.813	0.050	0.73	1.800	11.800
2025-843	113	ROCHE COBA		44	4.418	0.977	22.11	0	9.400
2025-843	146	APELLICA		21	16.110	1.771	10.99	11.100	21.100
2025-844	58	VITROS		47	155.664	9.878	6.35	116.700	194.600
2025-844	62	SIEM DIM.		39	113.577	1.668	1.47	85.200	142.000
2025-844	79	BECK. COUL		19	100.368	3.419	3.41	75.300	125.500
2025-844	93	ARCHITECT		16	95.933	2.716	2.83	72.000	119.900
2025-844	113	ROCHE COBA		44	89.184	1.949	2.19	66.900	111.500
2025-844	146	APELLICA		21	111.914	1.540	1.38	83.900	139.900

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS			
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
065	URINA-PROTEIN QUANT.	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	25	% OR 5.00	{GREATER}			
2025-845	58 VITROS			47	146.145	9.566	6.55	109.600	182.700
2025-845	62 SIEM DIM.			39	108.600	1.741	1.60	81.500	135.800
2025-845	79 BECK. COUL			19	97.779	3.070	3.14	73.300	122.200
2025-845	93 ARCHITECT			16	97.927	2.642	2.70	73.400	122.400
2025-845	113 ROCHE COBA			44	91.045	1.910	2.10	68.300	113.800
2025-845	146 ATELLICA			21	107.350	1.516	1.41	80.500	134.200
067	URI-SPECIFIC GRAVITY		EVALUATION CRITERIA: TARGET VALUE	3	SD				
2025-841	11 AMES NM10S			31	1.016	0.004	0.39	1.004	1.028
2025-841	13 BAYER CLI			19	1.016	0.003	0.32	1.006	1.025
2025-841	67 URISCAN			54	1.015	0.003	0.27	1.006	1.023
2025-841	72 URS-9-TECO			53	1.015	0.005	0.45	1.002	1.029
2025-841	80 ROCHE (CHE			36	1.011	0.002	0.23	1.004	1.018
2025-841	89 AIMSTRIP			163	1.014	0.003	0.29	1.006	1.023
2025-841	94 CLINITEK			102	1.015	0.003	0.29	1.006	1.024
2025-841	102 ACON LAB			114	1.015	0.003	0.33	1.005	1.026
2025-841	131 iCHEM VELO			35	1.025	0.001	0.09	1.023	1.028
2025-841	140 MISSION A			35	1.016	0.003	0.31	1.006	1.025
2025-841	145 CLINITEK			46	1.031	0.001	0.06	1.029	1.033
2025-841	147 Mission120			37	1.019	0.002	0.22	1.013	1.026
2025-841	148 Mission500			152	1.016	0.003	0.28	1.007	1.024
2025-841	151 Clari. Uro			31	1.015	0.002	0.22	1.009	1.022
2025-842	11 AMES NM10S			31	1.019	0.003	0.28	1.010	1.027
2025-842	13 BAYER CLI			19	1.019	0.002	0.22	1.012	1.025
2025-842	67 URISCAN			54	1.015	0.003	0.25	1.007	1.022
2025-842	72 URS-9-TECO			53	1.017	0.005	0.46	1.003	1.031
2025-842	80 ROCHE (CHE			36	1.010	0.000	0.00	1.010	1.010
2025-842	89 AIMSTRIP			163	1.016	0.003	0.29	1.008	1.025
2025-842	94 CLINITEK			102	1.019	0.002	0.20	1.013	1.025

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2025-842	102	ACON LAB		114	1.016	0.003	0.25	1.009	1.024	
2025-842	131	iCHEM VELO		35	1.028	0.001	0.09	1.025	1.030	
2025-842	140	MISSION A		35	1.016	0.003	0.29	1.007	1.025	
2025-842	145	CLINITEK		46	1.031	0.001	0.07	1.029	1.033	
2025-842	147	Mission120		37	1.019	0.002	0.19	1.014	1.025	
2025-842	148	Mission500		152	1.016	0.002	0.23	1.009	1.023	
2025-842	151	Clari. Uro		31	1.016	0.002	0.15	1.011	1.020	
067 URI-SPECIFIC GRAVITY		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD						
2025-843	11	AMES NM10S		31	1.020	0.003	0.32	1.011	1.030	
2025-843	13	BAYER CLI		19	1.018	0.003	0.32	1.009	1.028	
2025-843	67	URISCAN		54	1.021	0.003	0.32	1.012	1.031	
2025-843	72	URS-9-TECO		53	1.019	0.005	0.53	1.003	1.035	
2025-843	80	ROCHE (CHE		36	1.017	0.002	0.23	1.010	1.024	
2025-843	89	AIMSTRIP		163	1.020	0.003	0.32	1.011	1.030	
2025-843	94	CLINITEK		102	1.021	0.003	0.30	1.012	1.030	
2025-843	102	ACON LAB		114	1.021	0.002	0.24	1.014	1.028	
2025-843	131	iCHEM VELO		35	1.027	0.001	0.09	1.025	1.030	
2025-843	140	MISSION A		35	1.021	0.002	0.19	1.015	1.027	
2025-843	145	CLINITEK		46	1.034	0.001	0.10	1.031	1.037	
2025-843	147	Mission120		37	1.020	0.002	0.20	1.014	1.026	
2025-843	148	Mission500		152	1.021	0.002	0.21	1.015	1.027	
2025-843	151	Clari. Uro		31	1.023	0.004	0.35	1.012	1.034	
2025-844	11	AMES NM10S		31	1.021	0.003	0.32	1.011	1.031	
2025-844	13	BAYER CLI		19	1.020	0.000	0.00	1.020	1.020	
2025-844	67	URISCAN		54	1.019	0.003	0.26	1.011	1.027	
2025-844	72	URS-9-TECO		53	1.019	0.005	0.47	1.005	1.033	
2025-844	80	ROCHE (CHE		36	1.015	0.002	0.20	1.009	1.021	
2025-844	89	AIMSTRIP		163	1.019	0.002	0.23	1.012	1.026	
2025-844	94	CLINITEK		102	1.021	0.003	0.26	1.013	1.029	

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2025-844	102	ACON LAB		114	1.019	0.002	0.19	1.014	1.025
2025-844	131	iCHEM VELO		35	1.025	0.001	0.10	1.022	1.028
2025-844	140	MISSION A		35	1.018	0.003	0.30	1.009	1.027
2025-844	145	CLINITEK		46	1.027	0.001	0.06	1.025	1.029
2025-844	147	Mission120		37	1.021	0.002	0.22	1.014	1.028
2025-844	148	Mission500		152	1.020	0.000	0.00	1.020	1.020
2025-844	151	Clari. Uro		31	1.018	0.002	0.24	1.010	1.025
067 URI-SPECIFIC GRAVITY		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD					
2025-845	11	AMES NM10S		31	1.023	0.003	0.30	1.014	1.032
2025-845	13	BAYER CLI		19	1.022	0.002	0.23	1.015	1.029
2025-845	67	URISCAN		54	1.021	0.003	0.32	1.011	1.030
2025-845	72	URS-9-TECO		53	1.020	0.004	0.43	1.007	1.033
2025-845	80	ROCHE (CHE		36	1.015	0.000	0.00	1.015	1.015
2025-845	89	AIMSTRIP		163	1.020	0.002	0.19	1.014	1.026
2025-845	94	CLINITEK		102	1.023	0.003	0.27	1.014	1.031
2025-845	102	ACON LAB		114	1.020	0.002	0.21	1.014	1.027
2025-845	131	iCHEM VELO		35	1.025	0.001	0.09	1.023	1.028
2025-845	140	MISSION A		35	1.020	0.003	0.26	1.012	1.028
2025-845	145	CLINITEK		46	1.031	0.001	0.12	1.028	1.035
2025-845	147	Mission120		37	1.022	0.002	0.23	1.015	1.029
2025-845	148	Mission500		152	1.020	0.000	0.00	1.020	1.020
2025-845	151	Clari. Uro		31	1.020	0.003	0.25	1.012	1.027
166 MICROALBUMIN				EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}					
2025-841	58	VITROS		59	6.017	0.130	2.16	1.000	11.000
2025-841	62	SIEM DIM.		65	5.000	0.000	0.00	0.000	10.000
2025-841	62	SIEM DIM.		65	2.105	1.419	67.41	0	7.100
2025-841	79	BECK. COUL		20	2.825	3.089	109.33	0	7.800
2025-841	85	Rx DAYTONA		10	1.550	2.030	130.99	0	6.600
2025-841	93	ARCHITECT		19	5.000	0.000	0.00	0.000	10.000
2025-841	95	INTEGRA		19	3.026	1.424	47.05	0	8.000

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 50 URINALYSIS		GRP: 70 URINALYSIS					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2025-841	113	ROCHE COBA		52	12.000	0.000	0.00	7.000	17.000
2025-841	146	ATELLICA		25	3.000	0.000	0.00	0	8.000
2025-841	154	CS400DIRUI		13	4.262	3.979	93.37	0	9.300
166 MICROALBUMIN		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}					
2025-842	58	VITROS		59	858.731	33.849	3.94	644.000	1073.400
2025-842	62	SIEM DIM.		65	855.492	44.941	5.25	641.600	1069.400
2025-842	62	SIEM DIM.		65	908.333	16.680	1.84	681.300	1135.400
2025-842	79	BECK. COUL		20	794.295	93.346	11.75	595.700	992.900
2025-842	85	Rx DAYTONA		10	730.750	116.133	15.89	548.100	913.400
2025-842	93	ARCHITECT		19	820.537	24.426	2.98	615.400	1025.700
2025-842	95	INTEGRA		19	836.816	32.816	3.92	627.600	1046.000
2025-842	113	ROCHE COBA		52	825.478	45.153	5.47	619.100	1031.800
2025-842	146	ATELLICA		25	707.267	20.918	2.96	530.500	884.100
2025-842	154	CS400DIRUI		13	713.892	81.150	11.37	535.400	892.400
2025-843	58	VITROS		59	6.017	0.130	2.16	1.000	11.000
2025-843	62	SIEM DIM.		65	5.000	0.000	0.00	0.000	10.000
2025-843	62	SIEM DIM.		65	3.894	1.737	44.62	0	8.900
2025-843	79	BECK. COUL		20	2.870	3.071	107.01	0	7.900
2025-843	85	Rx DAYTONA		10	2.850	2.441	85.63	0	7.900
2025-843	93	ARCHITECT		19	5.000	0.000	0.00	0.000	10.000
2025-843	95	INTEGRA		19	3.005	1.382	45.97	0	8.000
2025-843	113	ROCHE COBA		52	12.000	0.000	0.00	7.000	17.000
2025-843	146	ATELLICA		25	3.000	0.000	0.00	0	8.000
2025-843	154	CS400DIRUI		13	8.738	8.524	97.55	3.700	13.700
2025-844	58	VITROS		59	859.746	40.745	4.74	644.800	1074.700
2025-844	62	SIEM DIM.		65	847.327	49.193	5.81	635.500	1059.200
2025-844	62	SIEM DIM.		65	896.667	17.913	2.00	672.500	1120.800
2025-844	79	BECK. COUL		20	787.495	91.071	11.56	590.600	984.400

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2025-844	85	Rx DAYTONA		10	743.460	105.266	14.16	557.600	929.300	
2025-844	93	ARCHITECT		19	822.032	19.168	2.33	616.500	1027.500	
2025-844	95	INTEGRA		19	826.605	32.224	3.90	620.000	1033.300	
2025-844	113	ROCHE COBA		52	812.553	53.374	6.57	609.400	1015.700	
2025-844	146	ATELLICA		25	694.979	21.689	3.12	521.200	868.700	
2025-844	154	CS400DIRUI		13	696.154	74.907	10.76	522.100	870.200	
166	MICROALBUMIN		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}					
2025-845	58	VITROS		59	887.574	36.129	4.07	665.700	1109.500	
2025-845	62	SIEM DIM.		65	915.667	15.107	1.65	686.800	1144.600	
2025-845	62	SIEM DIM.		65	884.065	57.466	6.50	663.000	1105.100	
2025-845	79	BECK. COUL		20	803.755	100.537	12.51	602.800	1004.700	
2025-845	85	Rx DAYTONA		10	755.550	86.317	11.42	566.700	944.400	
2025-845	93	ARCHITECT		19	856.089	23.201	2.71	642.100	1070.100	
2025-845	95	INTEGRA		19	850.142	36.950	4.35	637.600	1062.700	
2025-845	113	ROCHE COBA		52	831.794	53.865	6.48	623.800	1039.700	
2025-845	146	ATELLICA		25	715.108	21.135	2.96	536.300	893.900	
2025-845	154	CS400DIRUI		13	726.823	82.176	11.31	545.100	908.500	
167	CREATININE									
2025-841	58	VITROS		66	251.934	10.398	4.13	189.000	314.900	
2025-841	62	SIEM DIM.		63	245.621	7.832	3.19	184.200	307.000	
2025-841	62	SIEM DIM.		63	264.000	3.559	1.35	198.000	330.000	
2025-841	79	BECK. COUL		21	215.890	11.831	5.48	161.900	269.900	
2025-841	93	ARCHITECT		18	237.800	6.871	2.89	178.400	297.300	
2025-841	95	INTEGRA		19	249.963	14.563	5.83	187.500	312.500	
2025-841	113	ROCHE COBA		52	249.160	9.440	3.79	186.900	311.400	
2025-841	146	ATELLICA		26	231.681	6.460	2.79	173.800	289.600	
2025-841	154	CS400DIRUI		12	234.850	17.569	7.48	176.100	293.600	
2025-842	58	VITROS		66	239.661	7.321	3.05	179.700	299.600	
2025-842	62	SIEM DIM.		63	251.333	2.494	0.99	188.500	314.200	

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2025-842	62	SIEM DIM.		63	235.220	9.024	3.84	176.400	294.000	
2025-842	79	BECK. COUL		21	197.910	11.340	5.73	148.400	247.400	
2025-842	93	ARCHITECT		18	229.850	6.830	2.97	172.400	287.300	
2025-842	95	INTEGRA		19	240.347	14.928	6.21	180.300	300.400	
2025-842	113	ROCHE COBA		52	242.908	8.856	3.65	182.200	303.600	
2025-842	146	ATELLICA		26	220.436	4.173	1.89	165.300	275.500	
2025-842	154	CS400DIRUI		12	222.333	15.919	7.16	166.800	277.900	
167 CREATININE		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}							
2025-843	58	VITROS		66	3.197	0.025	0.77	0	8.200	
2025-843	62	SIEM DIM.		63	8.729	5.605	64.21	3.700	13.700	
2025-843	62	SIEM DIM.		63	14.367	1.933	13.45	9.400	19.400	
2025-843	79	BECK. COUL		21	0.445	0.459	103.10	0	5.400	
2025-843	93	ARCHITECT		18	4.722	0.786	16.64	0	9.700	
2025-843	95	INTEGRA		19	0.268	0.419	156.22	0	5.300	
2025-843	113	ROCHE COBA		52	3.608	1.359	37.68	0	8.600	
2025-843	146	ATELLICA		26	3.000	0.000	0.00	0	8.000	
2025-843	154	CS400DIRUI		12	4.333	5.383	124.23	0	9.300	
2025-844	58	VITROS		66	238.220	7.623	3.20	178.700	297.800	
2025-844	62	SIEM DIM.		63	260.333	3.300	1.27	195.300	325.400	
2025-844	62	SIEM DIM.		63	245.107	9.981	4.07	183.800	306.400	
2025-844	79	BECK. COUL		21	214.705	10.824	5.04	161.000	268.400	
2025-844	93	ARCHITECT		18	235.139	7.091	3.02	176.400	293.900	
2025-844	95	INTEGRA		19	246.042	15.031	6.11	184.500	307.600	
2025-844	113	ROCHE COBA		52	248.963	9.449	3.80	186.700	311.200	
2025-844	146	ATELLICA		26	227.858	6.258	2.75	170.900	284.800	
2025-844	154	CS400DIRUI		12	231.300	20.376	8.81	173.500	289.100	
2025-845	58	VITROS		66	3.197	0.025	0.77	0	8.200	
2025-845	62	SIEM DIM.		63	8.681	5.663	65.23	3.700	13.700	

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS				
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2025-845	62	SIEM DIM.		63	14.367	1.933	13.45	9.400	19.400	
2025-845	79	BECK. COUL		21	0.515	0.398	77.25	0	5.500	
2025-845	93	ARCHITECT		18	4.722	0.786	16.64	0	9.700	
2025-845	95	INTEGRA		19	0.442	0.300	67.78	0	5.400	
2025-845	113	ROCHE COBA		52	3.557	1.462	41.11	0	8.600	
2025-845	146	ATELLICA		26	3.000	0.000	0.00	0	8.000	
2025-845	154	CS400DIRUI		12	2.233	2.790	124.94	0	7.200	

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS						
TEST	LEVEL 1	LEVEL 2	LEVEL 3	PART	REFEREE	COMMER	REPORTED	PART #	LABS #	# "SF"	Score	
SAMPLE	RESULT CODE	RESULT CODE	RESULT CODE	LOW/HIGH	LOW/HIGH	LOW/HIGH	VALUE	LABS	ANSW	LABS		
057 URINALYSIS-BILIRUBIN												
2025-841	011	AMES NM10S		057	057	057	057	057 - NEGATIVE	31	31	31	100
2025-841	013	BAYER CLI		057	057	057	057	057 - NEGATIVE	19	19	19	100
2025-841	067	URISCAN		057	057	057	057	057 - NEGATIVE	54	54	54	100
2025-841	072	URS-9-TECO		057	057	057	057	057 - NEGATIVE	54	54	54	100
2025-841	080	ROCHE (CHE		057	057	057	057	057 - NEGATIVE	35	35	35	100
2025-841	089	AIMSTRIP		057	057	057	057	057 - NEGATIVE	159	159	159	100
2025-841	094	CLINITEK		057	057	057	057	057 - NEGATIVE	102	102	102	100
2025-841	102	ACON LAB		057	057	057	057	057 - NEGATIVE	111	111	111	100
2025-841	131	iCHEM VELO		057	057	057	057	057 - NEGATIVE	35	35	35	100
2025-841	140	MISSION A		057	057	057	057	057 - NEGATIVE	33	33	33	100
2025-841	145	CLINITEK		057	057	057	057	057 - NEGATIVE	46	46	46	100
2025-841	147	Mission120		057	057	057	057	057 - NEGATIVE	39	39	39	100
2025-841	148	Mission500		057	057	057	057	057 - NEGATIVE	154	154	154	100
2025-841	151	Clari. Uro		057	057	057	057	057 - NEGATIVE	33	33	33	100
2025-842	011	AMES NM10S		058	060	057	059	059 - 2+	31	25	31	100
2025-842	011	AMES NM10S		058	060	057	059	058 - TRACES, 1+	31	3	31	100

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-842	011	AMES NM10S		058 060	057 059		060 - 3+	31	3	31	100
2025-842	013	BAYER CLI		058 060	057 059		058 - TRACES, 1+	19	3	19	100
2025-842	013	BAYER CLI		058 060	057 059		059 - 2+	19	16	19	100
2025-842	067	URISCAN		057 059	057 059		057 - NEGATIVE	54	18	54	100
2025-842	067	URISCAN		057 059	057 059		059 - 2+	54	1	54	100
2025-842	067	URISCAN		057 059	057 059		058 - TRACES, 1+	54	35	54	100
2025-842	072	URS-9-TECO		057 059	057 059		057 - NEGATIVE	54	1	49	100
2025-842	072	URS-9-TECO		057 059	057 059		059 - 2+	54	19	49	100
2025-842	072	URS-9-TECO		057 059	057 059		058 - TRACES, 1+	54	29	49	100
2025-842	072	URS-9-TECO		057 059	057 059		060 - 3+	54	5	49	0
2025-842	080	ROCHE (CHE		057 059	057 059		058 - TRACES, 1+	35	27	32	100
2025-842	080	ROCHE (CHE		057 059	057 059		059 - 2+	35	5	32	100
2025-842	080	ROCHE (CHE		057 059	057 059		060 - 3+	35	3	32	0
2025-842	089	AIMSTRIP		057 059	057 059		060 - 3+	159	7	152	0
2025-842	089	AIMSTRIP		057 059	057 059		058 - TRACES, 1+	159	110	152	100
2025-842	089	AIMSTRIP		057 059	057 059		059 - 2+	159	40	152	100
2025-842	089	AIMSTRIP		057 059	057 059		057 - NEGATIVE	159	2	152	100
2025-842	094	CLINITEK		058 060	057 059		058 - TRACES, 1+	102	12	102	100
2025-842	094	CLINITEK		058 060	057 059		059 - 2+	102	88	102	100
2025-842	094	CLINITEK		058 060	057 059		060 - 3+	102	2	102	100
2025-842	102	ACON LAB		057 059	057 059		058 - TRACES, 1+	111	76	102	100
2025-842	102	ACON LAB		057 059	057 059		059 - 2+	111	26	102	100
2025-842	102	ACON LAB		057 059	057 059		060 - 3+	111	9	102	0
2025-842	131	iCHEM VELO		057 057	057 059		057 - NEGATIVE	35	35	35	100
2025-842	140	MISSION A		057 059	057 059		059 - 2+	33	12	31	100
2025-842	140	MISSION A		057 059	057 059		058 - TRACES, 1+	33	19	31	100
2025-842	140	MISSION A		057 059	057 059		060 - 3+	33	2	31	0
2025-842	145	CLINITEK		057 057	057 059		057 - NEGATIVE	46	44	46	100
2025-842	145	CLINITEK		057 057	057 059		059 - 2+	46	1	46	100
2025-842	145	CLINITEK		057 057	057 059		058 - TRACES, 1+	46	1	46	100

Participant Summary
MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2025-842	147	Mission120		057 059	057 059		059 - 2+	39	14	39	100		
2025-842	147	Mission120		057 059	057 059		058 - TRACES,1+	39	25	39	100		
2025-842	148	Mission500		057 059	057 059		059 - 2+	154	14	154	100		
2025-842	148	Mission500		057 059	057 059		058 - TRACES,1+	154	140	154	100		
2025-842	151	Clari. Uro		057 059	057 059		059 - 2+	33	5	33	100		
2025-842	151	Clari. Uro		057 059	057 059		058 - TRACES,1+	33	28	33	100		
057 URINALYSIS-BILIRUBIN													
2025-843	011	AMES NM10S		057 057	057 057		057 - NEGATIVE	31	30	30	100		
2025-843	011	AMES NM10S		057 057	057 057		059 - 2+	31	1	30	0		
2025-843	013	BAYER CLI		057 057	057 057		057 - NEGATIVE	19	19	19	100		
2025-843	067	URISCAN		057 057	057 057		057 - NEGATIVE	54	54	54	100		
2025-843	072	URS-9-TECO		057 057	057 057		057 - NEGATIVE	54	54	54	100		
2025-843	080	ROCHE (CHE		057 057	057 057		057 - NEGATIVE	35	35	35	100		
2025-843	089	AIMSTRIP		057 057	057 057		058 - TRACES,1+	159	2	157	0		
2025-843	089	AIMSTRIP		057 057	057 057		057 - NEGATIVE	159	157	157	100		
2025-843	094	CLINITEK		057 057	057 057		057 - NEGATIVE	102	102	102	100		
2025-843	102	ACON LAB		057 057	057 057		057 - NEGATIVE	111	111	111	100		
2025-843	131	iCHEM VELO		057 057	057 057		057 - NEGATIVE	35	35	35	100		
2025-843	140	MISSION A		057 057	057 057		057 - NEGATIVE	33	33	33	100		
2025-843	145	CLINITEK		057 057	057 057		057 - NEGATIVE	46	46	46	100		
2025-843	147	Mission120		057 057	057 057		057 - NEGATIVE	39	39	39	100		
2025-843	148	Mission500		057 057	057 057		057 - NEGATIVE	154	154	154	100		
2025-843	151	Clari. Uro		057 057	057 057		057 - NEGATIVE	33	33	33	100		
2025-844	011	AMES NM10S		057 057	057 057		057 - NEGATIVE	31	31	31	100		
2025-844	013	BAYER CLI		057 057	057 057		057 - NEGATIVE	19	19	19	100		
2025-844	067	URISCAN		057 057	057 057		057 - NEGATIVE	54	54	54	100		
2025-844	072	URS-9-TECO		057 057	057 057		057 - NEGATIVE	54	54	54	100		
2025-844	080	ROCHE (CHE		057 057	057 057		057 - NEGATIVE	35	35	35	100		

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS				
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-844	089 AIMSTRIP			057 057	057 057		057 - NEGATIVE	159	159	159	100	
2025-844	094 CLINITEK			057 057	057 057		057 - NEGATIVE	102	102	102	100	
2025-844	102 ACON LAB			057 057	057 057		057 - NEGATIVE	111	111	111	100	
2025-844	131 iCHEM VELO			057 057	057 057		057 - NEGATIVE	35	35	35	100	
2025-844	140 MISSION A			057 057	057 057		057 - NEGATIVE	33	33	33	100	
2025-844	145 CLINITEK			057 057	057 057		057 - NEGATIVE	46	46	46	100	
2025-844	147 Mission120			057 057	057 057		057 - NEGATIVE	39	39	39	100	
2025-844	148 Mission500			057 057	057 057		057 - NEGATIVE	154	154	154	100	
2025-844	151 Clari. Uro			057 057	057 057		057 - NEGATIVE	33	33	33	100	
057 URINALYSIS-BILIRUBIN												
2025-845	011 AMES NM10S			057 057	057 057		057 - NEGATIVE	31	31	31	100	
2025-845	013 BAYER CLI			057 057	057 057		057 - NEGATIVE	19	19	19	100	
2025-845	067 URISCAN			057 057	057 057		057 - NEGATIVE	54	54	54	100	
2025-845	072 URS-9-TECO			057 057	057 057		057 - NEGATIVE	54	54	54	100	
2025-845	080 ROCHE (CHE			057 057	057 057		057 - NEGATIVE	35	35	35	100	
2025-845	089 AIMSTRIP			057 057	057 057		057 - NEGATIVE	159	159	159	100	
2025-845	094 CLINITEK			057 057	057 057		057 - NEGATIVE	102	102	102	100	
2025-845	102 ACON LAB			057 057	057 057		057 - NEGATIVE	111	111	111	100	
2025-845	131 iCHEM VELO			057 057	057 057		057 - NEGATIVE	35	35	35	100	
2025-845	140 MISSION A			057 057	057 057		057 - NEGATIVE	33	33	33	100	
2025-845	145 CLINITEK			057 057	057 057		057 - NEGATIVE	46	46	46	100	
2025-845	147 Mission120			057 057	057 057		057 - NEGATIVE	39	39	39	100	
2025-845	148 Mission500			057 057	057 057		057 - NEGATIVE	154	154	154	100	
2025-845	151 Clari. Uro			057 057	057 057		057 - NEGATIVE	33	33	33	100	
058 URINALYSIS-GLUCOSE												
2025-841	011 AMES NM10S			076 078	076 078	075 077	076 - 500mg/dl2+	30	5	30	100	
2025-841	011 AMES NM10S			076 078	076 078	075 077	078 - 2000mg/dl	30	2	30	100	
2025-841	011 AMES NM10S			076 078	076 078	075 077	077 - 1000mg/dl	30	22	30	100	
2025-841	011 AMES NM10S			076 078	076 078	075 077	075 - 250mg/dl-+	30	1	30	100	

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-841	013	BAYER CLI		075 077	076 078		075 - 250mg/dl-+	19	1	19	100
2025-841	013	BAYER CLI		075 077	076 078		077 - 1000mg/dl	19	9	19	100
2025-841	013	BAYER CLI		075 077	076 078		076 - 500mg/dl2+	19	9	19	100
2025-841	067	URISCAN		077 078	076 078		076 - 500mg/dl2+	53	4	53	100
2025-841	067	URISCAN		077 078	076 078		078 - 2000mg/dl	53	36	53	100
2025-841	067	URISCAN		077 078	076 078		077 - 1000mg/dl	53	13	53	100
2025-841	072	URS-9-TECO		076 078	076 078		076 - 500mg/dl2+	54	18	53	100
2025-841	072	URS-9-TECO		076 078	076 078		077 - 1000mg/dl	54	29	53	100
2025-841	072	URS-9-TECO		076 078	076 078		073 - NEGATIVE	54	1	53	0
2025-841	072	URS-9-TECO		076 078	076 078		078 - 2000mg/dl	54	6	53	100
2025-841	080	ROCHE (CHE		076 078	076 078		078 - 2000mg/dl	36	2	36	100
2025-841	080	ROCHE (CHE		076 078	076 078		077 - 1000mg/dl	36	33	36	100
2025-841	080	ROCHE (CHE		076 078	076 078		076 - 500mg/dl2+	36	1	36	100
2025-841	089	AIMSTRIP		076 078	076 078	075 077	077 - 1000mg/dl	163	104	163	100
2025-841	089	AIMSTRIP		076 078	076 078	075 077	076 - 500mg/dl2+	163	52	163	100
2025-841	089	AIMSTRIP		076 078	076 078	075 077	078 - 2000mg/dl	163	1	163	100
2025-841	089	AIMSTRIP		076 078	076 078	075 077	075 - 250mg/dl-+	163	6	163	100
2025-841	094	CLINITEK		076 078	076 078	075 077	078 - 2000mg/dl	102	1	102	100
2025-841	094	CLINITEK		076 078	076 078	075 077	075 - 250mg/dl-+	102	2	102	100
2025-841	094	CLINITEK		076 078	076 078	075 077	077 - 1000mg/dl	102	64	102	100
2025-841	094	CLINITEK		076 078	076 078	075 077	076 - 500mg/dl2+	102	35	102	100
2025-841	102	ACON LAB		076 078	076 078	075 077	076 - 500mg/dl2+	113	44	113	100
2025-841	102	ACON LAB		076 078	076 078	075 077	077 - 1000mg/dl	113	57	113	100
2025-841	102	ACON LAB		076 078	076 078	075 077	078 - 2000mg/dl	113	11	113	100
2025-841	102	ACON LAB		076 078	076 078	075 077	075 - 250mg/dl-+	113	1	113	100
2025-841	131	iCHEM VELO		075 077	076 078		077 - 1000mg/dl	35	2	35	100
2025-841	131	iCHEM VELO		075 077	076 078		076 - 500mg/dl2+	35	33	35	100
2025-841	140	MISSION A		076 078	076 078		078 - 2000mg/dl	35	5	35	100
2025-841	140	MISSION A		076 078	076 078		077 - 1000mg/dl	35	22	35	100
2025-841	140	MISSION A		076 078	076 078		076 - 500mg/dl2+	35	8	35	100

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2025-841	145	CLINITEK		076 078	076 078		078 - 2000mg/dl	46	1	46	100		
2025-841	145	CLINITEK		076 078	076 078		076 - 500mg/dl2+	46	9	46	100		
2025-841	145	CLINITEK		076 078	076 078		077 - 1000mg/dl	46	36	46	100		
2025-841	147	Mission120		076 078	076 078		076 - 500mg/dl2+	37	3	37	100		
2025-841	147	Mission120		076 078	076 078		077 - 1000mg/dl	37	19	37	100		
2025-841	147	Mission120		076 078	076 078		078 - 2000mg/dl	37	15	37	100		
2025-841	148	Mission500		076 078	076 078		073 - NEGATIVE	153	1	150	0		
2025-841	148	Mission500		076 078	076 078		077 - 1000mg/dl	153	65	150	100		
2025-841	148	Mission500		076 078	076 078		078 - 2000mg/dl	153	41	150	100		
2025-841	148	Mission500		076 078	076 078		075 - 250mg/dl-+	153	2	150	0		
2025-841	148	Mission500		076 078	076 078		076 - 500mg/dl2+	153	44	150	100		
2025-841	151	Clari. Uro		076 078	076 078	076 078	076 - 500mg/dl2+	32	10	31	100		
2025-841	151	Clari. Uro		076 078	076 078	076 078	075 - 250mg/dl-+	32	1	31	0		
2025-841	151	Clari. Uro		076 078	076 078	076 078	077 - 1000mg/dl	32	21	31	100		
058 URINALYSIS-GLUCOSE													
2025-842	011	AMES NM10S		073 073	073 073	073 073	073 - NEGATIVE	30	30	30	100		
2025-842	013	BAYER CLI		073 073	073 073		073 - NEGATIVE	19	19	19	100		
2025-842	067	URISCAN		073 073	073 073		073 - NEGATIVE	53	53	53	100		
2025-842	072	URS-9-TECO		073 073	073 073		073 - NEGATIVE	54	54	54	100		
2025-842	080	ROCHE (CHE		073 073	073 073		073 - NEGATIVE	36	36	36	100		
2025-842	089	AIMSTRIP		073 073	073 073	073 073	073 - NEGATIVE	163	163	163	100		
2025-842	094	CLINITEK		073 073	073 073	073 073	073 - NEGATIVE	102	102	102	100		
2025-842	102	ACON LAB		073 073	073 073	073 073	073 - NEGATIVE	113	113	113	100		
2025-842	131	iCHEM VELO		073 073	073 073		073 - NEGATIVE	35	35	35	100		
2025-842	140	MISSION A		073 073	073 073		073 - NEGATIVE	35	35	35	100		
2025-842	145	CLINITEK		073 073	073 073		073 - NEGATIVE	46	46	46	100		
2025-842	147	Mission120		073 073	073 073		073 - NEGATIVE	37	37	37	100		
2025-842	148	Mission500		073 073	073 073		073 - NEGATIVE	153	152	152	100		
2025-842	148	Mission500		073 073	073 073		075 - 250mg/dl-+	153	1	152	0		
2025-842	151	Clari. Uro		073 073	073 073	073 073	073 - NEGATIVE	32	32	32	100		

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
058 URINALYSIS-GLUCOSE													
2025-843	011 AMES NM10S			073 075	074 076	074 076	075 - 250mg/dl-+	30	11	30	100		
2025-843	011 AMES NM10S			073 075	074 076	074 076	073 - NEGATIVE	30	1	30	100		
2025-843	011 AMES NM10S			073 075	074 076	074 076	074 - TRACES	30	18	30	100		
2025-843	013 BAYER CLI			074 076	074 076		074 - TRACES	19	8	19	100		
2025-843	013 BAYER CLI			074 076	074 076		075 - 250mg/dl-+	19	11	19	100		
2025-843	067 URISCAN			075 077	074 076		075 - 250mg/dl-+	53	15	51	100		
2025-843	067 URISCAN			075 077	074 076		078 - 2000mg/dl	53	1	51	0		
2025-843	067 URISCAN			075 077	074 076		073 - NEGATIVE	53	1	51	0		
2025-843	067 URISCAN			075 077	074 076		076 - 500mg/dl2+	53	27	51	100		
2025-843	067 URISCAN			075 077	074 076		077 - 1000mg/dl	53	8	51	100		
2025-843	067 URISCAN			075 077	074 076		074 - TRACES	53	1	51	100		
2025-843	072 URS-9-TECO				074 076		076 - 500mg/dl2+	54	1	37	100		
2025-843	072 URS-9-TECO				074 076		075 - 250mg/dl-+	54	25	37	100		
2025-843	072 URS-9-TECO				074 076		073 - NEGATIVE	54	17	37	0		
2025-843	072 URS-9-TECO				074 076		074 - TRACES	54	11	37	100		
2025-843	080 ROCHE (CHE			076 078	074 076		077 - 1000mg/dl	36	31	36	100		
2025-843	080 ROCHE (CHE			076 078	074 076		075 - 250mg/dl-+	36	2	36	100		
2025-843	080 ROCHE (CHE			076 078	074 076		078 - 2000mg/dl	36	3	36	100		
2025-843	089 AIMSTRIP			074 076	074 076	074 076	074 - TRACES	163	23	151	100		
2025-843	089 AIMSTRIP			074 076	074 076	074 076	073 - NEGATIVE	163	12	151	0		
2025-843	089 AIMSTRIP			074 076	074 076	074 076	075 - 250mg/dl-+	163	128	151	100		
2025-843	094 CLINITEK			073 075	074 076	074 076	074 - TRACES	102	54	102	100		
2025-843	094 CLINITEK			073 075	074 076	074 076	073 - NEGATIVE	102	1	102	100		
2025-843	094 CLINITEK			073 075	074 076	074 076	075 - 250mg/dl-+	102	47	102	100		
2025-843	102 ACON LAB			074 076	074 076	075 077	073 - NEGATIVE	113	5	108	0		
2025-843	102 ACON LAB			074 076	074 076	075 077	074 - TRACES	113	16	108	100		
2025-843	102 ACON LAB			074 076	074 076	075 077	075 - 250mg/dl-+	113	92	108	100		
2025-843	131 iCHEM VELO			075 077	074 076		077 - 1000mg/dl	35	2	35	100		
2025-843	131 iCHEM VELO			075 077	074 076		076 - 500mg/dl2+	35	33	35	100		

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2025-843	140 MISSION A			074 076	074 076		075 - 250mg/dl-+	35	30	35	100		
2025-843	140 MISSION A			074 076	074 076		074 - TRACES	35	5	35	100		
2025-843	145 CLINITEK			076 078	074 076		077 - 1000mg/dl	46	38	46	100		
2025-843	145 CLINITEK			076 078	074 076		074 - TRACES	46	1	46	100		
2025-843	145 CLINITEK			076 078	074 076		076 - 500mg/dl2+	46	4	46	100		
2025-843	145 CLINITEK			076 078	074 076		078 - 2000mg/dl	46	1	46	100		
2025-843	145 CLINITEK			076 078	074 076		075 - 250mg/dl-+	46	2	46	100		
2025-843	147 Mission120			074 076	074 076		074 - TRACES	37	8	37	100		
2025-843	147 Mission120			074 076	074 076		075 - 250mg/dl-+	37	29	37	100		
2025-843	148 Mission500			074 076	074 076		074 - TRACES	153	12	153	100		
2025-843	148 Mission500			074 076	074 076		075 - 250mg/dl-+	153	141	153	100		
2025-843	151 Clari. Uro			074 076	074 076	073 075	074 - TRACES	32	9	32	100		
2025-843	151 Clari. Uro			074 076	074 076	073 075	075 - 250mg/dl-+	32	21	32	100		
2025-843	151 Clari. Uro			074 076	074 076	073 075	073 - NEGATIVE	32	2	32	100		
058 URINALYSIS-GLUCOSE													
2025-844	011 AMES NM10S			073 073	073 073	073 073	073 - NEGATIVE	30	30	30	100		
2025-844	013 BAYER CLI			073 073	073 073		073 - NEGATIVE	19	19	19	100		
2025-844	067 URISCAN			073 073	073 073		073 - NEGATIVE	53	53	53	100		
2025-844	072 URS-9-TECO			073 073	073 073		073 - NEGATIVE	54	54	54	100		
2025-844	080 ROCHE (CHE			073 073	073 073		073 - NEGATIVE	36	36	36	100		
2025-844	089 AIMSTRIP			073 073	073 073	073 073	073 - NEGATIVE	163	163	163	100		
2025-844	094 CLINITEK			073 073	073 073	073 073	073 - NEGATIVE	102	102	102	100		
2025-844	102 ACON LAB			073 073	073 073	073 073	073 - NEGATIVE	113	112	112	100		
2025-844	102 ACON LAB			073 073	073 073	073 073	075 - 250mg/dl-+	113	1	112	0		
2025-844	131 iCHEM VELO			073 073	073 073		073 - NEGATIVE	35	35	35	100		
2025-844	140 MISSION A			073 073	073 073		074 - TRACES	35	1	34	0		
2025-844	140 MISSION A			073 073	073 073		073 - NEGATIVE	35	34	34	100		
2025-844	145 CLINITEK			073 073	073 073		073 - NEGATIVE	46	46	46	100		
2025-844	147 Mission120			073 073	073 073		073 - NEGATIVE	37	37	37	100		
2025-844	148 Mission500			073 073	073 073		073 - NEGATIVE	153	153	153	100		

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score			
2025-844	151	Clari. Uro		073 073	073 073	073 073	073 - NEGATIVE	32	32	32	100			
058 URINALYSIS-GLUCOSE														
2025-845	011	AMES NM10S		076 078	076 078	076 078	076 - 500mg/dl2+	30	5	29	100			
2025-845	011	AMES NM10S		076 078	076 078	076 078	077 - 1000mg/dl	30	21	29	100			
2025-845	011	AMES NM10S		076 078	076 078	076 078	075 - 250mg/dl-+	30	1	29	0			
2025-845	011	AMES NM10S		076 078	076 078	076 078	078 - 2000mg/dl	30	3	29	100			
2025-845	013	BAYER CLI		076 078	076 078		076 - 500mg/dl2+	19	6	19	100			
2025-845	013	BAYER CLI		076 078	076 078		077 - 1000mg/dl	19	13	19	100			
2025-845	067	URISCAN		077 078	076 078		078 - 2000mg/dl	53	38	53	100			
2025-845	067	URISCAN		077 078	076 078		076 - 500mg/dl2+	53	2	53	100			
2025-845	067	URISCAN		077 078	076 078		077 - 1000mg/dl	53	13	53	100			
2025-845	072	URS-9-TECO		076 078	076 078		078 - 2000mg/dl	54	6	54	100			
2025-845	072	URS-9-TECO		076 078	076 078		076 - 500mg/dl2+	54	17	54	100			
2025-845	072	URS-9-TECO		076 078	076 078		077 - 1000mg/dl	54	31	54	100			
2025-845	080	ROCHE (CHE		076 078	076 078		076 - 500mg/dl2+	36	1	36	100			
2025-845	080	ROCHE (CHE		076 078	076 078		078 - 2000mg/dl	36	3	36	100			
2025-845	080	ROCHE (CHE		076 078	076 078		077 - 1000mg/dl	36	32	36	100			
2025-845	089	AIMSTRIP		076 078	076 078	076 078	076 - 500mg/dl2+	163	46	157	100			
2025-845	089	AIMSTRIP		076 078	076 078	076 078	075 - 250mg/dl-+	163	5	157	0			
2025-845	089	AIMSTRIP		076 078	076 078	076 078	078 - 2000mg/dl	163	2	157	100			
2025-845	089	AIMSTRIP		076 078	076 078	076 078	077 - 1000mg/dl	163	109	157	100			
2025-845	089	AIMSTRIP		076 078	076 078	076 078	073 - NEGATIVE	163	1	157	0			
2025-845	094	CLINITEK		076 078	076 078	076 078	077 - 1000mg/dl	102	69	101	100			
2025-845	094	CLINITEK		076 078	076 078	076 078	076 - 500mg/dl2+	102	30	101	100			
2025-845	094	CLINITEK		076 078	076 078	076 078	075 - 250mg/dl-+	102	1	101	0			
2025-845	094	CLINITEK		076 078	076 078	076 078	078 - 2000mg/dl	102	2	101	100			
2025-845	102	ACON LAB		076 078	076 078	075 077	077 - 1000mg/dl	113	57	112	100			
2025-845	102	ACON LAB		076 078	076 078	075 077	078 - 2000mg/dl	113	6	112	100			
2025-845	102	ACON LAB		076 078	076 078	075 077	075 - 250mg/dl-+	113	2	112	100			
2025-845	102	ACON LAB		076 078	076 078	075 077	076 - 500mg/dl2+	113	47	112	100			

Participant Summary
MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score			
2025-845	102	ACON LAB		076 078	076 078	075 077	073 - NEGATIVE	113	1	112	0			
2025-845	131	iCHEM VELO		075 077	076 078		076 - 500mg/dl2+	35	32	34	100			
2025-845	131	iCHEM VELO		075 077	076 078		077 - 1000mg/dl	35	2	34	100			
2025-845	131	iCHEM VELO		075 077	076 078		074 - TRACES	35	1	34	0			
2025-845	140	MISSION A		076 078	076 078		076 - 500mg/dl2+	35	5	35	100			
2025-845	140	MISSION A		076 078	076 078		077 - 1000mg/dl	35	21	35	100			
2025-845	140	MISSION A		076 078	076 078		078 - 2000mg/dl	35	9	35	100			
2025-845	145	CLINITEK		076 078	076 078		076 - 500mg/dl2+	46	2	45	100			
2025-845	145	CLINITEK		076 078	076 078		077 - 1000mg/dl	46	41	45	100			
2025-845	145	CLINITEK		076 078	076 078		078 - 2000mg/dl	46	2	45	100			
2025-845	145	CLINITEK		076 078	076 078		074 - TRACES	46	1	45	0			
2025-845	147	Mission120		077 078	076 078		077 - 1000mg/dl	37	16	37	100			
2025-845	147	Mission120		077 078	076 078		078 - 2000mg/dl	37	18	37	100			
2025-845	147	Mission120		077 078	076 078		076 - 500mg/dl2+	37	3	37	100			
2025-845	148	Mission500		076 078	076 078		078 - 2000mg/dl	153	44	151	100			
2025-845	148	Mission500		076 078	076 078		075 - 250mg/dl-+	153	2	151	0			
2025-845	148	Mission500		076 078	076 078		077 - 1000mg/dl	153	72	151	100			
2025-845	148	Mission500		076 078	076 078		076 - 500mg/dl2+	153	35	151	100			
2025-845	151	Clari. Uro		076 078	076 078	076 078	076 - 500mg/dl2+	32	7	32	100			
2025-845	151	Clari. Uro		076 078	076 078	076 078	077 - 1000mg/dl	32	25	32	100			
059 URINALYS.HG.OR BLOOD														
2025-841	011	AMES NM10S		066 066	066 066		066 - NEGATIVE	30	30	30	100			
2025-841	013	BAYER CLI		066 066	066 066		066 - NEGATIVE	19	19	19	100			
2025-841	067	URISCAN		066 066	066 066		066 - NEGATIVE	54	54	54	100			
2025-841	072	URS-9-TECO		066 066	066 066		066 - NEGATIVE	53	53	53	100			
2025-841	080	ROCHE (CHE		066 066	066 066	066 066	066 - NEGATIVE	35	35	35	100			
2025-841	089	AIMSTRIP		066 066	066 066	066 066	067 - TRACES	162	1	161	0			
2025-841	089	AIMSTRIP		066 066	066 066	066 066	066 - NEGATIVE	162	161	161	100			
2025-841	094	CLINITEK		066 066	066 066		066 - NEGATIVE	102	102	102	100			
2025-841	102	ACON LAB		066 066	066 066		066 - NEGATIVE	115	115	115	100			

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-841	131	iCHEM VELO		066 066	066 066		066 - NEGATIVE	35	35	35	100	
2025-841	140	MISSION A		066 066	066 066		066 - NEGATIVE	33	33	33	100	
2025-841	145	CLINITEK		066 066	066 066		066 - NEGATIVE	46	46	46	100	
2025-841	147	Mission120		066 066	066 066		066 - NEGATIVE	38	38	38	100	
2025-841	148	Mission500		066 066	066 066		066 - NEGATIVE	153	153	153	100	
2025-841	151	Clari. Uro		066 066	066 066		066 - NEGATIVE	32	32	32	100	
059 URINALYS.HG.OR BLOOD												
2025-842	011	AMES NM10S		068 069	068 069		069 - POS.(3+))	30	27	30	100	
2025-842	011	AMES NM10S		068 069	068 069		068 - POS.(1-2+)	30	3	30	100	
2025-842	013	BAYER CLI		068 069	068 069		068 - POS.(1-2+)	19	1	19	100	
2025-842	013	BAYER CLI		068 069	068 069		069 - POS.(3+))	19	18	19	100	
2025-842	067	URISCAN		068 069	068 069		068 - POS.(1-2+)	54	8	54	100	
2025-842	067	URISCAN		068 069	068 069		069 - POS.(3+))	54	46	54	100	
2025-842	072	URS-9-TECO		068 069	068 069		068 - POS.(1-2+)	53	14	53	100	
2025-842	072	URS-9-TECO		068 069	068 069		069 - POS.(3+))	53	39	53	100	
2025-842	080	ROCHE (CHE		068 069	068 069	068 069	069 - POS.(3+))	35	32	35	100	
2025-842	080	ROCHE (CHE		068 069	068 069	068 069	068 - POS.(1-2+)	35	3	35	100	
2025-842	089	AIMSTRIP		068 069	068 069	068 069	069 - POS.(3+))	162	159	161	100	
2025-842	089	AIMSTRIP		068 069	068 069	068 069	067 - TRACES	162	1	161	0	
2025-842	089	AIMSTRIP		068 069	068 069	068 069	068 - POS.(1-2+)	162	2	161	100	
2025-842	094	CLINITEK		068 069	068 069		069 - POS.(3+))	102	100	102	100	
2025-842	094	CLINITEK		068 069	068 069		068 - POS.(1-2+)	102	2	102	100	
2025-842	102	ACON LAB		068 069	068 069		069 - POS.(3+))	115	113	115	100	
2025-842	102	ACON LAB		068 069	068 069		068 - POS.(1-2+)	115	2	115	100	
2025-842	131	iCHEM VELO		068 069	068 069		069 - POS.(3+))	35	18	35	100	
2025-842	131	iCHEM VELO		068 069	068 069		068 - POS.(1-2+)	35	17	35	100	
2025-842	140	MISSION A		068 069	068 069		069 - POS.(3+))	33	31	33	100	
2025-842	140	MISSION A		068 069	068 069		068 - POS.(1-2+)	33	2	33	100	
2025-842	145	CLINITEK		068 069	068 069		068 - POS.(1-2+)	46	10	46	100	
2025-842	145	CLINITEK		068 069	068 069		069 - POS.(3+))	46	36	46	100	

Participant Summary
MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2025-842	147	Mission120		068 069	068 069		069 - POS.(3+))	38	38	38	100		
2025-842	148	Mission500		068 069	068 069		069 - POS.(3+))	153	151	152	100		
2025-842	148	Mission500		068 069	068 069		066 - NEGATIVE	153	1	152	0		
2025-842	148	Mission500		068 069	068 069		068 - POS.(1-2+)	153	1	152	100		
2025-842	151	Clari. Uro		068 069	068 069		069 - POS.(3+))	32	31	32	100		
2025-842	151	Clari. Uro		068 069	068 069		068 - POS.(1-2+)	32	1	32	100		
059 URINALYS.HG.OR BLOOD													
2025-843	011	AMES NM10S		066 066	066 066		066 - NEGATIVE	30	30	30	100		
2025-843	013	BAYER CLI		066 066	066 066		066 - NEGATIVE	19	19	19	100		
2025-843	067	URISCAN		066 066	066 066		066 - NEGATIVE	54	54	54	100		
2025-843	072	URS-9-TECO		066 066	066 066		066 - NEGATIVE	53	53	53	100		
2025-843	080	ROCHE (CHE		066 066	066 066	066 066	066 - NEGATIVE	35	35	35	100		
2025-843	089	AIMSTRIP		066 066	066 066	066 066	066 - NEGATIVE	162	162	162	100		
2025-843	094	CLINITEK		066 066	066 066		066 - NEGATIVE	102	102	102	100		
2025-843	102	ACON LAB		066 066	066 066		069 - POS.(3+))	115	1	114	0		
2025-843	102	ACON LAB		066 066	066 066		066 - NEGATIVE	115	114	114	100		
2025-843	131	iCHEM VELO		066 066	066 066		066 - NEGATIVE	35	34	34	100		
2025-843	131	iCHEM VELO		066 066	066 066		068 - POS.(1-2+)	35	1	34	0		
2025-843	140	MISSION A		066 066	066 066		066 - NEGATIVE	33	33	33	100		
2025-843	145	CLINITEK		066 066	066 066		066 - NEGATIVE	46	45	45	100		
2025-843	145	CLINITEK		066 066	066 066		068 - POS.(1-2+)	46	1	45	0		
2025-843	147	Mission120		066 066	066 066		066 - NEGATIVE	38	38	38	100		
2025-843	148	Mission500		066 066	066 066		068 - POS.(1-2+)	153	1	152	0		
2025-843	148	Mission500		066 066	066 066		066 - NEGATIVE	153	152	152	100		
2025-843	151	Clari. Uro		066 066	066 066		066 - NEGATIVE	32	32	32	100		
2025-844	011	AMES NM10S		068 069	068 069		069 - POS.(3+))	30	29	30	100		
2025-844	011	AMES NM10S		068 069	068 069		068 - POS.(1-2+)	30	1	30	100		
2025-844	013	BAYER CLI		068 069	068 069		068 - POS.(1-2+)	19	1	19	100		

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2025-844	013	BAYER CLI		068 069	068 069		069 - POS.(3+))	19	18	19	100		
2025-844	067	URISCAN		068 069	068 069		068 - POS.(1-2+)	54	7	54	100		
2025-844	067	URISCAN		068 069	068 069		069 - POS.(3+))	54	47	54	100		
2025-844	072	URS-9-TECO		068 069	068 069		069 - POS.(3+))	53	45	53	100		
2025-844	072	URS-9-TECO		068 069	068 069		068 - POS.(1-2+)	53	8	53	100		
2025-844	080	ROCHE (CHE		068 069	068 069	068 069	066 - NEGATIVE	35	1	34	0		
2025-844	080	ROCHE (CHE		068 069	068 069	068 069	068 - POS.(1-2+)	35	3	34	100		
2025-844	080	ROCHE (CHE		068 069	068 069	068 069	069 - POS.(3+))	35	31	34	100		
2025-844	089	AIMSTRIP		068 069	068 069	068 069	066 - NEGATIVE	162	2	160	0		
2025-844	089	AIMSTRIP		068 069	068 069	068 069	069 - POS.(3+))	162	159	160	100		
2025-844	089	AIMSTRIP		068 069	068 069	068 069	068 - POS.(1-2+)	162	1	160	100		
2025-844	094	CLINITEK		068 069	068 069		068 - POS.(1-2+)	102	1	102	100		
2025-844	094	CLINITEK		068 069	068 069		069 - POS.(3+))	102	101	102	100		
2025-844	102	ACON LAB		068 069	068 069		069 - POS.(3+))	115	112	114	100		
2025-844	102	ACON LAB		068 069	068 069		068 - POS.(1-2+)	115	2	114	100		
2025-844	102	ACON LAB		068 069	068 069		066 - NEGATIVE	115	1	114	0		
2025-844	131	iCHEM VELO		068 069	068 069		069 - POS.(3+))	35	33	35	100		
2025-844	131	iCHEM VELO		068 069	068 069		068 - POS.(1-2+)	35	2	35	100		
2025-844	140	MISSION A		068 069	068 069		068 - POS.(1-2+)	33	1	33	100		
2025-844	140	MISSION A		068 069	068 069		069 - POS.(3+))	33	32	33	100		
2025-844	145	CLINITEK		068 069	068 069		069 - POS.(3+))	46	43	46	100		
2025-844	145	CLINITEK		068 069	068 069		068 - POS.(1-2+)	46	3	46	100		
2025-844	147	Mission120		068 069	068 069		069 - POS.(3+))	38	38	38	100		
2025-844	148	Mission500		068 069	068 069		069 - POS.(3+))	153	152	152	100		
2025-844	148	Mission500		068 069	068 069		066 - NEGATIVE	153	1	152	0		
2025-844	151	Clari. Uro		068 069	068 069		069 - POS.(3+))	32	32	32	100		
059 URINALYS.HG.OR BLOOD													
2025-845	011	AMES NM10S		066 068	066 066		067 - TRACES	30	17	30	100		
2025-845	011	AMES NM10S		066 068	066 066		066 - NEGATIVE	30	13	30	100		
2025-845	013	BAYER CLI		066 068	066 066		067 - TRACES	19	12	19	100		

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-845	013	BAYER CLI		066 068	066 066		066 - NEGATIVE	19	7	19	100
2025-845	067	URISCAN		066 066	066 066		066 - NEGATIVE	54	54	54	100
2025-845	072	URS-9-TECO		066 066	066 066		066 - NEGATIVE	53	53	53	100
2025-845	080	ROCHE (CHE		066 066	066 066	067 069	066 - NEGATIVE	35	32	35	100
2025-845	080	ROCHE (CHE		066 066	066 066	067 069	067 - TRACES	35	3	35	100
2025-845	089	AIMSTRIP		066 066	066 066	066 068	066 - NEGATIVE	162	143	161	100
2025-845	089	AIMSTRIP		066 066	066 066	066 068	069 - POS.(3+)	162	1	161	0
2025-845	089	AIMSTRIP		066 066	066 066	066 068	067 - TRACES	162	18	161	100
2025-845	094	CLINITEK		066 068	066 066		068 - POS.(1-2+)	102	2	102	100
2025-845	094	CLINITEK		066 068	066 066		067 - TRACES	102	77	102	100
2025-845	094	CLINITEK		066 068	066 066		066 - NEGATIVE	102	23	102	100
2025-845	102	ACON LAB			066 066		066 - NEGATIVE	115	79	79	100
2025-845	102	ACON LAB			066 066		067 - TRACES	115	31	79	0
2025-845	102	ACON LAB			066 066		068 - POS.(1-2+)	115	5	79	0
2025-845	131	iCHEM VELO		067 069	066 066		067 - TRACES	35	11	35	100
2025-845	131	iCHEM VELO		067 069	066 066		068 - POS.(1-2+)	35	24	35	100
2025-845	140	MISSION A			066 066		067 - TRACES	33	8	25	0
2025-845	140	MISSION A			066 066		066 - NEGATIVE	33	25	25	100
2025-845	145	CLINITEK		066 066	066 066		067 - TRACES	46	2	44	0
2025-845	145	CLINITEK		066 066	066 066		066 - NEGATIVE	46	44	44	100
2025-845	147	Mission120		066 066	066 066		067 - TRACES	38	7	31	0
2025-845	147	Mission120		066 066	066 066		066 - NEGATIVE	38	31	31	100
2025-845	148	Mission500			066 066		066 - NEGATIVE	153	85	85	100
2025-845	148	Mission500			066 066		067 - TRACES	153	66	85	0
2025-845	148	Mission500			066 066		068 - POS.(1-2+)	153	2	85	0
2025-845	151	Clari. Uro		066 066	066 066		067 - TRACES	32	3	29	0
2025-845	151	Clari. Uro		066 066	066 066		066 - NEGATIVE	32	29	29	100
060 URINALYSIS-KETONES											
2025-841	011	AMES NM10S		090 090	090 090		090 - NEGATIVE	30	30	30	100
2025-841	013	BAYER CLI		090 090	090 090		090 - NEGATIVE	19	19	19	100

Participant Summary
MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-841	067	URISCAN		090 090	090 090		090 - NEGATIVE	54	54	54	100	
2025-841	072	URS-9-TECO		090 090	090 090		090 - NEGATIVE	52	52	52	100	
2025-841	080	ROCHE (CHE		090 090	090 090		090 - NEGATIVE	36	36	36	100	
2025-841	089	AIMSTRIP		090 090	090 090		090 - NEGATIVE	162	162	162	100	
2025-841	094	CLINITEK		090 090	090 090		090 - NEGATIVE	102	102	102	100	
2025-841	102	ACON LAB		090 090	090 090		090 - NEGATIVE	114	114	114	100	
2025-841	131	iCHEM VELO		090 090	090 090		090 - NEGATIVE	35	35	35	100	
2025-841	140	MISSION A		090 090	090 090		090 - NEGATIVE	37	37	37	100	
2025-841	145	CLINITEK		090 090	090 090		090 - NEGATIVE	46	46	46	100	
2025-841	147	Mission120		090 090	090 090		090 - NEGATIVE	37	37	37	100	
2025-841	148	Mission500		090 090	090 090		090 - NEGATIVE	152	152	152	100	
2025-841	151	Clari. Uro		090 090	090 090		090 - NEGATIVE	32	32	32	100	
060 URINALYSIS-KETONES												
2025-842	011	AMES NM10S		093 094	093 094		094 - LARGE-3-4+	30	26	29	100	
2025-842	011	AMES NM10S		093 094	093 094		092 - SMALL (1+)	30	1	29	0	
2025-842	011	AMES NM10S		093 094	093 094		093 - MOD. (2+)	30	3	29	100	
2025-842	013	BAYER CLI		093 094	093 094		093 - MOD. (2+)	19	2	19	100	
2025-842	013	BAYER CLI		093 094	093 094		094 - LARGE-3-4+	19	17	19	100	
2025-842	067	URISCAN		093 094	093 094		094 - LARGE-3-4+	54	35	53	100	
2025-842	067	URISCAN		093 094	093 094		092 - SMALL (1+)	54	1	53	0	
2025-842	067	URISCAN		093 094	093 094		093 - MOD. (2+)	54	18	53	100	
2025-842	072	URS-9-TECO		093 094	093 094		092 - SMALL (1+)	52	1	51	0	
2025-842	072	URS-9-TECO		093 094	093 094		093 - MOD. (2+)	52	2	51	100	
2025-842	072	URS-9-TECO		093 094	093 094		094 - LARGE-3-4+	52	49	51	100	
2025-842	080	ROCHE (CHE		093 094	093 094		093 - MOD. (2+)	36	5	35	100	
2025-842	080	ROCHE (CHE		093 094	093 094		092 - SMALL (1+)	36	1	35	0	
2025-842	080	ROCHE (CHE		093 094	093 094		094 - LARGE-3-4+	36	30	35	100	
2025-842	089	AIMSTRIP		093 094	093 094		092 - SMALL (1+)	162	1	161	0	
2025-842	089	AIMSTRIP		093 094	093 094		094 - LARGE-3-4+	162	158	161	100	
2025-842	089	AIMSTRIP		093 094	093 094		093 - MOD. (2+)	162	3	161	100	

Participant Summary
MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-842	094	CLINITEK		093 094	093 094		093 - MOD. (2+)	102	8	102	100	
2025-842	094	CLINITEK		093 094	093 094		094 - LARGE-3-4+	102	94	102	100	
2025-842	102	ACON LAB		093 094	093 094		094 - LARGE-3-4+	114	109	114	100	
2025-842	102	ACON LAB		093 094	093 094		093 - MOD. (2+)	114	5	114	100	
2025-842	131	iCHEM VELO		092 094	093 094		094 - LARGE-3-4+	35	17	35	100	
2025-842	131	iCHEM VELO		092 094	093 094		093 - MOD. (2+)	35	18	35	100	
2025-842	140	MISSION A		093 094	093 094		094 - LARGE-3-4+	37	36	37	100	
2025-842	140	MISSION A		093 094	093 094		093 - MOD. (2+)	37	1	37	100	
2025-842	145	CLINITEK		093 094	093 094		094 - LARGE-3-4+	46	46	46	100	
2025-842	147	Mission120		093 094	093 094		094 - LARGE-3-4+	37	37	37	100	
2025-842	148	Mission500		093 094	093 094		090 - NEGATIVE	152	1	151	0	
2025-842	148	Mission500		093 094	093 094		094 - LARGE-3-4+	152	149	151	100	
2025-842	148	Mission500		093 094	093 094		093 - MOD. (2+)	152	2	151	100	
2025-842	151	Clari. Uro		093 094	093 094		094 - LARGE-3-4+	32	32	32	100	
060 URINALYSIS-KETONES												
2025-843	011	AMES NM10S		092 094	092 094		092 - SMALL (1+)	30	7	30	100	
2025-843	011	AMES NM10S		092 094	092 094		093 - MOD. (2+)	30	21	30	100	
2025-843	011	AMES NM10S		092 094	092 094		094 - LARGE-3-4+	30	2	30	100	
2025-843	013	BAYER CLI		092 094	092 094		092 - SMALL (1+)	19	8	19	100	
2025-843	013	BAYER CLI		092 094	092 094		093 - MOD. (2+)	19	11	19	100	
2025-843	067	URISCAN		092 094	092 094		094 - LARGE-3-4+	54	10	54	100	
2025-843	067	URISCAN		092 094	092 094		093 - MOD. (2+)	54	38	54	100	
2025-843	067	URISCAN		092 094	092 094		092 - SMALL (1+)	54	6	54	100	
2025-843	072	URS-9-TECO		092 094	092 094		091 - TRACE	52	1	51	0	
2025-843	072	URS-9-TECO		092 094	092 094		094 - LARGE-3-4+	52	5	51	100	
2025-843	072	URS-9-TECO		092 094	092 094		092 - SMALL (1+)	52	6	51	100	
2025-843	072	URS-9-TECO		092 094	092 094		093 - MOD. (2+)	52	40	51	100	
2025-843	080	ROCHE (CHE		092 094	092 094		094 - LARGE-3-4+	36	5	36	100	
2025-843	080	ROCHE (CHE		092 094	092 094		092 - SMALL (1+)	36	9	36	100	
2025-843	080	ROCHE (CHE		092 094	092 094		093 - MOD. (2+)	36	22	36	100	

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-843	089	AIMSTRIP		092 094	092 094		091 - TRACE	162	1	161	0	
2025-843	089	AIMSTRIP		092 094	092 094		093 - MOD. (2+)	162	97	161	100	
2025-843	089	AIMSTRIP		092 094	092 094		092 - SMALL (1+)	162	27	161	100	
2025-843	089	AIMSTRIP		092 094	092 094		094 - LARGE-3-4+	162	37	161	100	
2025-843	094	CLINITEK		092 094	092 094		092 - SMALL (1+)	102	30	101	100	
2025-843	094	CLINITEK		092 094	092 094		094 - LARGE-3-4+	102	1	101	100	
2025-843	094	CLINITEK		092 094	092 094		091 - TRACE	102	1	101	0	
2025-843	094	CLINITEK		092 094	092 094		093 - MOD. (2+)	102	70	101	100	
2025-843	102	ACON LAB		092 094	092 094		093 - MOD. (2+)	114	92	111	100	
2025-843	102	ACON LAB		092 094	092 094		092 - SMALL (1+)	114	10	111	100	
2025-843	102	ACON LAB		092 094	092 094		094 - LARGE-3-4+	114	9	111	100	
2025-843	102	ACON LAB		092 094	092 094		091 - TRACE	114	1	111	0	
2025-843	102	ACON LAB		092 094	092 094		090 - NEGATIVE	114	2	111	0	
2025-843	131	iCHEM VELO		091 093	092 094		090 - NEGATIVE	35	1	34	0	
2025-843	131	iCHEM VELO		091 093	092 094		093 - MOD. (2+)	35	7	34	100	
2025-843	131	iCHEM VELO		091 093	092 094		092 - SMALL (1+)	35	27	34	100	
2025-843	140	MISSION A		092 094	092 094		094 - LARGE-3-4+	37	8	37	100	
2025-843	140	MISSION A		092 094	092 094		092 - SMALL (1+)	37	4	37	100	
2025-843	140	MISSION A		092 094	092 094		093 - MOD. (2+)	37	25	37	100	
2025-843	145	CLINITEK		092 094	092 094		093 - MOD. (2+)	46	39	46	100	
2025-843	145	CLINITEK		092 094	092 094		092 - SMALL (1+)	46	7	46	100	
2025-843	147	Mission120		092 094	092 094		093 - MOD. (2+)	37	20	37	100	
2025-843	147	Mission120		092 094	092 094		092 - SMALL (1+)	37	2	37	100	
2025-843	147	Mission120		092 094	092 094		094 - LARGE-3-4+	37	15	37	100	
2025-843	148	Mission500		092 094	092 094		093 - MOD. (2+)	152	142	152	100	
2025-843	148	Mission500		092 094	092 094		092 - SMALL (1+)	152	3	152	100	
2025-843	148	Mission500		092 094	092 094		094 - LARGE-3-4+	152	7	152	100	
2025-843	151	Clari. Uro		092 094	092 094		094 - LARGE-3-4+	32	5	32	100	
2025-843	151	Clari. Uro		092 094	092 094		092 - SMALL (1+)	32	1	32	100	
2025-843	151	Clari. Uro		092 094	092 094		093 - MOD. (2+)	32	26	32	100	

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
060 URINALYSIS-KETONES												
2025-844	011	AMES NM10S		090 090	090 090		090 - NEGATIVE	30	30	30	100	
2025-844	013	BAYER CLI		090 090	090 090		090 - NEGATIVE	19	19	19	100	
2025-844	067	URISCAN		090 090	090 090		090 - NEGATIVE	54	54	54	100	
2025-844	072	URS-9-TECO		090 090	090 090		090 - NEGATIVE	52	52	52	100	
2025-844	080	ROCHE (CHE		090 090	090 090		090 - NEGATIVE	36	36	36	100	
2025-844	089	AIMSTRIP		090 090	090 090		090 - NEGATIVE	162	162	162	100	
2025-844	094	CLINITEK		090 090	090 090		090 - NEGATIVE	102	102	102	100	
2025-844	102	ACON LAB		090 090	090 090		090 - NEGATIVE	114	113	113	100	
2025-844	102	ACON LAB		090 090	090 090		093 - MOD. (2+)	114	1	113	0	
2025-844	131	iCHEM VELO		090 090	090 090		090 - NEGATIVE	35	35	35	100	
2025-844	140	MISSION A		090 090	090 090		090 - NEGATIVE	37	37	37	100	
2025-844	145	CLINITEK		090 090	090 090		090 - NEGATIVE	46	46	46	100	
2025-844	147	Mission120		090 090	090 090		094 - LARGE-3-4+	37	1	36	0	
2025-844	147	Mission120		090 090	090 090		090 - NEGATIVE	37	36	36	100	
2025-844	148	Mission500		090 090	090 090		090 - NEGATIVE	152	152	152	100	
2025-844	151	Clari. Uro		090 090	090 090		090 - NEGATIVE	32	32	32	100	
2025-845	011	AMES NM10S		090 090	090 090		090 - NEGATIVE	30	30	30	100	
2025-845	013	BAYER CLI		090 090	090 090		090 - NEGATIVE	19	19	19	100	
2025-845	067	URISCAN		090 090	090 090		090 - NEGATIVE	54	54	54	100	
2025-845	072	URS-9-TECO		090 090	090 090		090 - NEGATIVE	52	52	52	100	
2025-845	080	ROCHE (CHE		090 090	090 090		090 - NEGATIVE	36	36	36	100	
2025-845	089	AIMSTRIP		090 090	090 090		090 - NEGATIVE	162	162	162	100	
2025-845	094	CLINITEK		090 090	090 090		090 - NEGATIVE	102	102	102	100	
2025-845	102	ACON LAB		090 090	090 090		090 - NEGATIVE	114	113	113	100	
2025-845	102	ACON LAB		090 090	090 090		093 - MOD. (2+)	114	1	113	0	
2025-845	131	iCHEM VELO		090 090	090 090		090 - NEGATIVE	35	35	35	100	
2025-845	140	MISSION A		090 090	090 090		090 - NEGATIVE	37	37	37	100	

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-845	145	CLINITEK		090 090	090 090		090 - NEGATIVE	46	46	46	100	
2025-845	147	Mission120		090 090	090 090		090 - NEGATIVE	37	37	37	100	
2025-845	148	Mission500		090 090	090 090		090 - NEGATIVE	152	152	152	100	
2025-845	151	Clari. Uro		090 090	090 090		090 - NEGATIVE	32	32	32	100	
061 URINALYSIS-NITRATE												
2025-841	011	AMES NM10S		070 070	070 070		070 - NEGATIVE	30	30	30	100	
2025-841	013	BAYER CLI		070 070	070 070		070 - NEGATIVE	20	20	20	100	
2025-841	067	URISCAN		070 070	070 070		070 - NEGATIVE	54	54	54	100	
2025-841	072	URS-9-TECO		070 070	070 070		070 - NEGATIVE	53	53	53	100	
2025-841	080	ROCHE (CHE		070 070	070 070		070 - NEGATIVE	36	35	35	100	
2025-841	080	ROCHE (CHE		070 070	070 070		072 - POSITIVE	36	1	35	0	
2025-841	089	AIMSTRIP		070 070	070 070		070 - NEGATIVE	162	162	162	100	
2025-841	094	CLINITEK		070 070	070 070		070 - NEGATIVE	102	102	102	100	
2025-841	102	ACON LAB		070 070	070 070		070 - NEGATIVE	114	114	114	100	
2025-841	131	iCHEM VELO		070 070	070 070		070 - NEGATIVE	35	35	35	100	
2025-841	140	MISSION A		070 070	070 070		070 - NEGATIVE	34	34	34	100	
2025-841	145	CLINITEK		070 070	070 070		070 - NEGATIVE	46	46	46	100	
2025-841	147	Mission120		070 070	070 070		070 - NEGATIVE	38	38	38	100	
2025-841	148	Mission500		070 070	070 070		070 - NEGATIVE	152	152	152	100	
2025-841	151	Clari. Uro		070 070	070 070		070 - NEGATIVE	32	32	32	100	
2025-842	011	AMES NM10S		070 070	070 070		070 - NEGATIVE	30	30	30	100	
2025-842	013	BAYER CLI		070 070	070 070		070 - NEGATIVE	20	20	20	100	
2025-842	067	URISCAN		070 070	070 070		070 - NEGATIVE	54	54	54	100	
2025-842	072	URS-9-TECO		070 070	070 070		070 - NEGATIVE	53	53	53	100	
2025-842	080	ROCHE (CHE		070 070	070 070		070 - NEGATIVE	36	36	36	100	
2025-842	089	AIMSTRIP		070 070	070 070		070 - NEGATIVE	162	162	162	100	
2025-842	094	CLINITEK		070 070	070 070		070 - NEGATIVE	102	102	102	100	
2025-842	102	ACON LAB		070 070	070 070		070 - NEGATIVE	114	114	114	100	

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-842	131	iCHEM VELO		070 070	070 070		070 - NEGATIVE	35	35	35	100	
2025-842	140	MISSION A		070 070	070 070		070 - NEGATIVE	34	34	34	100	
2025-842	145	CLINITEK		070 070	070 070		070 - NEGATIVE	46	46	46	100	
2025-842	147	Mission120		070 070	070 070		070 - NEGATIVE	38	38	38	100	
2025-842	148	Mission500		070 070	070 070		070 - NEGATIVE	152	151	151	100	
2025-842	148	Mission500		070 070	070 070		072 - POSITIVE	152	1	151	0	
2025-842	151	Clari. Uro		070 070	070 070		070 - NEGATIVE	32	32	32	100	
061 URINALYSIS-NITRATE												
2025-843	011	AMES NM10S		071 072	071 072		072 - POSITIVE	30	30	30	100	
2025-843	013	BAYER CLI		071 072	071 072		072 - POSITIVE	20	20	20	100	
2025-843	067	URISCAN		071 072	071 072		072 - POSITIVE	54	54	54	100	
2025-843	072	URS-9-TECO		071 072	071 072		072 - POSITIVE	53	53	53	100	
2025-843	080	ROCHE (CHE		071 072	071 072		072 - POSITIVE	36	36	36	100	
2025-843	089	AIMSTRIP		071 072	071 072		071 - WEAK POS.	162	3	162	100	
2025-843	089	AIMSTRIP		071 072	071 072		072 - POSITIVE	162	159	162	100	
2025-843	094	CLINITEK		071 072	071 072		072 - POSITIVE	102	101	102	100	
2025-843	094	CLINITEK		071 072	071 072		071 - WEAK POS.	102	1	102	100	
2025-843	102	ACON LAB		071 072	071 072		070 - NEGATIVE	114	2	112	0	
2025-843	102	ACON LAB		071 072	071 072		072 - POSITIVE	114	112	112	100	
2025-843	131	iCHEM VELO		071 072	071 072		072 - POSITIVE	35	35	35	100	
2025-843	140	MISSION A		071 072	071 072		072 - POSITIVE	34	34	34	100	
2025-843	145	CLINITEK		071 072	071 072		072 - POSITIVE	46	46	46	100	
2025-843	147	Mission120		071 072	071 072		072 - POSITIVE	38	38	38	100	
2025-843	148	Mission500		071 072	071 072		072 - POSITIVE	152	151	151	100	
2025-843	148	Mission500		071 072	071 072		070 - NEGATIVE	152	1	151	0	
2025-843	151	Clari. Uro		071 072	071 072		072 - POSITIVE	32	32	32	100	
2025-844	011	AMES NM10S		070 070	070 070		070 - NEGATIVE	30	30	30	100	
2025-844	013	BAYER CLI		070 070	070 070		070 - NEGATIVE	20	20	20	100	

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-844	067	URISCAN		070 070	070 070		070 - NEGATIVE	54	53	53	100	
2025-844	067	URISCAN		070 070	070 070		072 - POSITIVE	54	1	53	0	
2025-844	072	URS-9-TECO		070 070	070 070		070 - NEGATIVE	53	53	53	100	
2025-844	080	ROCHE (CHE		070 070	070 070		072 - POSITIVE	36	1	35	0	
2025-844	080	ROCHE (CHE		070 070	070 070		070 - NEGATIVE	36	35	35	100	
2025-844	089	AIMSTRIP		070 070	070 070		070 - NEGATIVE	162	162	162	100	
2025-844	094	CLINITEK		070 070	070 070		070 - NEGATIVE	102	102	102	100	
2025-844	102	ACON LAB		070 070	070 070		070 - NEGATIVE	114	113	113	100	
2025-844	102	ACON LAB		070 070	070 070		072 - POSITIVE	114	1	113	0	
2025-844	131	iCHEM VELO		070 070	070 070		070 - NEGATIVE	35	35	35	100	
2025-844	140	MISSION A		070 070	070 070		070 - NEGATIVE	34	34	34	100	
2025-844	145	CLINITEK		070 070	070 070		070 - NEGATIVE	46	46	46	100	
2025-844	147	Mission120		070 070	070 070		070 - NEGATIVE	38	38	38	100	
2025-844	148	Mission500		070 070	070 070		070 - NEGATIVE	152	152	152	100	
2025-844	151	Clari. Uro		070 070	070 070		070 - NEGATIVE	32	32	32	100	
061 URINALYSIS-NITRATE												
2025-845	011	AMES NM10S		070 070	070 070		070 - NEGATIVE	30	30	30	100	
2025-845	013	BAYER CLI		070 070	070 070		070 - NEGATIVE	20	20	20	100	
2025-845	067	URISCAN		070 070	070 070		070 - NEGATIVE	54	54	54	100	
2025-845	072	URS-9-TECO		070 070	070 070		070 - NEGATIVE	53	53	53	100	
2025-845	080	ROCHE (CHE		070 070	070 070		070 - NEGATIVE	36	36	36	100	
2025-845	089	AIMSTRIP		070 070	070 070		070 - NEGATIVE	162	162	162	100	
2025-845	094	CLINITEK		070 070	070 070		070 - NEGATIVE	102	102	102	100	
2025-845	102	ACON LAB		070 070	070 070		070 - NEGATIVE	114	113	113	100	
2025-845	102	ACON LAB		070 070	070 070		072 - POSITIVE	114	1	113	0	
2025-845	131	iCHEM VELO		070 070	070 070		070 - NEGATIVE	35	35	35	100	
2025-845	140	MISSION A		070 070	070 070		070 - NEGATIVE	34	34	34	100	
2025-845	145	CLINITEK		070 070	070 070		070 - NEGATIVE	46	45	45	100	
2025-845	145	CLINITEK		070 070	070 070		072 - POSITIVE	46	1	45	0	
2025-845	147	Mission120		070 070	070 070		070 - NEGATIVE	38	38	38	100	

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2025-845	148	Mission500		070 070	070 070		070 - NEGATIVE	152	152	152	100		
2025-845	151	Clari. Uro		070 070	070 070		070 - NEGATIVE	32	32	32	100		
062 URINALYSIS-pH													
2025-841	011	AMES NM10S		085 088	084 088		087 - 7.5	30	20	30	100		
2025-841	011	AMES NM10S		085 088	084 088		086 - 7.0	30	10	30	100		
2025-841	013	BAYER CLI		085 088	084 088		086 - 7.0	19	7	19	100		
2025-841	013	BAYER CLI		085 088	084 088		087 - 7.5	19	12	19	100		
2025-841	067	URISCAN		084 088	084 088		086 - 7.0	54	45	54	100		
2025-841	067	URISCAN		084 088	084 088		085 - 6.5	54	7	54	100		
2025-841	067	URISCAN		084 088	084 088		087 - 7.5	54	2	54	100		
2025-841	072	URS-9-TECO		084 088	084 088		087 - 7.5	53	9	53	100		
2025-841	072	URS-9-TECO		084 088	084 088		086 - 7.0	53	41	53	100		
2025-841	072	URS-9-TECO		084 088	084 088		085 - 6.5	53	3	53	100		
2025-841	080	ROCHE (CHE		084 088	084 088		086 - 7.0	36	36	36	100		
2025-841	089	AIMSTRIP		084 088	084 088		087 - 7.5	162	26	162	100		
2025-841	089	AIMSTRIP		084 088	084 088		086 - 7.0	162	133	162	100		
2025-841	089	AIMSTRIP		084 088	084 088		085 - 6.5	162	3	162	100		
2025-841	094	CLINITEK		085 088	084 088		087 - 7.5	102	64	102	100		
2025-841	094	CLINITEK		085 088	084 088		086 - 7.0	102	38	102	100		
2025-841	102	ACON LAB		084 088	084 088		086 - 7.0	117	98	117	100		
2025-841	102	ACON LAB		084 088	084 088		085 - 6.5	117	2	117	100		
2025-841	102	ACON LAB		084 088	084 088		087 - 7.5	117	17	117	100		
2025-841	131	iCHEM VELO		084 088	084 088		086 - 7.0	35	35	35	100		
2025-841	140	MISSION A		084 088	084 088		086 - 7.0	35	30	35	100		
2025-841	140	MISSION A		084 088	084 088		087 - 7.5	35	5	35	100		
2025-841	145	CLINITEK		085 088	084 088		087 - 7.5	46	42	46	100		
2025-841	145	CLINITEK		085 088	084 088		086 - 7.0	46	4	46	100		
2025-841	147	Mission120		084 088	084 088		086 - 7.0	37	35	37	100		
2025-841	147	Mission120		084 088	084 088		085 - 6.5	37	2	37	100		
2025-841	148	Mission500		084 088	084 088		086 - 7.0	150	146	150	100		

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-841	148	Mission500		084 088	084 088		087 - 7.5	150	3	150	100	
2025-841	148	Mission500		084 088	084 088		084 - 6.0	150	1	150	100	
2025-841	151	Clari. Uro		084 088	084 088		086 - 7.0	32	30	32	100	
2025-841	151	Clari. Uro		084 088	084 088		087 - 7.5	32	2	32	100	
062 URINALYSIS-pH												
2025-842	011	AMES NM10S		085 088	085 088		086 - 7.0	30	1	30	100	
2025-842	011	AMES NM10S		085 088	085 088		088 - 8.0OR MORE	30	1	30	100	
2025-842	011	AMES NM10S		085 088	085 088		087 - 7.5	30	28	30	100	
2025-842	013	BAYER CLI		085 088	085 088		087 - 7.5	19	19	19	100	
2025-842	067	URISCAN		084 088	085 088		086 - 7.0	54	33	54	100	
2025-842	067	URISCAN		084 088	085 088		087 - 7.5	54	21	54	100	
2025-842	072	URS-9-TECO		085 088	085 088		086 - 7.0	53	24	53	100	
2025-842	072	URS-9-TECO		085 088	085 088		088 - 8.0OR MORE	53	2	53	100	
2025-842	072	URS-9-TECO		085 088	085 088		087 - 7.5	53	27	53	100	
2025-842	080	ROCHE (CHE		084 088	085 088		086 - 7.0	36	36	36	100	
2025-842	089	AIMSTRIP		085 088	085 088		086 - 7.0	162	41	162	100	
2025-842	089	AIMSTRIP		085 088	085 088		087 - 7.5	162	121	162	100	
2025-842	094	CLINITEK		085 088	085 088		088 - 8.0OR MORE	102	3	102	100	
2025-842	094	CLINITEK		085 088	085 088		086 - 7.0	102	2	102	100	
2025-842	094	CLINITEK		085 088	085 088		087 - 7.5	102	97	102	100	
2025-842	102	ACON LAB		085 088	085 088		086 - 7.0	117	29	116	100	
2025-842	102	ACON LAB		085 088	085 088		084 - 6.0	117	1	116	0	
2025-842	102	ACON LAB		085 088	085 088		087 - 7.5	117	87	116	100	
2025-842	131	iCHEM VELO		084 088	085 088		086 - 7.0	35	35	35	100	
2025-842	140	MISSION A		085 088	085 088		087 - 7.5	35	29	35	100	
2025-842	140	MISSION A		085 088	085 088		086 - 7.0	35	6	35	100	
2025-842	145	CLINITEK		085 088	085 088		087 - 7.5	46	46	46	100	
2025-842	147	Mission120		085 088	085 088		086 - 7.0	37	13	37	100	
2025-842	147	Mission120		085 088	085 088		087 - 7.5	37	24	37	100	
2025-842	148	Mission500		085 088	085 088		087 - 7.5	150	108	150	100	

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-842	148	Mission500		085 088	085 088		086 - 7.0	150	41	150	100	
2025-842	148	Mission500		085 088	085 088		085 - 6.5	150	1	150	100	
2025-842	151	Clari. Uro		085 088	085 088		086 - 7.0	32	13	32	100	
2025-842	151	Clari. Uro		085 088	085 088		087 - 7.5	32	19	32	100	
062 URINALYSIS-pH												
2025-843	011	AMES NM10S		082 086	080 084		084 - 6.0	30	13	30	100	
2025-843	011	AMES NM10S		082 086	080 084		083 - 5.5	30	11	30	100	
2025-843	011	AMES NM10S		082 086	080 084		082 - 5.0	30	6	30	100	
2025-843	013	BAYER CLI		080 084	080 084		082 - 5.0	19	7	19	100	
2025-843	013	BAYER CLI		080 084	080 084		083 - 5.5	19	5	19	100	
2025-843	013	BAYER CLI		080 084	080 084		084 - 6.0	19	7	19	100	
2025-843	067	URISCAN		080 084	080 084		083 - 5.5	54	1	54	100	
2025-843	067	URISCAN		080 084	080 084		084 - 6.0	54	1	54	100	
2025-843	067	URISCAN		080 084	080 084		082 - 5.0	54	52	54	100	
2025-843	072	URS-9-TECO		082 086	080 084		083 - 5.5	53	10	53	100	
2025-843	072	URS-9-TECO		082 086	080 084		084 - 6.0	53	28	53	100	
2025-843	072	URS-9-TECO		082 086	080 084		085 - 6.5	53	6	53	100	
2025-843	072	URS-9-TECO		082 086	080 084		082 - 5.0	53	9	53	100	
2025-843	080	ROCHE (CHE		080 084	080 084		084 - 6.0	36	5	36	100	
2025-843	080	ROCHE (CHE		080 084	080 084		082 - 5.0	36	31	36	100	
2025-843	089	AIMSTRIP		082 086	080 084		082 - 5.0	162	29	162	100	
2025-843	089	AIMSTRIP		082 086	080 084		083 - 5.5	162	35	162	100	
2025-843	089	AIMSTRIP		082 086	080 084		084 - 6.0	162	98	162	100	
2025-843	094	CLINITEK		082 086	080 084		082 - 5.0	102	14	101	100	
2025-843	094	CLINITEK		082 086	080 084		087 - 7.5	102	1	101	0	
2025-843	094	CLINITEK		082 086	080 084		083 - 5.5	102	27	101	100	
2025-843	094	CLINITEK		082 086	080 084		084 - 6.0	102	60	101	100	
2025-843	102	ACON LAB		082 086	080 084		086 - 7.0	117	1	117	100	
2025-843	102	ACON LAB		082 086	080 084		082 - 5.0	117	28	117	100	
2025-843	102	ACON LAB		082 086	080 084		083 - 5.5	117	18	117	100	

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-843	102	ACON LAB		082 086	080 084		084 - 6.0	117	69	117	100
2025-843	102	ACON LAB		082 086	080 084		085 - 6.5	117	1	117	100
2025-843	131	iCHEM VELO		080 084	080 084		082 - 5.0	35	35	35	100
2025-843	140	MISSION A		081 085	080 084		082 - 5.0	35	5	35	100
2025-843	140	MISSION A		081 085	080 084		083 - 5.5	35	18	35	100
2025-843	140	MISSION A		081 085	080 084		084 - 6.0	35	12	35	100
2025-843	145	CLINITEK		081 085	080 084		083 - 5.5	46	26	46	100
2025-843	145	CLINITEK		081 085	080 084		082 - 5.0	46	19	46	100
2025-843	145	CLINITEK		081 085	080 084		084 - 6.0	46	1	46	100
2025-843	147	Mission120		081 085	080 084		083 - 5.5	37	19	37	100
2025-843	147	Mission120		081 085	080 084		084 - 6.0	37	2	37	100
2025-843	147	Mission120		081 085	080 084		082 - 5.0	37	16	37	100
2025-843	148	Mission500		082 086	080 084		084 - 6.0	150	137	150	100
2025-843	148	Mission500		082 086	080 084		083 - 5.5	150	12	150	100
2025-843	148	Mission500		082 086	080 084		082 - 5.0	150	1	150	100
2025-843	151	Clari. Uro		082 086	080 084		082 - 5.0	32	3	32	100
2025-843	151	Clari. Uro		082 086	080 084		084 - 6.0	32	24	32	100
2025-843	151	Clari. Uro		082 086	080 084		083 - 5.5	32	5	32	100
062 URINALYSIS-pH											
2025-844	011	AMES NM10S		084 088	084 088		086 - 7.0	30	26	30	100
2025-844	011	AMES NM10S		084 088	084 088		085 - 6.5	30	4	30	100
2025-844	013	BAYER CLI		084 088	084 088		086 - 7.0	19	19	19	100
2025-844	067	URISCAN		083 087	084 088		084 - 6.0	54	2	54	100
2025-844	067	URISCAN		083 087	084 088		086 - 7.0	54	8	54	100
2025-844	067	URISCAN		083 087	084 088		085 - 6.5	54	44	54	100
2025-844	072	URS-9-TECO		084 088	084 088		085 - 6.5	53	14	53	100
2025-844	072	URS-9-TECO		084 088	084 088		086 - 7.0	53	38	53	100
2025-844	072	URS-9-TECO		084 088	084 088		087 - 7.5	53	1	53	100
2025-844	080	ROCHE (CHE		084 088	084 088		086 - 7.0	36	34	36	100
2025-844	080	ROCHE (CHE		084 088	084 088		085 - 6.5	36	2	36	100

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-844	089	AIMSTRIP		084 088	084 088		086 - 7.0	162	122	162	100	
2025-844	089	AIMSTRIP		084 088	084 088		085 - 6.5	162	40	162	100	
2025-844	094	CLINITEK		084 088	084 088		085 - 6.5	102	1	102	100	
2025-844	094	CLINITEK		084 088	084 088		086 - 7.0	102	101	102	100	
2025-844	102	ACON LAB		084 088	084 088		085 - 6.5	117	27	117	100	
2025-844	102	ACON LAB		084 088	084 088		084 - 6.0	117	4	117	100	
2025-844	102	ACON LAB		084 088	084 088		086 - 7.0	117	86	117	100	
2025-844	131	iCHEM VELO		084 088	084 088		084 - 6.0	35	2	35	100	
2025-844	131	iCHEM VELO		084 088	084 088		086 - 7.0	35	33	35	100	
2025-844	140	MISSION A		083 087	084 088		086 - 7.0	35	13	35	100	
2025-844	140	MISSION A		083 087	084 088		085 - 6.5	35	22	35	100	
2025-844	145	CLINITEK		084 088	084 088		086 - 7.0	46	46	46	100	
2025-844	147	Mission120		083 087	084 088		086 - 7.0	37	1	37	100	
2025-844	147	Mission120		083 087	084 088		085 - 6.5	37	36	37	100	
2025-844	148	Mission500		084 088	084 088		086 - 7.0	150	136	150	100	
2025-844	148	Mission500		084 088	084 088		085 - 6.5	150	14	150	100	
2025-844	151	Clari. Uro		083 087	084 088		085 - 6.5	32	21	32	100	
2025-844	151	Clari. Uro		083 087	084 088		086 - 7.0	32	11	32	100	
062 URINALYSIS-pH												
2025-845	011	AMES NM10S		084 088	084 088		085 - 6.5	30	5	30	100	
2025-845	011	AMES NM10S		084 088	084 088		086 - 7.0	30	25	30	100	
2025-845	013	BAYER CLI		084 088	084 088		085 - 6.5	19	2	19	100	
2025-845	013	BAYER CLI		084 088	084 088		086 - 7.0	19	17	19	100	
2025-845	067	URISCAN		083 087	084 088		086 - 7.0	54	1	53	100	
2025-845	067	URISCAN		083 087	084 088		082 - 5.0	54	1	53	0	
2025-845	067	URISCAN		083 087	084 088		085 - 6.5	54	49	53	100	
2025-845	067	URISCAN		083 087	084 088		084 - 6.0	54	3	53	100	
2025-845	072	URS-9-TECO		083 087	084 088		085 - 6.5	53	26	53	100	
2025-845	072	URS-9-TECO		083 087	084 088		086 - 7.0	53	22	53	100	
2025-845	072	URS-9-TECO		083 087	084 088		084 - 6.0	53	5	53	100	

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-845	080	ROCHE (CHE		083 087	084 088		085 - 6.5	36	29	36	100
2025-845	080	ROCHE (CHE		083 087	084 088		086 - 7.0	36	7	36	100
2025-845	089	AIMSTRIP		083 087	084 088		086 - 7.0	162	55	162	100
2025-845	089	AIMSTRIP		083 087	084 088		085 - 6.5	162	103	162	100
2025-845	089	AIMSTRIP		083 087	084 088		084 - 6.0	162	4	162	100
2025-845	094	CLINITEK		084 088	084 088		086 - 7.0	102	90	102	100
2025-845	094	CLINITEK		084 088	084 088		085 - 6.5	102	12	102	100
2025-845	102	ACON LAB		083 087	084 088		086 - 7.0	117	24	117	100
2025-845	102	ACON LAB		083 087	084 088		085 - 6.5	117	85	117	100
2025-845	102	ACON LAB		083 087	084 088		084 - 6.0	117	7	117	100
2025-845	102	ACON LAB		083 087	084 088		083 - 5.5	117	1	117	100
2025-845	131	iCHEM VELO		082 086	084 088		086 - 7.0	35	5	35	100
2025-845	131	iCHEM VELO		082 086	084 088		084 - 6.0	35	30	35	100
2025-845	140	MISSION A		083 087	084 088		086 - 7.0	35	5	35	100
2025-845	140	MISSION A		083 087	084 088		085 - 6.5	35	28	35	100
2025-845	140	MISSION A		083 087	084 088		084 - 6.0	35	2	35	100
2025-845	145	CLINITEK		084 088	084 088		085 - 6.5	46	21	46	100
2025-845	145	CLINITEK		084 088	084 088		086 - 7.0	46	25	46	100
2025-845	147	Mission120		083 087	084 088		085 - 6.5	37	35	37	100
2025-845	147	Mission120		083 087	084 088		084 - 6.0	37	2	37	100
2025-845	148	Mission500		083 087	084 088		084 - 6.0	150	1	150	100
2025-845	148	Mission500		083 087	084 088		086 - 7.0	150	20	150	100
2025-845	148	Mission500		083 087	084 088		085 - 6.5	150	128	150	100
2025-845	148	Mission500		083 087	084 088		083 - 5.5	150	1	150	100
2025-845	151	Clari. Uro		083 087	084 088		084 - 6.0	32	6	32	100
2025-845	151	Clari. Uro		083 087	084 088		086 - 7.0	32	2	32	100
2025-845	151	Clari. Uro		083 087	084 088		085 - 6.5	32	24	32	100
064 URIN-PROTEIN QUALI.											
2025-841	011	AMES NM10S		051 051	051 051		051 - NEGATIVE	31	31	31	100
2025-841	013	BAYER CLI		051 051	051 051		051 - NEGATIVE	19	19	19	100

Participant Summary
MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-841	067	URISCAN		051 051	051 051		051 - NEGATIVE	55	55	55	100	
2025-841	072	URS-9-TECO		051 051	051 051		051 - NEGATIVE	53	53	53	100	
2025-841	080	ROCHE (CHE		051 051	051 051		052 - TRACES	36	2	31	0	
2025-841	080	ROCHE (CHE		051 051	051 051		051 - NEGATIVE	36	31	31	100	
2025-841	080	ROCHE (CHE		051 051	051 051		053 - 1+	36	3	31	0	
2025-841	089	AIMSTRIP		051 051	051 051		052 - TRACES	160	2	158	0	
2025-841	089	AIMSTRIP		051 051	051 051		051 - NEGATIVE	160	158	158	100	
2025-841	094	CLINITEK		051 051	051 051		051 - NEGATIVE	102	102	102	100	
2025-841	102	ACON LAB		051 051	051 051		052 - TRACES	115	1	114	0	
2025-841	102	ACON LAB		051 051	051 051		051 - NEGATIVE	115	114	114	100	
2025-841	131	iCHEM VELO		051 051	051 051		051 - NEGATIVE	35	35	35	100	
2025-841	140	MISSION A		051 051	051 051		051 - NEGATIVE	34	34	34	100	
2025-841	145	CLINITEK		051 051	051 051		051 - NEGATIVE	46	46	46	100	
2025-841	147	Mission120		051 051	051 051		051 - NEGATIVE	38	38	38	100	
2025-841	148	Mission500		051 051	051 051		051 - NEGATIVE	153	153	153	100	
2025-841	151	Clari. Uro		051 051	051 051		051 - NEGATIVE	32	32	32	100	
064 URIN-PROTEIN QUALI.												
2025-842	011	AMES NM10S		053 055	053 055		054 - 2+	31	18	31	100	
2025-842	011	AMES NM10S		053 055	053 055		055 - 3+	31	13	31	100	
2025-842	013	BAYER CLI		053 055	053 055		055 - 3+	19	7	19	100	
2025-842	013	BAYER CLI		053 055	053 055		053 - 1+	19	1	19	100	
2025-842	013	BAYER CLI		053 055	053 055		054 - 2+	19	11	19	100	
2025-842	067	URISCAN		053 055	053 055		055 - 3+	55	4	55	100	
2025-842	067	URISCAN		053 055	053 055		054 - 2+	55	44	55	100	
2025-842	067	URISCAN		053 055	053 055		053 - 1+	55	7	55	100	
2025-842	072	URS-9-TECO		053 055	053 055		055 - 3+	53	26	53	100	
2025-842	072	URS-9-TECO		053 055	053 055		054 - 2+	53	27	53	100	
2025-842	080	ROCHE (CHE		053 055	053 055		054 - 2+	36	28	36	100	
2025-842	080	ROCHE (CHE		053 055	053 055		055 - 3+	36	8	36	100	
2025-842	089	AIMSTRIP		053 055	053 055		053 - 1+	160	2	160	100	

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-842	089	AIMSTRIP		053 055	053 055		055 - 3+	160	43	160	100	
2025-842	089	AIMSTRIP		053 055	053 055		054 - 2+	160	115	160	100	
2025-842	094	CLINITEK		053 055	053 055		055 - 3+	102	16	102	100	
2025-842	094	CLINITEK		053 055	053 055		054 - 2+	102	85	102	100	
2025-842	094	CLINITEK		053 055	053 055		053 - 1+	102	1	102	100	
2025-842	102	ACON LAB		053 055	053 055		055 - 3+	115	29	115	100	
2025-842	102	ACON LAB		053 055	053 055		053 - 1+	115	4	115	100	
2025-842	102	ACON LAB		053 055	053 055		054 - 2+	115	82	115	100	
2025-842	131	iCHEM VELO		053 055	053 055		053 - 1+	35	1	32	100	
2025-842	131	iCHEM VELO		053 055	053 055		054 - 2+	35	18	32	100	
2025-842	131	iCHEM VELO		053 055	053 055		056 - 4+	35	3	32	0	
2025-842	131	iCHEM VELO		053 055	053 055		055 - 3+	35	13	32	100	
2025-842	140	MISSION A		053 055	053 055		055 - 3+	34	8	34	100	
2025-842	140	MISSION A		053 055	053 055		054 - 2+	34	25	34	100	
2025-842	140	MISSION A		053 055	053 055		053 - 1+	34	1	34	100	
2025-842	145	CLINITEK		053 055	053 055		055 - 3+	46	12	44	100	
2025-842	145	CLINITEK		053 055	053 055		054 - 2+	46	30	44	100	
2025-842	145	CLINITEK		053 055	053 055		053 - 1+	46	2	44	100	
2025-842	145	CLINITEK		053 055	053 055		056 - 4+	46	2	44	0	
2025-842	147	Mission120		053 055	053 055		053 - 1+	38	3	38	100	
2025-842	147	Mission120		053 055	053 055		054 - 2+	38	35	38	100	
2025-842	148	Mission500		053 055	053 055		056 - 4+	153	1	152	0	
2025-842	148	Mission500		053 055	053 055		054 - 2+	153	110	152	100	
2025-842	148	Mission500		053 055	053 055		053 - 1+	153	7	152	100	
2025-842	148	Mission500		053 055	053 055		055 - 3+	153	35	152	100	
2025-842	151	Clari. Uro		053 055	053 055		053 - 1+	32	1	32	100	
2025-842	151	Clari. Uro		053 055	053 055		054 - 2+	32	28	32	100	
2025-842	151	Clari. Uro		053 055	053 055		055 - 3+	32	3	32	100	
064 URIN-PROTEIN QUALI.												
2025-843	011	AMES NM10S		051 051	051 051		051 - NEGATIVE	31	31	31	100	

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-843	013	BAYER CLI		051 051	051 051		051 - NEGATIVE	19	19	19	100
2025-843	067	URISCAN		051 051	051 051		051 - NEGATIVE	55	55	55	100
2025-843	072	URS-9-TECO		051 051	051 051		051 - NEGATIVE	53	53	53	100
2025-843	080	ROCHE (CHE		051 051	051 051		051 - NEGATIVE	36	35	35	100
2025-843	080	ROCHE (CHE		051 051	051 051		053 - 1+	36	1	35	0
2025-843	089	AIMSTRIP		051 051	051 051		051 - NEGATIVE	160	160	160	100
2025-843	094	CLINITEK		051 051	051 051		051 - NEGATIVE	102	102	102	100
2025-843	102	ACON LAB		051 051	051 051		051 - NEGATIVE	115	114	114	100
2025-843	102	ACON LAB		051 051	051 051		054 - 2+	115	1	114	0
2025-843	131	iCHEM VELO		051 051	051 051		051 - NEGATIVE	35	35	35	100
2025-843	140	MISSION A		051 051	051 051		051 - NEGATIVE	34	34	34	100
2025-843	145	CLINITEK		051 051	051 051		051 - NEGATIVE	46	46	46	100
2025-843	147	Mission120		051 051	051 051		051 - NEGATIVE	38	38	38	100
2025-843	148	Mission500		051 051	051 051		051 - NEGATIVE	153	153	153	100
2025-843	151	Clari. Uro		051 051	051 051		051 - NEGATIVE	32	32	32	100
064 URIN-PROTEIN QUALI.											
2025-844	011	AMES NM10S		053 055	053 055		055 - 3+	31	11	30	100
2025-844	011	AMES NM10S		053 055	053 055		053 - 1+	31	1	30	100
2025-844	011	AMES NM10S		053 055	053 055		054 - 2+	31	18	30	100
2025-844	011	AMES NM10S		053 055	053 055		056 - 4+	31	1	30	0
2025-844	013	BAYER CLI		053 055	053 055		054 - 2+	19	12	19	100
2025-844	013	BAYER CLI		053 055	053 055		053 - 1+	19	1	19	100
2025-844	013	BAYER CLI		053 055	053 055		055 - 3+	19	6	19	100
2025-844	067	URISCAN		053 055	053 055		055 - 3+	55	1	55	100
2025-844	067	URISCAN		053 055	053 055		053 - 1+	55	12	55	100
2025-844	067	URISCAN		053 055	053 055		054 - 2+	55	42	55	100
2025-844	072	URS-9-TECO		053 055	053 055		054 - 2+	53	26	50	100
2025-844	072	URS-9-TECO		053 055	053 055		055 - 3+	53	24	50	100
2025-844	072	URS-9-TECO		053 055	053 055		051 - NEGATIVE	53	3	50	0
2025-844	080	ROCHE (CHE		053 055	053 055		055 - 3+	36	9	36	100

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-844	080	ROCHE (CHE		053	055	053	055	054 - 2+	36	27	36	100
2025-844	089	AIMSTRIP		053	055	053	055	054 - 2+	160	123	157	100
2025-844	089	AIMSTRIP		053	055	053	055	053 - 1+	160	2	157	100
2025-844	089	AIMSTRIP		053	055	053	055	056 - 4+	160	2	157	0
2025-844	089	AIMSTRIP		053	055	053	055	051 - NEGATIVE	160	1	157	0
2025-844	089	AIMSTRIP		053	055	053	055	055 - 3+	160	32	157	100
2025-844	094	CLINITEK		053	055	053	055	054 - 2+	102	87	102	100
2025-844	094	CLINITEK		053	055	053	055	053 - 1+	102	1	102	100
2025-844	094	CLINITEK		053	055	053	055	055 - 3+	102	14	102	100
2025-844	102	ACON LAB		053	055	053	055	053 - 1+	115	8	113	100
2025-844	102	ACON LAB		053	055	053	055	054 - 2+	115	78	113	100
2025-844	102	ACON LAB		053	055	053	055	051 - NEGATIVE	115	2	113	0
2025-844	102	ACON LAB		053	055	053	055	055 - 3+	115	27	113	100
2025-844	131	iCHEM VELO		053	055	053	055	055 - 3+	35	8	34	100
2025-844	131	iCHEM VELO		053	055	053	055	053 - 1+	35	1	34	100
2025-844	131	iCHEM VELO		053	055	053	055	054 - 2+	35	25	34	100
2025-844	131	iCHEM VELO		053	055	053	055	056 - 4+	35	1	34	0
2025-844	140	MISSION A		053	055	053	055	055 - 3+	34	4	34	100
2025-844	140	MISSION A		053	055	053	055	054 - 2+	34	29	34	100
2025-844	140	MISSION A		053	055	053	055	053 - 1+	34	1	34	100
2025-844	145	CLINITEK		053	055	053	055	056 - 4+	46	1	45	0
2025-844	145	CLINITEK		053	055	053	055	054 - 2+	46	32	45	100
2025-844	145	CLINITEK		053	055	053	055	055 - 3+	46	13	45	100
2025-844	147	Mission120		053	055	053	055	053 - 1+	38	4	38	100
2025-844	147	Mission120		053	055	053	055	054 - 2+	38	34	38	100
2025-844	148	Mission500		053	055	053	055	056 - 4+	153	2	151	0
2025-844	148	Mission500		053	055	053	055	055 - 3+	153	14	151	100
2025-844	148	Mission500		053	055	053	055	053 - 1+	153	7	151	100
2025-844	148	Mission500		053	055	053	055	054 - 2+	153	130	151	100
2025-844	151	Clari. Uro		053	055	053	055	055 - 3+	32	2	32	100

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2025-844	151	Clari. Uro		053 055	053 055		054 - 2+	32	29	32	100		
2025-844	151	Clari. Uro		053 055	053 055		053 - 1+	32	1	32	100		
064 URIN-PROTEIN QUALI.													
2025-845	011	AMES NM10S		053 055	053 055		055 - 3+	31	9	31	100		
2025-845	011	AMES NM10S		053 055	053 055		053 - 1+	31	2	31	100		
2025-845	011	AMES NM10S		053 055	053 055		054 - 2+	31	20	31	100		
2025-845	013	BAYER CLI		053 055	053 055		055 - 3+	19	4	19	100		
2025-845	013	BAYER CLI		053 055	053 055		053 - 1+	19	1	19	100		
2025-845	013	BAYER CLI		053 055	053 055		054 - 2+	19	14	19	100		
2025-845	067	URISCAN		053 055	053 055		053 - 1+	55	17	54	100		
2025-845	067	URISCAN		053 055	053 055		054 - 2+	55	34	54	100		
2025-845	067	URISCAN		053 055	053 055		055 - 3+	55	3	54	100		
2025-845	067	URISCAN		053 055	053 055		052 - TRACES	55	1	54	0		
2025-845	072	URS-9-TECO		053 055	053 055		054 - 2+	53	40	53	100		
2025-845	072	URS-9-TECO		053 055	053 055		053 - 1+	53	4	53	100		
2025-845	072	URS-9-TECO		053 055	053 055		055 - 3+	53	9	53	100		
2025-845	080	ROCHE (CHE		053 055	053 055		055 - 3+	36	7	36	100		
2025-845	080	ROCHE (CHE		053 055	053 055		054 - 2+	36	28	36	100		
2025-845	080	ROCHE (CHE		053 055	053 055		053 - 1+	36	1	36	100		
2025-845	089	AIMSTRIP		053 055	053 055		051 - NEGATIVE	160	1	159	0		
2025-845	089	AIMSTRIP		053 055	053 055		055 - 3+	160	18	159	100		
2025-845	089	AIMSTRIP		053 055	053 055		054 - 2+	160	135	159	100		
2025-845	089	AIMSTRIP		053 055	053 055		053 - 1+	160	6	159	100		
2025-845	094	CLINITEK		053 055	053 055		053 - 1+	102	1	102	100		
2025-845	094	CLINITEK		053 055	053 055		054 - 2+	102	91	102	100		
2025-845	094	CLINITEK		053 055	053 055		055 - 3+	102	10	102	100		
2025-845	102	ACON LAB		053 055	053 055		053 - 1+	115	7	114	100		
2025-845	102	ACON LAB		053 055	053 055		054 - 2+	115	91	114	100		
2025-845	102	ACON LAB		053 055	053 055		055 - 3+	115	16	114	100		
2025-845	102	ACON LAB		053 055	053 055		051 - NEGATIVE	115	1	114	0		

Participant Summary
MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-845	131	iCHEM VELO		053 055	053 055		055 - 3+	35	2	35	100
2025-845	131	iCHEM VELO		053 055	053 055		054 - 2+	35	32	35	100
2025-845	131	iCHEM VELO		053 055	053 055		053 - 1+	35	1	35	100
2025-845	140	MISSION A		053 055	053 055		053 - 1+	34	1	34	100
2025-845	140	MISSION A		053 055	053 055		054 - 2+	34	31	34	100
2025-845	140	MISSION A		053 055	053 055		055 - 3+	34	2	34	100
2025-845	145	CLINITEK		053 055	053 055		053 - 1+	46	1	46	100
2025-845	145	CLINITEK		053 055	053 055		054 - 2+	46	40	46	100
2025-845	145	CLINITEK		053 055	053 055		055 - 3+	46	5	46	100
2025-845	147	Mission120		053 055	053 055		054 - 2+	38	30	38	100
2025-845	147	Mission120		053 055	053 055		053 - 1+	38	8	38	100
2025-845	148	Mission500		053 055	053 055		053 - 1+	153	9	152	100
2025-845	148	Mission500		053 055	053 055		054 - 2+	153	138	152	100
2025-845	148	Mission500		053 055	053 055		056 - 4+	153	1	152	0
2025-845	148	Mission500		053 055	053 055		055 - 3+	153	5	152	100
2025-845	151	Clari. Uro		053 055	053 055		055 - 3+	32	1	32	100
2025-845	151	Clari. Uro		053 055	053 055		053 - 1+	32	3	32	100
2025-845	151	Clari. Uro		053 055	053 055		054 - 2+	32	28	32	100
066 URINAL.-UROBILINOGEN											
2025-841	011	AMES NM10S		061 061	061 061		061 - NORMAL,NEG	31	31	31	100
2025-841	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	19	19	19	100
2025-841	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	54	54	54	100
2025-841	072	URS-9-TECO		061 061	061 061		062 - 2	53	1	52	0
2025-841	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	53	52	52	100
2025-841	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	35	35	35	100
2025-841	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	161	161	161	100
2025-841	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	102	102	102	100
2025-841	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	113	113	113	100
2025-841	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	35	35	35	100
2025-841	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	33	33	33	100

Participant Summary
MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-841	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	45	45	45	100	
2025-841	147	Mission120		061 061	061 061		061 - NORMAL,NEG	38	38	38	100	
2025-841	148	Mission500		061 061	061 061		061 - NORMAL,NEG	154	154	154	100	
2025-841	151	Clari. Uro		061 061	061 061		061 - NORMAL,NEG	32	32	32	100	
066 URINAL.-UROBILINOGEN												
2025-842	011	AMES NM10S		062 064	061 063		061 - NORMAL,NEG	31	3	31	100	
2025-842	011	AMES NM10S		062 064	061 063		062 - 2	31	13	31	100	
2025-842	011	AMES NM10S		062 064	061 063		063 - 4	31	15	31	100	
2025-842	013	BAYER CLI		062 064	061 063		061 - NORMAL,NEG	19	3	19	100	
2025-842	013	BAYER CLI		062 064	061 063		062 - 2	19	7	19	100	
2025-842	013	BAYER CLI		062 064	061 063		063 - 4	19	9	19	100	
2025-842	067	URISCAN			061 063		063 - 4	54	33	49	100	
2025-842	067	URISCAN			061 063		062 - 2	54	2	49	100	
2025-842	067	URISCAN			061 063		064 - 8	54	5	49	0	
2025-842	067	URISCAN			061 063		061 - NORMAL,NEG	54	14	49	100	
2025-842	072	URS-9-TECO		061 063	061 063		062 - 2	53	31	49	100	
2025-842	072	URS-9-TECO		061 063	061 063		064 - 8	53	4	49	0	
2025-842	072	URS-9-TECO		061 063	061 063		061 - NORMAL,NEG	53	5	49	100	
2025-842	072	URS-9-TECO		061 063	061 063		063 - 4	53	13	49	100	
2025-842	080	ROCHE (CHE		061 061	061 063		062 - 2	35	4	35	100	
2025-842	080	ROCHE (CHE		061 061	061 063		061 - NORMAL,NEG	35	30	35	100	
2025-842	080	ROCHE (CHE		061 061	061 063		063 - 4	35	1	35	100	
2025-842	089	AIMSTRIP			061 063		061 - NORMAL,NEG	161	126	161	100	
2025-842	089	AIMSTRIP			061 063		063 - 4	161	8	161	100	
2025-842	089	AIMSTRIP			061 063		062 - 2	161	27	161	100	
2025-842	094	CLINITEK		062 064	061 063		062 - 2	102	26	102	100	
2025-842	094	CLINITEK		062 064	061 063		063 - 4	102	65	102	100	
2025-842	094	CLINITEK		062 064	061 063		064 - 8	102	1	102	100	
2025-842	094	CLINITEK		062 064	061 063		061 - NORMAL,NEG	102	10	102	100	
2025-842	102	ACON LAB			061 063		063 - 4	113	7	113	100	

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS				
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-842	102	ACON LAB			061 063		062 - 2	113	22	113	100
2025-842	102	ACON LAB			061 063		061 - NORMAL,NEG	113	84	113	100
2025-842	131	iCHEM VELO		062 064	061 063		063 - 4	35	35	35	100
2025-842	140	MISSION A			061 063		061 - NORMAL,NEG	33	26	33	100
2025-842	140	MISSION A			061 063		063 - 4	33	1	33	100
2025-842	140	MISSION A			061 063		062 - 2	33	6	33	100
2025-842	145	CLINITEK		061 063	061 063		061 - NORMAL,NEG	45	3	45	100
2025-842	145	CLINITEK		061 063	061 063		063 - 4	45	1	45	100
2025-842	145	CLINITEK		061 063	061 063		062 - 2	45	41	45	100
2025-842	147	Mission120		061 061	061 063		061 - NORMAL,NEG	38	36	38	100
2025-842	147	Mission120		061 061	061 063		062 - 2	38	2	38	100
2025-842	148	Mission500		061 061	061 063		062 - 2	154	1	154	100
2025-842	148	Mission500		061 061	061 063		063 - 4	154	2	154	100
2025-842	148	Mission500		061 061	061 063		061 - NORMAL,NEG	154	151	154	100
2025-842	151	Clari. Uro			061 063		061 - NORMAL,NEG	32	24	32	100
2025-842	151	Clari. Uro			061 063		062 - 2	32	5	32	100
2025-842	151	Clari. Uro			061 063		063 - 4	32	3	32	100
066 URINAL.-UROBILINOGEN											
2025-843	011	AMES NM10S		061 061	061 061		061 - NORMAL,NEG	31	31	31	100
2025-843	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	19	19	19	100
2025-843	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	54	54	54	100
2025-843	072	URS-9-TECO		061 061	061 061		062 - 2	53	2	51	0
2025-843	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	53	51	51	100
2025-843	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	35	35	35	100
2025-843	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	161	161	161	100
2025-843	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	102	102	102	100
2025-843	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	113	113	113	100
2025-843	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	35	35	35	100
2025-843	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	33	33	33	100
2025-843	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	45	45	45	100

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-843	147	Mission120		061 061	061 061		061 - NORMAL,NEG	38	38	38	100	
2025-843	148	Mission500		061 061	061 061		061 - NORMAL,NEG	154	154	154	100	
2025-843	151	Clari. Uro		061 061	061 061		061 - NORMAL,NEG	32	32	32	100	
066 URINAL.-UROBILINOGEN												
2025-844	011	AMES NM10S		061 061	061 061		061 - NORMAL,NEG	31	31	31	100	
2025-844	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	19	19	19	100	
2025-844	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	54	54	54	100	
2025-844	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	53	52	52	100	
2025-844	072	URS-9-TECO		061 061	061 061		062 - 2	53	1	52	0	
2025-844	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	35	35	35	100	
2025-844	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	161	161	161	100	
2025-844	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	102	102	102	100	
2025-844	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	113	113	113	100	
2025-844	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	35	35	35	100	
2025-844	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	33	33	33	100	
2025-844	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	45	45	45	100	
2025-844	147	Mission120		061 061	061 061		061 - NORMAL,NEG	38	38	38	100	
2025-844	148	Mission500		061 061	061 061		061 - NORMAL,NEG	154	154	154	100	
2025-844	151	Clari. Uro		061 061	061 061		061 - NORMAL,NEG	32	32	32	100	
2025-845	011	AMES NM10S		061 061	061 061		061 - NORMAL,NEG	31	31	31	100	
2025-845	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	19	19	19	100	
2025-845	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	54	54	54	100	
2025-845	072	URS-9-TECO		061 061	061 061		062 - 2	53	1	52	0	
2025-845	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	53	52	52	100	
2025-845	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	35	35	35	100	
2025-845	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	161	161	161	100	
2025-845	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	102	102	102	100	
2025-845	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	113	113	113	100	

Participant Summary
MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-845	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	35	35	35	100	
2025-845	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	33	33	33	100	
2025-845	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	45	45	45	100	
2025-845	147	Mission120		061 061	061 061		061 - NORMAL,NEG	38	38	38	100	
2025-845	148	Mission500		061 061	061 061		061 - NORMAL,NEG	154	154	154	100	
2025-845	151	Clari. Uro		061 061	061 061		061 - NORMAL,NEG	32	32	32	100	
184 URINALYSIS LEUKOCYTE												
2025-841	011	AMES NM10S		001 001	001 001		001 - Negative	32	32	32	100	
2025-841	013	BAYER CLI		001 001	001 001		001 - Negative	19	19	19	100	
2025-841	067	URISCAN		001 001	001 001		001 - Negative	54	54	54	100	
2025-841	072	URS-9-TECO		001 001	001 001		001 - Negative	50	50	50	100	
2025-841	080	ROCHE (CHE		001 001	001 001		001 - Negative	33	33	33	100	
2025-841	089	AIMSTRIP		001 001	001 001		001 - Negative	158	158	158	100	
2025-841	094	CLINITEK		001 001	001 001		001 - Negative	101	101	101	100	
2025-841	102	ACON LAB		001 001	001 001		001 - Negative	107	107	107	100	
2025-841	131	iCHEM VELO		001 001	001 001		002 - Traces	35	1	34	0	
2025-841	131	iCHEM VELO		001 001	001 001		001 - Negative	35	34	34	100	
2025-841	140	MISSION A		001 001	001 001		001 - Negative	38	38	38	100	
2025-841	145	CLINITEK		001 001	001 001		001 - Negative	45	45	45	100	
2025-841	147	Mission120		001 001	001 001		001 - Negative	37	37	37	100	
2025-841	148	Mission500		001 001	001 001		001 - Negative	155	155	155	100	
2025-841	151	Clari. Uro		001 001	001 001		001 - Negative	32	32	32	100	
2025-842	011	AMES NM10S		001 001	001 001		001 - Negative	32	32	32	100	
2025-842	013	BAYER CLI		001 001	001 001		001 - Negative	19	19	19	100	
2025-842	067	URISCAN		001 001	001 001		001 - Negative	54	54	54	100	
2025-842	072	URS-9-TECO		001 001	001 001		001 - Negative	50	50	50	100	
2025-842	080	ROCHE (CHE		001 001	001 001		001 - Negative	33	33	33	100	
2025-842	089	AIMSTRIP		001 001	001 001		001 - Negative	158	158	158	100	

Participant Summary
MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-842	094	CLINITEK		001 001	001 001		001 - Negative	101	101	101	100	
2025-842	102	ACON LAB		001 001	001 001		001 - Negative	107	107	107	100	
2025-842	131	iCHEM VELO		001 001	001 001		001 - Negative	35	35	35	100	
2025-842	140	MISSION A		001 001	001 001		001 - Negative	38	38	38	100	
2025-842	145	CLINITEK		001 001	001 001		002 - Traces	45	1	44	0	
2025-842	145	CLINITEK		001 001	001 001		001 - Negative	45	44	44	100	
2025-842	147	Mission120		001 001	001 001		001 - Negative	37	37	37	100	
2025-842	148	Mission500		001 001	001 001		001 - Negative	155	154	154	100	
2025-842	148	Mission500		001 001	001 001		002 - Traces	155	1	154	0	
2025-842	151	Clari. Uro		001 001	001 001		001 - Negative	32	32	32	100	
184 URINALYSIS LEUKOCYTE												
2025-843	011	AMES NM10S		002 004	003 005		005 - Large	32	1	32	100	
2025-843	011	AMES NM10S		002 004	003 005		004 - Moderate	32	5	32	100	
2025-843	011	AMES NM10S		002 004	003 005		003 - Small	32	26	32	100	
2025-843	013	BAYER CLI		002 004	003 005		002 - Traces	19	1	19	100	
2025-843	013	BAYER CLI		002 004	003 005		005 - Large	19	1	19	100	
2025-843	013	BAYER CLI		002 004	003 005		004 - Moderate	19	3	19	100	
2025-843	013	BAYER CLI		002 004	003 005		003 - Small	19	14	19	100	
2025-843	067	URISCAN		003 005	003 005		005 - Large	54	17	54	100	
2025-843	067	URISCAN		003 005	003 005		004 - Moderate	54	30	54	100	
2025-843	067	URISCAN		003 005	003 005		003 - Small	54	7	54	100	
2025-843	072	URS-9-TECO		002 004	003 005		003 - Small	50	26	50	100	
2025-843	072	URS-9-TECO		002 004	003 005		002 - Traces	50	1	50	100	
2025-843	072	URS-9-TECO		002 004	003 005		005 - Large	50	1	50	100	
2025-843	072	URS-9-TECO		002 004	003 005		004 - Moderate	50	22	50	100	
2025-843	080	ROCHE (CHE		004 005	003 005		004 - Moderate	33	3	33	100	
2025-843	080	ROCHE (CHE		004 005	003 005		005 - Large	33	30	33	100	
2025-843	089	AIMSTRIP		002 004	003 005		004 - Moderate	158	32	158	100	
2025-843	089	AIMSTRIP		002 004	003 005		002 - Traces	158	14	158	100	
2025-843	089	AIMSTRIP		002 004	003 005		005 - Large	158	2	158	100	

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-843	089	AIMSTRIP		002 004	003 005		003 - Small	158	110	158	100
2025-843	094	CLINITEK		002 004	003 005		004 - Moderate	101	9	101	100
2025-843	094	CLINITEK		002 004	003 005		005 - Large	101	1	101	100
2025-843	094	CLINITEK		002 004	003 005		002 - Traces	101	2	101	100
2025-843	094	CLINITEK		002 004	003 005		003 - Small	101	89	101	100
2025-843	102	ACON LAB		003 005	003 005		004 - Moderate	107	61	105	100
2025-843	102	ACON LAB		003 005	003 005		001 - Negative	107	1	105	0
2025-843	102	ACON LAB		003 005	003 005		003 - Small	107	39	105	100
2025-843	102	ACON LAB		003 005	003 005		002 - Traces	107	1	105	0
2025-843	102	ACON LAB		003 005	003 005		005 - Large	107	5	105	100
2025-843	131	iCHEM VELO		004 005	003 005		004 - Moderate	35	1	35	100
2025-843	131	iCHEM VELO		004 005	003 005		005 - Large	35	34	35	100
2025-843	140	MISSION A		003 005	003 005		004 - Moderate	38	25	38	100
2025-843	140	MISSION A		003 005	003 005		003 - Small	38	10	38	100
2025-843	140	MISSION A		003 005	003 005		005 - Large	38	3	38	100
2025-843	145	CLINITEK		003 005	003 005		003 - Small	45	1	45	100
2025-843	145	CLINITEK		003 005	003 005		004 - Moderate	45	44	45	100
2025-843	147	Mission120		003 005	003 005		002 - Traces	37	4	33	0
2025-843	147	Mission120		003 005	003 005		004 - Moderate	37	19	33	100
2025-843	147	Mission120		003 005	003 005		003 - Small	37	14	33	100
2025-843	148	Mission500		003 005	003 005		003 - Small	155	34	152	100
2025-843	148	Mission500		003 005	003 005		004 - Moderate	155	106	152	100
2025-843	148	Mission500		003 005	003 005		005 - Large	155	12	152	100
2025-843	148	Mission500		003 005	003 005		002 - Traces	155	3	152	0
2025-843	151	Clari. Uro		002 004	003 005		003 - Small	32	15	32	100
2025-843	151	Clari. Uro		002 004	003 005		002 - Traces	32	2	32	100
2025-843	151	Clari. Uro		002 004	003 005		005 - Large	32	2	32	100
2025-843	151	Clari. Uro		002 004	003 005		004 - Moderate	32	13	32	100
184 URINALYSIS LEUKOCYTE											
2025-844	011	AMES NM10S		001 001	001 001		001 - Negative	32	32	32	100

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2025-844	013	BAYER CLI		001 001	001 001		001 - Negative	19	19	19	100
2025-844	067	URISCAN		001 001	001 001		001 - Negative	54	54	54	100
2025-844	072	URS-9-TECO		001 001	001 001		001 - Negative	50	50	50	100
2025-844	080	ROCHE (CHE		001 001	001 001		001 - Negative	33	31	31	100
2025-844	080	ROCHE (CHE		001 001	001 001		004 - Moderate	33	1	31	0
2025-844	080	ROCHE (CHE		001 001	001 001		002 - Traces	33	1	31	0
2025-844	089	AIMSTRIP		001 001	001 001		001 - Negative	158	158	158	100
2025-844	094	CLINITEK		001 001	001 001		001 - Negative	101	101	101	100
2025-844	102	ACON LAB		001 001	001 001		001 - Negative	107	106	106	100
2025-844	102	ACON LAB		001 001	001 001		004 - Moderate	107	1	106	0
2025-844	131	iCHEM VELO		001 001	001 001		001 - Negative	35	35	35	100
2025-844	140	MISSION A		001 001	001 001		005 - Large	38	1	37	0
2025-844	140	MISSION A		001 001	001 001		001 - Negative	38	37	37	100
2025-844	145	CLINITEK		001 001	001 001		001 - Negative	45	45	45	100
2025-844	147	Mission120		001 001	001 001		001 - Negative	37	37	37	100
2025-844	148	Mission500		001 001	001 001		001 - Negative	155	155	155	100
2025-844	151	Clari. Uro		001 001	001 001		001 - Negative	32	32	32	100
184 URINALYSIS LEUKOCYTE											
2025-845	011	AMES NM10S		001 001	001 001		001 - Negative	32	32	32	100
2025-845	013	BAYER CLI		001 001	001 001		001 - Negative	19	19	19	100
2025-845	067	URISCAN		001 001	001 001		001 - Negative	54	54	54	100
2025-845	072	URS-9-TECO		001 001	001 001		001 - Negative	50	50	50	100
2025-845	080	ROCHE (CHE		001 001	001 001		002 - Traces	33	2	31	0
2025-845	080	ROCHE (CHE		001 001	001 001		001 - Negative	33	31	31	100
2025-845	089	AIMSTRIP		001 001	001 001		001 - Negative	158	158	158	100
2025-845	094	CLINITEK		001 001	001 001		001 - Negative	101	101	101	100
2025-845	102	ACON LAB		001 001	001 001		001 - Negative	107	107	107	100
2025-845	131	iCHEM VELO		001 001	001 001		001 - Negative	35	35	35	100
2025-845	140	MISSION A		001 001	001 001		001 - Negative	38	37	37	100
2025-845	140	MISSION A		001 001	001 001		004 - Moderate	38	1	37	0

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2025-845	145	CLINITEK		001 001	001 001		001 - Negative	45	45	45	100	
2025-845	147	Mission120		001 001	001 001		001 - Negative	37	37	37	100	
2025-845	148	Mission500		001 001	001 001		001 - Negative	155	155	155	100	
2025-845	151	Clari. Uro		001 001	001 001		001 - Negative	32	32	32	100	

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 80 PREGNANCY TEST						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
063 URI-PREGNANCY TEST												
2025-841	091	AIM STEP		001 001	001 001		001 - NEGATIVE	33	33	33	100	
2025-841	101	HCG Alere		001 001	001 001		001 - NEGATIVE	24	24	24	100	
2025-842	091	AIM STEP		002 002	002 002		002 - POSITIVE	33	33	33	100	
2025-842	101	HCG Alere		002 002	002 002		002 - POSITIVE	24	24	24	100	
2025-843	091	AIM STEP		001 001	001 001		001 - NEGATIVE	33	33	33	100	
2025-843	101	HCG Alere		001 001	001 001		001 - NEGATIVE	24	24	24	100	
2025-844	091	AIM STEP		002 002	002 002		002 - POSITIVE	33	33	33	100	
2025-844	101	HCG Alere		002 002	002 002		002 - POSITIVE	24	24	24	100	
2025-845	091	AIM STEP		001 001	001 001		001 - NEGATIVE	33	33	33	100	
2025-845	101	HCG Alere		001 001	001 001		001 - NEGATIVE	24	24	24	100	

Participant Summary

MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS			GRP: 75 URINALYSIS SEDIMENT						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
150 URINAL.- SEDIMENT											
2025-851					012	012	012 - TRANSITIO.	921	897	897	100
2025-851					012	012	010 - RENAL TUB.	921	23	897	0
2025-851					012	012	009 - LEUKOCYTE	921	1	897	0
2025-851					012	012		921	0	897	0
2025-852					031	031	031 - FIBERS	921	912	912	100
2025-852					031	031	032 - MUCOUS TH.	921	9	912	0
2025-852					031	031		921	0	912	0
2025-853					008	008	005 - RED CELL C	921	4	917	0
2025-853					008	008	008 - ERYTHROCYT	921	917	917	100
2025-853					008	008		921	0	917	0
2025-854					041	041	041 - T. vagina.	921	917	917	100
2025-854					041	041	043 - Giardia la	921	4	917	0
2025-854					041	041		921	0	917	0
2025-855					024	024	024 - AMMONIUM B	921	919	919	100
2025-855					024	024	013 - AMORPHOUS	921	2	919	0
2025-855					024	024		921	0	919	0

Participant Summary
MONTH 10 OF YEAR 2025

SPE: 10 CHEMISTRY				SUB: 60 SPECIAL TESTS				GRP: 98 OCCULT BLOOD				
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
154 FECAL OCCULT BLOOD												
2025-861	001	PEROXIDASE		002	002	002	002	001 - NEGATIVE	345	1	344	0
2025-861	001	PEROXIDASE		002	002	002	002	002 - POSITIVE	345	344	344	100
2025-861	002	INMMUASSAY		002	002	002	002	002 - POSITIVE	761	761	761	100
2025-862	001	PEROXIDASE		001	001	001	001	001 - NEGATIVE	345	344	344	100
2025-862	001	PEROXIDASE		001	001	001	001	002 - POSITIVE	345	1	344	0
2025-862	002	INMMUASSAY		001	001	001	001	001 - NEGATIVE	761	760	760	100
2025-862	002	INMMUASSAY		001	001	001	001	002 - POSITIVE	761	1	760	0
2025-863	001	PEROXIDASE		002	002	002	002	002 - POSITIVE	345	345	345	100
2025-863	002	INMMUASSAY		002	002	002	002	001 - NEGATIVE	761	1	760	0
2025-863	002	INMMUASSAY		002	002	002	002	002 - POSITIVE	761	760	760	100
2025-864	001	PEROXIDASE		001	001	001	001	002 - POSITIVE	345	1	344	0
2025-864	001	PEROXIDASE		001	001	001	001	001 - NEGATIVE	345	344	344	100
2025-864	002	INMMUASSAY		001	001	001	001	001 - NEGATIVE	761	760	760	100
2025-864	002	INMMUASSAY		001	001	001	001	002 - POSITIVE	761	1	760	0
2025-865	001	PEROXIDASE		002	002	002	002	002 - POSITIVE	345	345	345	100
2025-865	002	INMMUASSAY		002	002	002	002	002 - POSITIVE	761	760	760	100
2025-865	002	INMMUASSAY		002	002	002	002	001 - NEGATIVE	761	1	760	0

SPEC: 10 CHEMISTRY				SUB: 60 SPECIAL TESTS				GRP: 90 SPECIAL TEST			
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 90 SPECIAL TEST					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
068	CARCINOE. ANTIG. CEA	CLIA TEST ID #: 352	EVALUATION CRITERIA: TARGET VALUE	15	%	OR 1.00	{GREATER}				
2025-811	29 VITROS			10	5.630	0.127	2.25	4.600	6.600		
2025-811	38 ROCHE E			21	5.267	0.198	3.77	4.300	6.300		
2025-811	44 BECK.COUL.			18	5.917	0.263	4.44	4.900	6.900		
2025-811	50 ARC			10	5.750	0.361	6.28	4.800	6.800		
2025-811	58 ATELLICA			10	5.780	0.248	4.29	4.800	6.800		
2025-812	29 VITROS			10	10.690	0.435	4.07	9.100	12.300		
2025-812	38 ROCHE E			21	9.495	0.409	4.31	8.100	10.900		
2025-812	44 BECK.COUL.			18	11.006	0.582	5.28	9.400	12.700		
2025-812	50 ARC			10	10.690	0.485	4.53	9.100	12.300		
2025-812	58 ATELLICA			10	10.570	0.575	5.44	9.000	12.200		
2025-813	29 VITROS			10	0.640	0.049	7.65	0	1.600		
2025-813	38 ROCHE E			21	0.857	0.109	12.77	0	1.900		
2025-813	44 BECK.COUL.			18	0.671	0.057	8.50	0	1.700		
2025-813	50 ARC			10	1.150	0.461	40.08	0.200	2.200		
2025-813	58 ATELLICA			10	0.790	0.448	56.74	0	1.800		
2025-814	29 VITROS			10	26.390	0.832	3.15	22.400	30.300		
2025-814	38 ROCHE E			21	22.129	0.728	3.29	18.800	25.400		
2025-814	44 BECK.COUL.			18	27.161	1.659	6.11	23.100	31.200		
2025-814	50 ARC			10	25.080	1.269	5.06	21.300	28.800		
2025-814	58 ATELLICA			10	23.960	1.198	5.00	20.400	27.600		
2025-815	29 VITROS			10	17.640	0.664	3.76	15.000	20.300		
2025-815	38 ROCHE E			21	15.181	0.573	3.77	12.900	17.500		
2025-815	44 BECK.COUL.			18	18.456	1.120	6.07	15.700	21.200		
2025-815	50 ARC			10	17.330	0.966	5.58	14.700	19.900		
2025-815	58 ATELLICA			10	16.830	0.666	3.96	14.300	19.400		

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 90 SPECIAL TEST						
ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
069	PROS. SPEC-ANTIG-PSA	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	20	%	OR	0.20	{GREATER}		
2025-811	29 VITROS			46	2.504	0.094	3.76	2.000	3.000	
2025-811	38 ROCHE E			53	4.196	0.259	6.18	3.400	5.000	
2025-811	44 BECK.COUL.			45	4.140	0.296	7.15	3.300	5.000	
2025-811	50 ARC			21	3.481	0.224	6.43	2.800	4.200	
2025-811	57 S. EXL 200			47	4.132	0.183	4.44	3.300	5.000	
2025-811	58 ATELLICA			26	3.900	0.136	3.48	3.100	4.700	
2025-812	29 VITROS			46	4.515	0.153	3.39	3.600	5.400	
2025-812	38 ROCHE E			53	8.168	0.458	5.60	6.500	9.800	
2025-812	44 BECK.COUL.			45	7.942	0.491	6.18	6.400	9.500	
2025-812	50 ARC			21	6.795	0.434	6.38	5.400	8.200	
2025-812	57 S. EXL 200			47	8.179	0.395	4.83	6.500	9.800	
2025-812	58 ATELLICA			26	7.424	0.240	3.24	5.900	8.900	
2025-813	29 VITROS			46	0.300	0.000	0.00	0.100	0.500	
2025-813	38 ROCHE E			53	0.200	0.000	0.00	0.000	0.400	
2025-813	44 BECK.COUL.			45	0.258	0.049	19.16	0.100	0.500	
2025-813	50 ARC			21	0.200	0.000	0.00	0.000	0.400	
2025-813	57 S. EXL 200			47	0.213	0.033	15.68	0.000	0.400	
2025-813	58 ATELLICA			26	0.212	0.032	15.10	0.000	0.400	
2025-814	29 VITROS			46	10.598	0.394	3.71	8.500	12.700	
2025-814	38 ROCHE E			53	19.681	1.127	5.73	15.700	23.600	
2025-814	44 BECK.COUL.			45	18.949	1.251	6.60	15.200	22.700	
2025-814	50 ARC			21	17.329	1.145	6.61	13.900	20.800	
2025-814	57 S. EXL 200			47	20.115	0.760	3.78	16.100	24.100	
2025-814	58 ATELLICA			26	17.556	0.759	4.32	14.000	21.100	
2025-815	29 VITROS			46	7.278	0.272	3.73	5.800	8.700	

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 90 SPECIAL TEST					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2025-815	38	ROCHE E		53	13.489	0.755	5.60	10.800	16.200
2025-815	44	BECK.COUL.		45	13.173	0.883	6.70	10.500	15.800
2025-815	50	ARC		21	11.643	0.657	5.65	9.300	14.000
2025-815	57	S. EXL 200		47	13.785	0.561	4.07	11.000	16.500
2025-815	58	APELLICA		26	12.185	0.421	3.46	9.700	14.600
071 VITAMIN B 12		CLIA TEST ID #: 600	EVALUATION CRITERIA: TARGET VALUE 25 % OR 30.00 {GREATER}						
2025-811	29	VITROS		29	354.310	12.429	3.51	266.000	443.000
2025-811	38	ROCHE E		39	357.154	55.990	15.68	268.000	446.000
2025-811	44	BECK.COUL.		27	274.074	15.287	5.58	206.000	343.000
2025-811	50	ARC		21	375.619	21.779	5.80	282.000	470.000
2025-811	57	S. EXL 200		17	373.941	27.595	7.38	280.000	467.000
2025-811	58	APELLICA		21	304.810	36.029	11.82	229.000	381.000
2025-811	58	APELLICA		21	230.000	19.442	8.45	173.000	288.000
2025-812	29	VITROS		29	488.750	16.681	3.41	367.000	611.000
2025-812	38	ROCHE E		39	484.711	49.099	10.13	364.000	606.000
2025-812	44	BECK.COUL.		27	363.778	18.001	4.95	273.000	455.000
2025-812	50	ARC		21	485.667	31.682	6.52	364.000	607.000
2025-812	57	S. EXL 200		17	484.412	27.045	5.58	363.000	606.000
2025-812	58	APELLICA		21	400.333	58.616	14.64	300.000	500.000
2025-812	58	APELLICA		21	306.000	21.954	7.17	230.000	383.000
2025-813	29	VITROS		29	255.000	6.264	2.46	191.000	319.000
2025-813	38	ROCHE E		39	244.692	51.313	20.97	184.000	306.000
2025-813	44	BECK.COUL.		27	185.852	10.409	5.60	139.000	232.000
2025-813	50	ARC		21	256.905	18.111	7.05	193.000	321.000
2025-813	57	S. EXL 200		17	269.941	28.329	10.49	202.000	337.000
2025-813	58	APELLICA		21	161.000	10.708	6.65	121.000	201.000
2025-813	58	APELLICA		21	200.476	25.298	12.62	150.000	251.000

Participant Summary
MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY SUB: 60 SPECIAL TESTS GRP: 90 SPECIAL TEST

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE		
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
071 VITAMIN B 12				CLIA TEST ID #: 600						EVALUATION CRITERIA: TARGET VALUE 25 % OR 30.00 {GREATER}	
2025-814	29	VITROS		29	782.517	32.160	4.11	587.000	978.000		
2025-814	38	ROCHE E		39	887.053	61.882	6.98	665.000	1109.000		
2025-814	44	BECK.COUL.		27	610.885	27.126	4.44	458.000	764.000		
2025-814	50	ARC		21	829.190	52.972	6.39	622.000	1036.000		
2025-814	57	S. EXL 200		17	824.941	33.618	4.08	619.000	1031.000		
2025-814	58	ATELLICA		21	661.238	158.845	24.02	496.000	827.000		
2025-814	58	ATELLICA		21	485.667	37.985	7.82	364.000	607.000		
2025-815	29	VITROS		29	663.414	33.980	5.12	498.000	829.000		
2025-815	38	ROCHE E		39	675.289	50.608	7.49	506.000	844.000		
2025-815	44	BECK.COUL.		27	488.481	22.091	4.52	366.000	611.000		
2025-815	50	ARC		21	651.048	45.855	7.04	488.000	814.000		
2025-815	57	S. EXL 200		17	641.529	29.354	4.58	481.000	802.000		
2025-815	58	ATELLICA		21	531.571	100.318	18.87	399.000	664.000		
2025-815	58	ATELLICA		21	410.000	25.923	6.32	308.000	513.000		

SPEC: 10 CHEMISTRY SUB: 60 SPECIAL TESTS GRP: 95 GLYCOHEMOGLOBINE

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE		
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
146 GLYCOHEMOGLOBIN				CLIA TEST ID #: 420						EVALUATION CRITERIA: TARGET VALUE 8 %	
2025-821	12	COBAS/INT.		23	5.039	0.202	4.00	4.600	5.400		
2025-821	14	IMMUNOTUR.		13	6.067	0.094	1.55	5.600	6.600		
2025-821	14	IMMUNOTUR.		13	5.254	0.365	6.95	4.800	5.700		
2025-821	22	VITROS		64	4.834	0.108	2.23	4.400	5.200		
2025-821	31	IMMUNOTURB		56	4.878	0.220	4.50	4.500	5.300		
2025-821	40	SIEMENS DI		63	5.625	0.228	4.05	5.200	6.100		
2025-821	40	SIEMENS DI		63	5.040	0.141	2.79	4.600	5.400		
2025-821	46	ARCHITECT		16	4.847	0.109	2.24	4.500	5.200		

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 95 GLYCOHEMOGLOBINE					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2025-821	46	ARCHITECT		16	6.067	0.094	1.55	5.600	6.600
2025-821	48	ATELLICA		24	4.808	0.086	1.79	4.400	5.200
2025-821	50	CS400DIRUI		10	5.020	0.374	7.44	4.600	5.400
146	GLYCOHEMOGLOBIN		CLIA TEST ID #: 420		EVALUATION CRITERIA: TARGET VALUE 8 %				
2025-822	12	COBAS/INT.		23	6.083	0.204	3.35	5.600	6.600
2025-822	14	IMMUNOTUR.		13	6.300	0.218	3.47	5.800	6.800
2025-822	14	IMMUNOTUR.		13	7.200	0.163	2.27	6.600	7.800
2025-822	22	VITROS		64	5.986	0.148	2.47	5.500	6.500
2025-822	31	IMMUNOTURB		56	5.893	0.252	4.28	5.400	6.400
2025-822	40	SIEMENS DI		63	6.166	0.136	2.20	5.700	6.700
2025-822	40	SIEMENS DI		63	6.850	0.320	4.67	6.300	7.400
2025-822	46	ARCHITECT		16	7.200	0.163	2.27	6.600	7.800
2025-822	46	ARCHITECT		16	5.875	0.164	2.79	5.400	6.300
2025-822	48	ATELLICA		24	5.813	0.120	2.07	5.300	6.300
2025-822	50	CS400DIRUI		10	6.120	0.252	4.12	5.600	6.600
2025-823	12	COBAS/INT.		23	6.096	0.171	2.80	5.600	6.600
2025-823	14	IMMUNOTUR.		13	7.133	0.125	1.75	6.600	7.700
2025-823	14	IMMUNOTUR.		13	6.250	0.284	4.55	5.800	6.800
2025-823	22	VITROS		64	5.986	0.133	2.23	5.500	6.500
2025-823	31	IMMUNOTURB		56	5.942	0.240	4.04	5.500	6.400
2025-823	40	SIEMENS DI		63	6.525	0.295	4.52	6.000	7.000
2025-823	40	SIEMENS DI		63	6.182	0.151	2.44	5.700	6.700
2025-823	46	ARCHITECT		16	5.869	0.165	2.81	5.400	6.300
2025-823	46	ARCHITECT		16	7.133	0.125	1.75	6.600	7.700
2025-823	48	ATELLICA		24	5.796	0.102	1.76	5.300	6.300
2025-823	50	CS400DIRUI		10	6.140	0.269	4.38	5.600	6.600
2025-824	12	COBAS/INT.		23	8.391	0.241	2.87	7.700	9.100
2025-824	14	IMMUNOTUR.		13	8.692	0.281	3.24	8.000	9.400

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 95 GLYCOHEMOGLOBINE					
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2025-824	14	IMMUNOTUR.		13	9.333	0.205	2.20	8.600	10.100
2025-824	22	VITROS		64	8.306	0.222	2.68	7.600	9.000
2025-824	31	IMMUNOTURB		56	8.414	0.282	3.35	7.700	9.100
2025-824	40	SIEMENS DI		63	8.542	0.189	2.21	7.900	9.200
2025-824	40	SIEMENS DI		63	8.875	0.259	2.91	8.200	9.600
2025-824	46	ARCHITECT		16	9.333	0.205	2.20	8.600	10.100
2025-824	46	ARCHITECT		16	8.260	0.102	1.23	7.600	8.900
2025-824	48	ATELLICA		24	8.071	0.143	1.77	7.400	8.700
2025-824	50	CS400DIRUI		10	8.530	0.447	5.24	7.800	9.200
146 GLYCOHEMOGLOBIN		CLIA TEST ID #: 420		EVALUATION CRITERIA: TARGET VALUE 8 %					
2025-825	12	COBAS/INT.		23	6.100	0.215	3.52	5.600	6.600
2025-825	14	IMMUNOTUR.		13	7.233	0.125	1.72	6.700	7.800
2025-825	14	IMMUNOTUR.		13	6.200	0.260	4.20	5.700	6.700
2025-825	22	VITROS		64	5.995	0.150	2.51	5.500	6.500
2025-825	31	IMMUNOTURB		56	5.904	0.222	3.77	5.400	6.400
2025-825	40	SIEMENS DI		63	7.000	0.245	3.50	6.400	7.600
2025-825	40	SIEMENS DI		63	6.184	0.179	2.89	5.700	6.700
2025-825	46	ARCHITECT		16	7.233	0.125	1.72	6.700	7.800
2025-825	46	ARCHITECT		16	5.900	0.155	2.63	5.400	6.400
2025-825	48	ATELLICA		24	5.788	0.109	1.89	5.300	6.300
2025-825	50	CS400DIRUI		10	6.090	0.259	4.25	5.600	6.600

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 99 Vitamin D					
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
178 Vitamin D		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 20 %					
2025-301	3	VITROS		47	62.911	6.575	10.45	50.000	75.000
2025-301	5	ROCHE E		40	25.300	3.132	12.38	20.000	30.000
2025-301	9	BECK.COUL.		42	24.429	1.990	8.15	20.000	29.000

Participant Summary

MONTH 10 OF YEAR 2025

SPEC: 10 CHEMISTRY

SUB: 60 SPECIAL TESTS

GRP: 99 Vitamin D

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2025-301	9	BECK.COUL.		42	42.976	3.873	9.01	34.000	52.000
2025-301	11	ARC		19	31.579	1.139	3.61	25.000	38.000
2025-301	25	S. DIME		27	35.231	2.792	7.92	28.000	42.000
2025-301	27	APELLICA		23	64.870	4.287	6.61	52.000	78.000
178 Vitamin D			CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 20 %				
2025-302	3	VITROS		47	125.717	1.362	1.08	101.000	151.000
2025-302	5	ROCHE E		40	97.550	6.723	6.89	78.000	117.000
2025-302	9	BECK.COUL.		42	100.317	7.940	7.92	80.000	120.000
2025-302	9	BECK.COUL.		42	101.286	17.260	17.04	81.000	122.000
2025-302	11	ARC		19	91.000	5.047	5.55	73.000	109.000
2025-302	25	S. DIME		27	80.111	6.002	7.49	64.000	96.000
2025-302	27	APELLICA		23	123.870	5.885	4.75	99.000	149.000
2025-303	3	VITROS		47	122.109	5.301	4.34	98.000	147.000
2025-303	5	ROCHE E		40	73.425	5.687	7.75	59.000	88.000
2025-303	9	BECK.COUL.		42	78.143	3.523	4.51	63.000	94.000
2025-303	9	BECK.COUL.		42	84.293	5.553	6.59	67.000	101.000
2025-303	11	ARC		19	69.842	2.852	4.08	56.000	84.000
2025-303	25	S. DIME		27	67.333	4.815	7.15	54.000	81.000
2025-303	27	APELLICA		23	108.727	5.047	4.64	87.000	130.000
2025-304	3	VITROS		47	98.935	7.221	7.30	79.000	119.000
2025-304	5	ROCHE E		40	47.615	4.130	8.67	38.000	57.000
2025-304	9	BECK.COUL.		42	49.286	3.493	7.09	39.000	59.000
2025-304	9	BECK.COUL.		42	65.268	4.869	7.46	52.000	78.000
2025-304	11	ARC		19	50.789	2.353	4.63	41.000	61.000
2025-304	25	S. DIME		27	52.731	4.275	8.11	42.000	63.000
2025-304	27	APELLICA		23	90.261	4.980	5.52	72.000	108.000
2025-305	3	VITROS		47	23.957	2.858	11.93	19.000	29.000

Participant Summary**MONTH 10 OF YEAR 2025**

SPEC: 10 CHEMISTRY

SUB: 60 SPECIAL TESTS

GRP: 99 Vitamin D

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2025-305	5	ROCHE E		40	9.550	2.783	29.15	8.000	11.000
2025-305	9	BECK.COUL.		42	7.571	2.441	32.24	6.000	9.000
2025-305	9	BECK.COUL.		42	17.732	1.913	10.79	14.000	21.000
2025-305	11	ARC		19	12.421	0.674	5.43	10.000	15.000
2025-305	25	S. DIME		27	18.037	1.732	9.60	14.000	22.000
2025-305	27	ATELLICA		23	28.909	3.218	11.13	23.000	35.000